



Time to act on evidence from recent large scale observational studies of the efficacy of red blood cell transfusion? Insights from a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002154
Article Type:	Research
Date Submitted by the Author:	24-Sep-2012
Complete List of Authors:	Hopewell, Sally; University of Oxford, Centre for Statistics in Medicine Omar, Omar; University of Oxford, Centre for Statistics in Medicine Yu, Ly-Mee; University of Oxford, Centre for Statistics in Medicine Hyde, Chris; University of Exeter, Peninsula College of Medicine & Dentistry Doree, Carolyn; John Radcliffe Hospital, NHS Blood and Transplant Murphy, Mike; John Radcliffe Hospital, NHS Blood and Transplant
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	EPIDEMIOLOGY, Blood bank & transfusion medicine < HAEMATOLOGY, INTENSIVE & CRITICAL CARE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8 **Time to act on evidence from recent large scale observational studies**
9
10 **of the efficacy of red blood cell transfusion? Insights from a systematic**
11 **review**
12
13
14
15
16
17
18
19
20
21
22

23 Sally Hopewell^{1,2}, Omar Omar², Chris Hyde³, Ly-Mee Yu², Carolyn Doree¹, Mike F. Murphy¹
24
25
26

- 27
28 1. Systematic Review Initiative, NHS Blood and Transplant, Department of
29 Haematology, Oxford University Hospitals and University of Oxford, UK.
30
31 2. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
32
33 3. PenTAG, Peninsula College of Medicine and Dentistry, Exeter, UK
34
35
36
37
38
39

40 Correspondence to:

41
42 Dr Sally Hopewell, Centre for Statistics in Medicine, University of Oxford, Wolfson College,
43 Linton Road, Oxford, OX2 6UD, UK. Tel: +44 1865 284400; Fax: +44 1865 284424; Email:
44 sally.hopewell@csm.ox.ac.uk
45
46
47
48

49
50 **Keywords**

51
52 Systematic review, observational studies, transfusion, mortality.
53
54

55 Word count 4324
56
57
58
59
60

ABSTRACT

Objective: To carry out a systematic review of recent large observational studies on the efficacy of red blood cell transfusion (RBCT), with particular emphasis on the statistical methods used to adjust for confounding. Given the limited number of randomized trials of the efficacy of RBCT, clinicians often use evidence from observational studies. However, confounding factors, for example individuals receiving blood generally being sicker than those who do not, makes their interpretation challenging.

Design: Systematic review.

Information sources: We searched MEDLINE and EMBASE for studies published from 1 January 2006 to 31 December 2010.

Eligibility criteria for included studies: We included prospective cohort, case control studies or retrospective analyses of databases or disease registers where the effect of risk factors for mortality or survival was examined. Studies must have included more than 1000 participants receiving RBCT for any cause. We assessed the effects of RBCT versus no RBCT and different volumes and age of RBCT.

Results: Thirty two studies were included in the review; 23 assessed the effects of RBCT versus no RBCT; five assessed different volumes and four older versus newer RBCT. There was considerable variability in the patient populations, study designs and level of statistical adjustment. Overall, most studies showed a higher rate of mortality when comparing patients who received RBCT with those who did not, even when these rates were adjusted for confounding; the majority of these increases were statistically significant. The same pattern was observed in studies where protection from bias was likely to be greater, such as prospective studies.

Conclusion: Observational studies do show a consistent adverse effect of RBCT on mortality. Whether this is a true effect remains uncertain and should be addressed by conducting well designed and powered randomized controlled trials.

ARTICLE SUMMARY

Article focus

- Given the limited number of randomized trials of the efficacy of red blood cell transfusion (RBCT), clinicians often use evidence from observational studies.
- Confounding factors, for example individuals receiving blood generally being sicker than those who do not, can make their interpretation challenging.
- Our objective was to systematically review recent large observational studies (n>1000 patients) on the efficacy of RBCT, with particular emphasis on the statistical methods used to adjust for confounding.

Key messages

- We identified considerable variability in the patient populations, study designs and level of statistical adjustment.
- Most studies showed higher mortality rates when comparing patients who received RBCT with those who did not, even when adjusting for confounding. We identified similar patterns in studies where protection from bias was likely to be greatest.

Strengths and limitations of this study

- Overall, observational studies do show a consistent adverse effect of RBCT on mortality.
- However, even the best conducted adjustments for confounding cannot completely eliminate its impact, particularly when investigating the effect of RBCT on mortality.

Introduction

Randomized controlled trials are considered the gold standard with which to evaluate the efficacy of a particular health care intervention. In 2005, Blajchman (1) published a study that explored the impact that ten landmark randomized controlled trials have had on the practice of transfusion medicine. The use of randomized trials to evaluate transfusion medicine has only been established since the 1980s (1). Given the limited number of high quality randomized trials of the efficacy of blood transfusion and the challenges of conducting new trials, clinicians often rely on evidence from observational studies. In a randomized trial patients are allocated to comparison groups at random, so the level of disease is likely to be similar in each group and differences in disease severity unlikely to be the explanation for any differences in outcome seen. In an observational study whether a treatment is received or not is likely to be heavily influenced by perceived need by the treating doctor and this will be particularly true where the outcomes of transfused patients are being compared with those not transfused. In this case the groups of patients being compared are not likely to be comparable and the differences in prognostic factors may of themselves lead to difference in outcome. The impact of such “confounding” can be reduced by adjustment in the statistical analysis, but the success of this is dependent on the technique used, complete identification of the factors which might influence outcome and their accurate measurement in the patients in the study (2). As all the factors influencing outcome may never be known, adjustment is unlikely to ever completely account for the confounding occurring in observational studies. The unknown inter-dependence of multiple factors is also a major challenge.

The impact that the contribution of data from observational studies has made to the practice of transfusion medicine has not been systematically explored. However, given their publication in major journals, their impact on clinicians may be greater than is appropriate

1
2
3 for the types of studies and the limitations associated with their design. The aims of this
4
5 systematic review were to identify recent, large observational studies on the effectiveness of
6
7 red blood cell transfusion (RBCT), to critique them with particular emphasis on the statistical
8
9 methods and the assumptions made in the analyses of the observational data, to consider
10
11 the validity of these data as an evidence base for the practice of transfusion medicine and to
12
13 inform future research in this field.
14
15

16 17 18 **Methods**

19 20 **Criteria for selecting studies**

21 22 Type of participants

23
24 We included both adults and children receiving RBCT for any cause. We also included studies
25
26 which stated that patients received red blood cells and other blood products. When
27
28 reported by the primary studies we assessed the effects of RBCT separately from other
29
30 blood products.
31
32

33 34 35 Type of intervention and comparator

36
37 We included the following risk factors:

- 38
39 • RBCT versus no RBCT
- 40
41 • Volume 'A' of RBCT versus volume 'B' of RBCT (as defined by the primary studies)
- 42
43 • 'Older' RBCT versus 'newer' RBCT (as defined by the primary studies)
- 44
45

46 47 48 Type of outcome measure

49
50 Our primary outcome measure was death, mortality or survival measured at any time point.
51
52

53 54 55 Type of studies

1
2
3 We included prospective cohort, case control studies or retrospective analyses of databases
4
5 or disease registers where the effect of the above risk factors on death, mortality or survival
6
7 is examined. Studies must have included more than 1000 participants. This was a pragmatic
8
9 limit designed to focus attention on studies most likely to have had an impact and least likely
10
11 to have been affected by chance.
12

13 14 15 16 **Search strategy**

17
18 We carried out a comprehensive search of MEDLINE and EMBASE for studies published from
19
20 1 January 2006 to 31 December 2010 using the strategies in Appendix 1. We excluded
21
22 conference abstracts unless they had subsequently been published as full articles.
23

24 25 26 27 **Data collection and analysis**

28
29 One review author (CD) initially screened all search results for relevance against the
30
31 eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, another
32
33 author (SH) independently screened all remaining hits. We retrieved full text articles for all
34
35 those references where we are unable to decide on eligibility based on the title and abstract
36
37 alone. All full text articles were independently screened by two review authors (SH, MM) to
38
39 ensure that they met the eligibility criteria.
40
41
42
43

44 45 46 47 **Data extraction and management**

48
49 Two review authors (SH, OO) independently extracted data from all included studies. Any
50
51 disagreements were resolved by discussion or by consulting a third author if there was still
52
53 uncertainty. We extracted data on the following study characteristics: the study design, how
54
55 patients were recruited, the country where the study was conducted, the source of funding,
56
57 the type of participants, their age, disease area, setting, the type of intervention /
58
59 comparator and nature of the exposure, the number of participants in each group, whether
60

1
2
3 any formal prescribing guidance was reported, the type of outcome measure (i.e. mortality)
4
5 and the time point at which it was measured.
6
7

8
9 We also extracted information on the statistical methods used to adjust for differences
10
11 between study groups, in particular the number of study covariates measured, whether
12
13 important covariates relating to red cell transfusion were assessed (i.e. age, sex, co-
14
15 morbidity, hemoglobin) and whether these were incorporated into the analysis, whether the
16
17 choice of covariates were pre-specified or data driven and the statistical model used for the
18
19 statistical adjustment. We also assessed the effects of smoking as a study covariate in
20
21 relation to blood transfusion and its effect on mortality. In terms of the study results we
22
23 extracted data on the presentation of both the unadjusted and adjusted result for the effect
24
25 of red cell transfusion on mortality as reported by each study. If not reported by the primary
26
27 study we calculated (where there were sufficient data) the odds ratio for the effect of blood
28
29 transfusion on mortality for unadjusted analyses using STATA (version 11). We assessed, for
30
31 the unadjusted and adjusted result, whether the study reported summary statistics for each
32
33 comparison group, the treatment effect, confidence interval, p value and whether the result
34
35 was statistically significant. If a study reported more than one adjusted analysis we selected
36
37 in order of preference (i) the main adjusted analysis mentioned in the abstract, (ii) the main
38
39 adjusted analysis mentioned in the conclusions, (iii) the main adjusted analysis mentioned in
40
41 the results section. If mortality was assessed for more than one time point (i.e. at 30 days
42
43 and 1 year) then we used the shorter time point in our analysis.
44
45
46
47
48
49

50 **Assessment of methodological quality**

51
52 We also assessed whether studies met important methodological criteria for the reporting
53
54 of observational studies: whether the samples were representative of those to whom the
55
56 results might be generalised, whether important covariates in relation to RBCT and mortality
57
58
59
60

1
2
3 (e.g. sex, age, smoking, co-morbidity, hemoglobin level) were measured and incorporated
4
5 into the analysis, whether the method of dealing with confounding between patient groups
6
7 was adequate, whether a statistician was listed as an author of the study and whether the
8
9 data were collected prospectively following an agreed study design.
10

11 12 13 14 **Method of analysis**

15 We have presented the results separately for the three different types of comparisons.
16
17 Within each, due to the varied nature of the clinical conditions, study designs and level of
18
19 statistical adjustment, we decided a priori not to combine the results of individual studies in
20
21 a meta-analysis and instead present the results of the individual studies descriptively in the
22
23 text, tables and figures.
24
25
26
27

28 29 **Results**

30
31 Searches of MEDLINE and EMBASE identified 4318 possible records. 4272 did not meet the
32
33 eligibility criteria for this study. Full articles were retrieved for 46 studies; 14 further studies
34
35 were excluded as they did not fulfil our eligibility criteria (see Figure 1). Thirty two studies
36
37 were included in the review; 23 (3-26) studies assessed the effects of RBCT versus no RBCT,
38
39 five studies (27-31) assessed different volumes of RBCT and four (32-35) assessed giving
40
41 older versus newer RBCT.
42
43
44
45

46 47 **Red blood cell transfusion versus no red blood cell transfusion**

48
49 Twenty three studies (3-26) assessed the effects of RBCT versus no RBCT on mortality. Four
50
51 of these studies (4;8;10;17) included both red cell transfusion and other blood products (e.g.
52
53 platelets, plasma, cryoprecipitate); for one study, data were available separately for RBCT
54
55 and mortality (10). For three studies it was unclear if other blood products were transfused
56
57 along with red blood cells (7;9;18).
58
59
60

1
2
3
4
5 *Study characteristics (Table 1)*
6

7 Eight studies were prospective cohort studies following up a planned group of patients
8 (3;4;11;12;14;20-23), the other 15 studies assessed data from a retrospective patient
9 registry or database. Fourteen studies were conducted in the USA, two in the UK, two in
10 Israel and the remainder in Belgium, the Netherlands, Iran and Denmark; one study was
11 conducted in multiple countries. The time period assessed was between 1989 and 2008.
12 Twelve of the studies (3;5;7;8;11-14;16-18;20;22) specifically looked at adults undergoing
13 cardiac surgery, five were in patients in the intensive care unit (6;21;23;25;26), two were in
14 adults trauma patients (4;24), two were in patients following hip fracture/replacement
15 (9;15) one was in oncology patients (10) and the other in pediatric trauma patients (19).
16 Three of the studies (8;16;17) specifically looked at the effects of RBCT in older adults (e.g. >
17 60 years). The size of the studies varied from 1,624 participants to 504,208 participants with
18 an overall median sample size of 4344 (IQR 2085 to 11963); median 1068 (IQR 430 to 5812)
19 for patients undergoing RBCT compared to median 2325 (IQR 1636 to 6151) for patient with
20 no RBCT. The time period at which mortality was assessed also varied across studies from in-
21 hospital to mortality at seven years; the most common time point being mortality at or
22 within 30 days. Several studies reported mortality for more than one time period. Only
23 seven of the 23 studies provided any mention of guidelines for the prescription of RBCT; two
24 studies said no formal protocol was used (4;19), two studies stated a hemoglobin of <8g/dl
25 (6;9), one study stated a hematocrit of less than 25-26% (18) and two studies said
26 prescription was at the discretion of the patient care team (20;21). For full details of the
27 characteristics of the included studies see Appendix 2.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52
53
54
55 *Statistical methods (Table 2)*
56
57
58
59
60

1
2
3 All 23 studies provided information on the statistical methods used to adjust for differences
4 in the baseline characteristics of patients who received RBCT and those who did not.
5 However, the amount of detail and appropriateness of the method used varied across
6 studies. In 13 studies (3;5;6;10-15;18;20;21;23;26) the choices of covariates measured were
7 reported as pre-specified and not data driven, but this was unclear for the remaining 10
8 studies. The number of covariates measured and incorporated in the analysis also varied
9 across studies with half the studies reported to assess more than 20 different covariates.
10 Despite the high number of covariates assessed in these studies, not all measured covariates
11 which appeared to be of specific importance in relation to RBCT. All of the 23 studies did
12 report measuring the age and sex of the patients and 21 reported measuring patient co-
13 morbidity. Overall, only eight (3;7;8;11-14;18;25) studies measured and incorporated the
14 covariates age, sex, smoking, co-morbidity and haemoglobin level into the adjusted analysis..
15 Fourteen of the 23 studies reported using logistic regression (i.e. mortality was reported as a
16 binary outcome) as the method of adjusting for differences in the baseline characteristics
17 between the two patients groups; six studies reported using Cox proportional hazard (i.e.
18 mortality was reported as a time to event outcome) and three studies reporting using both
19 methods; in these three studies mortality was assessed for more than one time period. For
20 full details of the statistical methods see Appendix 3.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Presentation of adjusted and unadjusted results (Table 3)*

45
46 There were marked differences in the presentation and reporting of the unadjusted and
47 adjusted results when comparing the effects of RBCT versus no RBCT on mortality. Seven of
48 the 23 studies reported a summary statistic for each group for both the unadjusted and
49 adjusted analysis. Five studies reported a summary statistics for only the unadjusted analysis
50 and one study for the adjusted analysis only; no summary statistic comparing the effects of
51 RBCT versus no RBCT on mortality was reported in the remained 10 studies. Eight studies
52
53
54
55
56
57
58
59
60

1
2
3 reported the treatment effect (e.g. odds ratio, risk ratio, hazard ratio) and the corresponding
4
5 confident interval (six studies) for both the unadjusted and adjusted analysis (3;11;12;14-
6
7 16;20;22;26), whereas 12 studies reported the treatment effect and confident interval (10
8
9 studies) for adjusted analysis only and one study for the unadjusted analysis only. Where
10
11 possible we calculated the odds ratio for the effect of RBCT on mortality for unadjusted
12
13 analyses if it was not reported in the published article.
14
15

16
17
18 Seventeen of the 23 studies reported a statistically significant result for the unadjusted
19
20 analysis, and 15 for the adjusted analysis (Figure 2), when comparing the effect of RBCT
21
22 versus no RBCT on mortality, with more deaths occurring in patients receiving transfusion.
23
24 This effect was statistically non-significant in seven studies based on the result of the
25
26 adjusted analysis. Prospective studies were more likely to show a statistically significant
27
28 effect for blood transfusion on mortality compared to retrospective studies for both the
29
30 unadjusted and adjusted analysis. For full details see Appendix 4.
31
32

33 34 35 **Volume 'A' red blood versus volume 'B' red blood cells**

36
37 Five studies (27-31) assessed the effect of different volumes of RBCT on mortality. One of
38
39 these studies (31) included both RBCT and other blood products.
40
41

42 43 44 *Study characteristics (Table 1)*

45
46 One study assessed a prospective cohort and followed up a planned group of patients (31),
47
48 the other four studies assessed data from a retrospective patient registry or database. Two
49
50 of the studies (29;31) specifically looked at adults undergoing cardiac surgery, one was in
51
52 trauma patients (28), one was in patients undergoing major surgery (27) and one in patients
53
54 in the intensive care unit (30). The size of the studies varied from 1,841 participants to
55
56 125,177 participants, with an overall median sample size of 8215 (IQR 3037 to 8799). The
57
58
59
60

1
2
3 volume of RBCT varied considerably across studies from 1-2 units to more than eight units.
4
5 The time period at which mortality was assessed also varied across studies from in-hospital
6
7 to mortality at eight years. Three of the five studies provided any mention of guidelines for
8
9 the prescription of red blood cells, however only one gave any specific requirement stating a
10
11 hemoglobin of <8g/dl (30) (See Appendix 2).
12

13 14 15 16 *Statistical methods (Table 2)*

17
18 All five studies provided information on the statistical methods used to adjust for differences
19
20 in the baseline characteristics of patients who received different volumes of red blood
21
22 transfusion, however, as with the studies of RBCT versus no RBCT, the amount of detail and
23
24 appropriateness of the method used varied across studies. In all five studies (27-31) the
25
26 choices of covariates measured were reported as pre-specified. The number of covariates
27
28 measured and incorporated in the analysis varied across studies with two the studies
29
30 reported to assess more than 20 different covariates. Once again, despite the high number
31
32 of covariates assessed in these studies, not all measured covariates seem to be of specific
33
34 importance in relation to RBCT. All five studies reported measuring age and sex and patient
35
36 co-morbidity, however, one (27) measured and incorporated the covariates age, sex,
37
38 smoking, co-morbidity and hemoglobin level into the adjusted analysis.
39
40
41
42
43

44 *Presentation of adjusted and unadjusted results (Table 3)*

45
46 As with the studies of RBCT versus no RBCT, there were marked difference in the
47
48 presentation and reporting of the unadjusted and adjusted results when comparing the
49
50 effects of different volumes of RBCT on mortality. Two studies reported a statistically
51
52 significant result for the adjusted analysis with more deaths occurring in patients receiving
53
54 larger volumes of RBCT. This effect was statistically non significant in two studies based on
55
56 the result for adjusted analysis and was not reported for the remaining one study. No
57
58
59
60

1
2
3 studies reported on the statistical significance of the result of the unadjusted analysis (See
4
5 Appendix 3 and 4).
6
7
8

9 **'Older' red blood cells versus 'newer' red blood cells**

10
11 Four (32-35) studies assessed the effects of age of RBCT on mortality, one of which
12 specifically looked at leukodepleted RBCT (35).
13
14

15 *Study characteristics (Table 1)*

16
17 All four studies assessed data from a retrospective patient registry or database. Two of the
18 studies (33;34) specifically looked at adults undergoing cardiac surgery, one was in trauma
19 patients (35), while the other did not mention a specific patient group. The size of the
20 studies varied from 1,813 participants to 364,037 participants, with an overall median
21 sample size of 4358 (IQR 2264 to 185019). The period of time in which the blood was stored
22 varied considerably across studies. Two studies (33;35) assessed RBCT stored for less than 14
23 days compared to those stored for more than 14 days, one study (34) compared blood
24 stored for less than 18 days and with blood stored for more than 18 days and one study (32)
25 looked at multiple storage periods ranging from 1 to 42 days. None of the studies provided
26 any mention of guidelines for the prescription of red blood cells (See Appendix 2).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 *Statistical methods (Table 2)*

45
46 All four studies provided information on the statistical methods used to adjust for
47 differences in the baseline characteristics of patients who received RBCT stored for different
48 time periods, however, once again the amount of detail and appropriateness of the method
49 used varied across studies. The number of covariates measured and incorporated in the
50 analysis also varied across studies. All of the four studies reported measuring the age and
51 sex of the participants. Only one study reported measuring smoking status, two studies
52
53
54
55
56
57
58
59
60

1
2
3 reported measuring patient hemoglobin levels and three studies reported assessing patient
4
5 co-morbidities. Only one (33) of the four studies measured and incorporated the covariates
6
7 age, sex, smoking, co-morbidity and haemoglobin level into the adjusted analysis.
8
9

10 11 *Presentation of adjusted and unadjusted results (Table 3)*

12
13 As with the studies of RBCT versus no RBCT and of volume 'A' red blood cells versus volume
14
15 'B' RBCT, there were marked differences in the presentation and reporting of the unadjusted
16
17 and adjusted results when comparing the effects of RBCT stored for different time periods
18
19 on mortality. Two studies reported a statistically significant result for the unadjusted
20
21 analysis and one study reported a statistically significant result for the adjusted analysis. In
22
23 two of these three studies there were more deaths occurring in patients receiving older
24
25 blood and in one study there were more deaths in patients receiving newer blood. This
26
27 effect was statistically non significant in three studies based on the result for adjusted
28
29 analysis (See Appendix 3 and 4).
30
31
32
33
34

35 **Assessment of methodological quality (Table 4)**

36
37 Overall the assessment of methodological quality varied across studies and by study group
38
39 with only 10 of the 32 included studies assessing a prospective cohort following up a
40
41 planned group of patients over time, the remaining two-third of the studies assessed data
42
43 from a retrospective patient registry or database. In most studies the sample of patients
44
45 included in the study was considered representative of those to whom the results might be
46
47 generalised. Four studies (8;16;17;25) specifically focussed on older adults (>60 years) and
48
49 one study (19) on children, so the findings from these studies should only be interpreted in
50
51 relation to these specific patient groups. The baseline characteristics of patients who
52
53 received RBCT compared to those patients who did not receive RBCT (or patients who
54
55 received different volumes or age of blood) were often very different and so we wanted to
56
57
58
59
60

1
2
3 assess whether studies had adjusted for these differences when carrying out their statistical
4
5 analysis. Only 10 studies measured and incorporated in the analysis covariates which we
6
7 deemed of specific importance in relation to RBCT (i.e. age, sex, smoking, co-morbidity and
8
9 haemoglobin level), thus we deemed the method of dealing with confounding between
10
11 patient groups as adequate in only 31% of studies. Critically however, when we restricted
12
13 our analysis of results to studies with adequate methods, the pattern of an increase in
14
15 mortality associated with RBCT remained unchanged.
16
17
18
19

20 Discussion

21 *Summary of main findings*

22
23 We identified 32 observational studies of more than 1000 participants published between
24
25 2006 and 2010 assessing the effect of RBCT on mortality. Twenty three studies compared
26
27 RBCT versus no RBCT, five compared different volumes and four compared different storage
28
29 times. Overall there was considerable variability in the characteristics of the observational
30
31 studies. However, the majority, of studies were retrospective designs assessing patients
32
33 from an existing patient register or database.
34
35
36
37
38
39

40 We also identified considerable variability in the statistical methods used to adjust for
41
42 differences in the baseline characteristics of patients who received RBCT and those who did
43
44 not. It was often unclear if the choice of covariates measured and used in the adjusted
45
46 analyses were pre-specified at the start of the study or were driven by the underlying data.
47
48 Perhaps most importantly, around half of the 32 studies did not measure and adjust for
49
50 covariates which we deemed of specific importance to blood transfusion - for example,
51
52 patient hemoglobin levels, age, sex and existing co-morbidities. Less than a third of studies
53
54 assessed smoking which, while not directly correlated with transfusion, is an important
55
56 covariate when assessing mortality.
57
58
59
60

1
2
3
4
5 Overall, more studies found a higher rate of mortality in patients receiving RBCT compared
6
7 with those who did not, and this effect was seen in both the adjusted and unadjusted
8
9 results. In general, where measured equivalently within the same study, the unadjusted
10
11 estimate of risk was greater than the adjusted risk, emphasising that adverse prognostic
12
13 factors are more common in patients receiving RBCT and that adjusting for them leads to a
14
15 smaller estimate of risk. Considering the adjusted risks, although the size of the effect was
16
17 not consistent across all studies, the direction of the effect was. Most studies suggest an
18
19 increased risk of mortality associated with RBCT. Further, those studies which were designed
20
21 prospectively and which used better methods of adjusting for differences in the baseline
22
23 characteristics between groups were more likely to show an increase in the risk of mortality
24
25 compared to studies which were based on retrospective registries or databases, although,
26
27 again the size of the effect was not consistent across all studies. However, it is important to
28
29 remember that even with the best methods of adjustment it cannot completely eliminate
30
31 the impact of confounding (2), as the sicker the patients (thus an increased risk of mortality)
32
33 the more likely they are to have received RBCT.
34
35
36
37
38
39

40 *Comparison with other studies*

41
42 We are aware of one other systematic review of observational studies looking at the effects
43
44 of RBCT on mortality, which focussed specifically on critically ill adults in intensive care units
45
46 and adult trauma and surgical patients (36). This systematic review by Marik and colleagues
47
48 included more studies (n=45) than our review as it did not restrict its inclusion criteria to
49
50 studies with >1000 patients; the median number of patients analysed was 687. They also
51
52 found that RBCT was associated with an increased risk of mortality based on a meta-analysis
53
54 of 12 studies (odds ratio 1.7; 95% CI 1.4 to 1.9). However there was considerable
55
56 heterogeneity in the meta-analysis, suggesting that it might not have been appropriate to
57
58
59
60

1
2
3 combine the results of the individual studies and supports our decision not to conduct a
4
5 meta-analysis.
6
7

8
9
10 In an overview of evidence from randomized controlled trials Wilkinson and colleagues (37)
11 identified 142 trials in RBCT. The majority compared the effects of leucoreduced RBCT or
12 different transfusion triggers (n=71). However, they did identify 12 trials comparing the
13 effects of RBCT versus no transfusion, seven looking at different volumes of RBCT and 11
14 different ages of red blood cells. The size of the trials was very small (median 30 to 40
15 patients) and the overview did not specifically examine the effect of RBCT on mortality.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Currently, we are aware of at least 14 ongoing or recently completed randomized controlled trials examining the effects of the age of RBCT on clinical outcomes including the ARIPI (Age of Red blood cells In Premature Infants) (38) ABLE, (Age of BLOOD Evaluation trial in the resuscitation of critically ill patients) (39), RECESS (REd CELL Storage duration Study) (40) and INFORM (Effects of transfusing fresh versus standard-issue red cells on in-hospital mortality) trials, for which mortality or survival is a specified outcome measure.

Limitations

Our study has several limitations. Firstly, we only included studies published in the last five years and which included more than 1,000 patients. This was because we hypothesised that studies with a larger sample size are more likely to show a truer effect of the intervention (41) and that more recent studies are more likely to use better statistical methods. It is possible therefore that the overall effect seen here might be different in older studies and/or in those carried out in smaller numbers of patients. Secondly, we decided not to combine the results of individual studies because of the variability in clinical settings and study methods, and instead presented the results of individual studies descriptively in the text and in tables and figures. More formal statistical analysis might have given a more

1
2
3 precise indication of the overall effect of red cell transfusion on mortality, but would have
4
5 ignored the significant amount of clinical and methodological heterogeneity between
6
7 studies which we identified a priori and which was very apparent in the analysis done by
8
9 Marik and colleagues (36). However, in the absence of a more formal statistical analysis we
10
11 have inevitably had to rely on a vote-counting approach which also has great dangers,
12
13 particularly the assumption that each included study has equal weight. Our main protection
14
15 against this is the very pronounced nature of the pattern we have observed and the fact that
16
17 we have limited our conclusions to the direction of effect.
18
19

20
21
22 Finally, we limited our inclusion criteria to published articles and excluded unpublished
23
24 studies or those published only as conference abstracts; thus our study could be subject to
25
26 publication bias , as studies which did not show a significant effect of red cell transfusion on
27
28 mortality might be less likely to be published in full (42). Outcome reporting bias may also be
29
30 a problem, although difficult to combat, in the case where a risk has been measured at
31
32 different time points but only those time points which are “positive” are reported. However,
33
34 in the case of both publication and outcome reporting bias, the extreme nature of the
35
36 pattern makes it relatively implausible that there are sufficient unpublished studies or time
37
38 points to reverse it.
39
40
41
42

43 44 *Conclusion*

45
46 The findings from this systematic review of recent large scale observational studies show
47
48 considerable variability in the patient populations and study methods when comparing the
49
50 effects of RBCT on mortality. Overall, observational studies do show a consistent adverse
51
52 effect of RBCT on mortality. Although it seems unlikely that this can be entirely explained by
53
54 selective sampling or a predominance of poorer quality observational studies, it remains
55
56 possible that even the best conducted adjustments cannot completely eliminate the impact
57
58
59
60

1
2
3 of confounding, particularly when investigating the effect of RBCT. We therefore believe that
4
5 this can only be resolved through well designed and adequately powered randomized
6
7 controlled trials. Before these can be conducted, the importance of the research question
8
9 and the uncertainty of the current evidence need to be accepted. This requires clearer and
10
11 more widespread presentation and understanding of the existing research evidence, to
12
13 which we believe this study is a significant contribution.
14
15

16
17
18 **Author contributions:** SH and OO were involved in the design, implementation, and analysis
19
20 of the study and in writing the final manuscript. CH, MM and LY were involved in the design
21
22 and analysis of the study and in writing the final manuscript.
23

24
25 **Financial disclosures:** None reported.
26

27
28 **Funding/support:** This study was funded by NHS Blood and Transplant, Research and
29
30 Development, UK.

31
32 **Additional contributions:** We are grateful to Susan Brunskill for her helpful comments on
33
34 this manuscript.

35
36 **Data Sharing:** We are willing to share data from our study.
37

38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

References

- (1) Blajchman MA. Landmark studies that have changed the practice of transfusion medicine. *Transfusion* 2005 September;45(9):1523-30.
- (2) Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG. Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7(27):iii-173.
- (3) Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H. Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. *Am J Cardiol* 2008 July 15;102(2):115-9.
- (4) Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Meyer W, Scalea TM. Outcome analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted study. *World J Surg* 2008 October;32(10):2185-9.
- (5) Engoren M, Habib RH, Hadaway J, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A. The effect on long-term survival of erythrocyte transfusion given for cardiac valve operations. *Ann Thorac Surg* 2009 July;88(1):95-100, 100.

- 1
2
3 (6) Engoren M, Arslanian-Engoren C. Long-term survival in the intensive care unit after
4 erythrocyte blood transfusion. *Am J Crit Care* 2009 March;18(2):124-31.
- 5
6 (7) Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, Mittelman M, Battler
7 A, Shotan A, Gottlieb S, Caspi A, Hasdai D. Blood transfusion for acute
8 decompensated heart failure--friend or foe? *Am Heart J* 2009 October;158(4):653-8.
- 9
10 (8) Jani SM, Smith DE, Share D, Kline-Rogers E, Khanal S, O'Donnell MJ, Gardin J,
11 Moscucci M. Blood transfusion and in-hospital outcomes in anemic patients with
12 myocardial infarction undergoing percutaneous coronary intervention. *Clin Cardiol*
13 2007 October;30(10 Suppl 2):II49-II56.
- 14
15 (9) Johnston P, Wynn-Jones H, Chakravarty D, Boyle A, Parker MJ. Is perioperative blood
16 transfusion a risk factor for mortality or infection after hip fracture? *J Orthop*
17 *Trauma* 2006 November;20(10):675-9.
- 18
19 (10) Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood
20 transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch*
21 *Intern Med* 2008 November 24;168(21):2377-81.
- 22
23 (11) Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone
24 EH. Morbidity and mortality risk associated with red blood cell and blood-
25 component transfusion in isolated coronary artery bypass grafting. *Crit Care Med*
26 2006 June;34(6):1608-16.
- 27
28 (12) Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion
29 in coronary artery bypass grafting is associated with reduced long-term survival. *Ann*
30 *Thorac Surg* 2006 May;81(5):1650-7.
- 31
32 (13) Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased
33 mortality, postoperative morbidity, and cost after red blood cell transfusion in
34 patients having cardiac surgery. *Circulation* 2007 November 27;116(22):2544-52.
- 35
36 (14) Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ,
37 Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of
38 blood transfusion after primary angioplasty for acute myocardial infarction: analysis
39 from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late
40 Angioplasty Complications) Trial. *JACC Cardiovasc Interv* 2009 July;2(7):624-32.
- 41
42 (15) Pedersen AB, Mehnert F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and
43 prognosis following total hip replacement: a population-based follow up study. *BMC*
44 *Musculoskelet Disord* 2009;10:167.
- 45
46 (16) Rogers MA, Blumberg N, Saint SK, Kim C, Nallamotheu BK, Langa KM. Allogeneic blood
47 transfusions explain increased mortality in women after coronary artery bypass graft
48 surgery. *Am Heart J* 2006 December;152(6):1028-34.
- 49
50 (17) Rogers MA, Blumberg N, Saint S, Langa KM, Nallamotheu BK. Hospital variation in
51 transfusion and infection after cardiac surgery: a cohort study. *BMC Med* 2009;7:37.
- 52
53 (18) Salehiomran A, Ahmadi H, Karimi A, Tazik M, Dowlatshahi S, Fathollahi M.S., Abbasi
54 S.H. Transfusion associated in-hospital mortality and morbidity in isolated coronary
55 artery bypass graft surgery. *Central European Journal of Medicine* 2009;4(3):286-92.
- 56
57
58
59
60

- 1
2
3 (19) Stone TJ, Riesenman PJ, Charles AG. Red blood cell transfusion within the first 24
4 hours of admission is associated with increased mortality in the pediatric trauma
5 population: a retrospective cohort study. *J Trauma Manag Outcomes* 2008;2(1):9.
6
7 (20) Surgenor SD, Kramer RS, Olmstead EM, Ross CS, Sellke FW, Likosky DS, Marrin CA,
8 Helm RE, Jr., Leavitt BJ, Morton JR, Charlesworth DC, Clough RA, Hernandez F,
9 Frumiento C, Benak A, DioData C, O'Connor GT. The association of perioperative red
10 blood cell transfusions and decreased long-term survival after cardiac surgery.
11 *Anesth Analg* 2009 June;108(6):1741-6.
12
13 (21) Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K,
14 Cappadoro C, Fu M, Plisco MS, Sadaka FG, Veremakis C. Red blood cell transfusions
15 and nosocomial infections in critically ill patients. *Crit Care Med* 2006
16 September;34(9):2302-8.
17
18 (22) van Straten AH, Bekker MW, Soliman Hamad MA, van Zundert AA, Martens EJ,
19 Schonberger JP, de Wolf AM. Transfusion of red blood cells: the impact on short-
20 term and long-term survival after coronary artery bypass grafting, a ten-year follow-
21 up. *Interact Cardiovasc Thorac Surg* 2010 January;10(1):37-42.
22
23 (23) Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated
24 with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients
25 study. *Anesthesiology* 2008 January;108(1):31-9.
26
27 (24) Weinberg JA, McGwin G, Jr., Marques MB, Cherry SA, III, Reiff DA, Kerby JD, Rue LW,
28 III. Transfusions in the less severely injured: does age of transfused blood affect
29 outcomes? *J Trauma* 2008 October;65(4):794-8.
30
31 (25) Wu WC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G, Mor V, Sharma SC,
32 Vezeridis M, Khuri SF, Friedmann PD. Operative blood loss, blood transfusion, and
33 30-day mortality in older patients after major noncardiac surgery. *Ann Surg* 2010
34 July;252(1):11-7.
35
36 (26) Zilberberg MD, Stern LS, Wiederkehr DP, Doyle JJ, Shorr AF. Anemia, transfusions
37 and hospital outcomes among critically ill patients on prolonged acute mechanical
38 ventilation: a retrospective cohort study. *Crit Care* 2008;12(2):R60.
39
40 (27) Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB.
41 Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with
42 increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general
43 surgery patients. *J Am Coll Surg* 2009 May;208(5):931-7, 937.
44
45 (28) Charles A, Shaikh AA, Walters M, Huehl S, Pomerantz R. Blood transfusion is an
46 independent predictor of mortality after blunt trauma. *Am Surg* 2007
47 January;73(1):1-5.
48
49 (29) O'Keeffe SD, Davenport DL, Minion DJ, Sorial EE, Endean ED, Xenos ES. Blood
50 transfusion is associated with increased morbidity and mortality after lower
51 extremity revascularization. *J Vasc Surg* 2010 March;51(3):616-21, 621.
52
53 (30) Ruttinger D, Wolf H, Kuchenhoff H, Jauch KW, Hartl WH. Red cell transfusion: an
54 essential factor for patient prognosis in surgical critical illness? *Shock* 2007
55 August;28(2):165-71.
56
57
58
59
60

- 1
2
3 (31) Weightman WM, Gibbs NM, Sheminant MR, Newman MA, Grey DE. Moderate
4 exposure to allogeneic blood products is not associated with reduced long-term
5 survival after surgery for coronary artery disease. *Anesthesiology* 2009
6 August;111(2):327-33.
7
- 8 (32) Edgren G, Kamper-Jorgensen M, Eloranta S, Rostgaard K, Custer B, Ullum H, Murphy
9 EL, Busch MP, Reilly M, Melbye M, Hjalgrim H, Nyren O. Duration of red blood cell
10 storage and survival of transfused patients (CME). *Transfusion* 2010
11 June;50(6):1185-95.
12
- 13 (33) Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH.
14 Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*
15 2008 March 20;358(12):1229-39.
16
- 17 (34) van de Watering L, Lorinser J, Versteegh M, Westendorp R, Brand A. Effects of
18 storage time of red blood cell transfusions on the prognosis of coronary artery
19 bypass graft patients. *Transfusion* 2006 October;46(10):1712-8.
20
- 21 (35) Weinberg JA, McGwin G, Jr., Griffin RL, Huynh VQ, Cherry SA, III, Marques MB, Reiff
22 DA, Kerby JD, Rue LW, III. Age of transfused blood: an independent predictor of
23 mortality despite universal leukoreduction. *J Trauma* 2008 August;65(2):279-82.
24
- 25 (36) Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a
26 systematic review of the literature. *Crit Care Med* 2008 September;36(9):2667-74.
27
- 28 (37) Wilkinson KL, Brunskill SJ, Doree C, Hopewell S, Stanworth S, Murphy MF, Hyde C.
29 The clinical effects of red blood cell transfusions: an overview of the randomized
30 controlled trials evidence base. *Transfus Med Rev* 2011 April;25(2):145-55.
31
- 32 (38) Fergusson D, Hutton B, Hogan DL, LeBel L, Blajchman MA, Ford JC, Hebert P,
33 Kakadekar A, Kovacs L, Lee S, Sankaran K, Shapiro S, Smyth JA, Ramesh K, Bouali NR,
34 Tinmouth A, Walker R. The age of red blood cells in premature infants (ARIPi)
35 randomized controlled trial: study design. *Transfus Med Rev* 2009 January;23(1):55-
36 61.
37
- 38 (39) Lacroix J, Hebert P, Fergusson D, Tinmouth A, Blajchman MA, Callum J, Cook D,
39 Marshall JC, McIntyre L, Turgeon AF. The Age of Blood Evaluation (ABLE) randomized
40 controlled trial: study design. *Transfus Med Rev* 2011 July;25(3):197-205.
41
- 42 (40) Steiner ME, Assmann SF, Levy JH, Marshall J, Pulkrabek S, Sloan SR, Triulzi D, Stowell
43 CP. Addressing the question of the effect of RBC storage on clinical outcomes: the
44 Red Cell Storage Duration Study (RECESS) (Section 7). *Transfus Apher Sci* 2010
45 August;43(1):107-16.
46
- 47 (41) Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show
48 larger treatment effects than multicenter trials: evidence from a meta-epidemiologic
49 study. *Ann Intern Med* 2011 July 5;155(1):39-51.
50
- 51 (42) Scherer RW, Langenberg P, von EE. Full publication of results initially presented in
52 abstracts. *Cochrane Database Syst Rev* 2007;(2):MR000005.
53
54
55
56
57
58
59
60

Figure 1: Flow diagram of study inclusion (1 January 2006 to 31 December 2010)




Figure 2: Effect of red blood cell transfusion versus no red blood cell transfusion on mortality (adjusted results)




Table 1: Summary of characteristics of included studies

Type of comparison	RBC vs. no RBC (n=23)	Volume 'A' vs. Volume 'B'(n=5)	Old RBC vs. new RBC (n=4)
Design			
Prospective	8 (35%)	1 (20%)	
Retrospective	15 (65%)	4 (80%)	4 (100%)
Country			
Australia		1 (20%)	
Belgium	1 (4%)		
Denmark	1 (4%)		
Germany		1 (20%)	
Iran	1 (4%)		
Israel	2 (9%)		
Netherlands	1 (4%)		1 (25%)
Sweden			1 (25%)
USA	14 (61%)	3 (60%)	2 (50%)
UK (multiple sites)	2 (9%) 1 (4%)		
Time period assessed			
	1989-2008	1993-2007	1993-2007
Sample size (median, IQR)			
All patients	4344 (IQR 2085-11963)	8215 (IQR 3037-8799)	4358 (2264-185019)
RBC transfusion	1068 (IQR 430-5812)		
No RBC transfusion	2325 (IQR 1636-6151)		
Disease area			
Cardiac surgery	12 (52%)	2 (40%)	2 (50%)
Hip fracture/replacement	2 (9%)		
Intensive care	5 (22%)	1 (20%)	
Oncology	1 (4%)		
Surgery		1 (20%)	
Trauma adults	2 (9%)	1 (20%)	1 (25%)
Trauma paediatrics	1 (4%)		
Not reported			1 (25%)
Prescribing guidance			
Reported	7 (30%)	3 (60%)	
Not reported	16 (70%)	2 (40%)	4 (100%)
Mortality assessed*			
In hospital	8	2	2
30 days	10	2	1
3 months	3		
6 months	3		
>1 year	4	1	2
Time period not specified	2		1

*studies reported mortality for >1 time point based on binary only and / or time-to-event outcome

Table 2: Method of adjusted analysis

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Choice of covariates			
Pre-specified	13 (57%)	5 (100%)	4 (100%)
Post hoc			
Unclear	10 (43%)		
No. of covariates measured			
1-5	2 (9%)		
6-10	4 (17%)	1 (20%)	2 (50%)
11-20	3 (13%)	2 (40%)	
>20	12 (52%)	2 (40%)	1 (25%)
Unclear	2 (9%)		1 (25%)
Important covariates assessed			
Age	23 (100%)	5 (100%)	4 (100%)
Sex	23 (100%)	5 (100%)	4 (100%)
Smoking	8 (35%)	1 (20%)	1 (25%)
Co-morbidity	21 (91%)	5 (100%)	3 (75%)
Hb level	14 (61%)	4 (80%)	2 (50%)
Important covariates incorporated into analysis			
Yes	8 (35%)	1 (20%)	1 (25%)
No	15 (65%)	4 (80%)	3 (75%)
Method of adjustment			
Cox proportional hazard	6 (26%)	1 (20%)	1 (25%)
Logistic regression	14 (61%)	4 (80%)	2 (50%)
Both *	3 (13%)		
Not reported			1 (25%)

*studies reported >1 method of adjustment when mortality was assessed for >1 time point

Table 3: Presentation of results for unadjusted and adjusted analysis (mortality)

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Summary statistic for each group			
Unadjusted only	5 (22%)	2 (40%)	
Adjusted only	1 (4%)		
Both	7 (30%)		1 (25%)
Not reported	10 (44%)	3 (60%)	3 (75%)
Treatment effect			
Unadjusted only	1 (4%)		
Adjusted only	12 (52%)	5 (100%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	2 (9%)		1 (25%)
Confidence interval of treatment effect			
Unadjusted only			
Adjusted only	10 (43%)	3 (60%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	5 (22%)	2 (40%)	1 (25%)
P-value for treatment effect			
Unadjusted only	7 (30%)		
Adjusted only		1 (20%)	
Both	1 (4%)		1 (25%)
Not reported	15 (66%)	4 (80%)	3 (75%)
Unadjusted analysis*			
Statistically significant	17 (74%)		2 (50%)
Statistically non-significant	1 (4%)		
Not reported	5 (22%)	5 (100%)	2 (50%)
Adjusted analysis*			
Statistically significant	15 (65%)	2 (40%)	1 (25%)
Statistically non-significant	7 (31%)	2 (40%)	3 (75%)
Not reported	1 (4%)	1 (20%)	

*mortality outcome – if >1 time point analysed the time point with the non-significant result was recorded

Table 4: Assessment of methodological quality of the included studies

Study ID	Data collected prospectively	Sample representative	Important covariates measured	Important covariates incorporated into analysis	Method of dealing with confounding adequate*
Aronson 2008 (3)	Yes	Unclear	Yes	Yes	Yes
Bernard 2009 (27)	No	Yes	Yes	Yes	Yes
Bochicchio 2008 (4)	Yes	Yes	No	No	No
Charles 2007 (28)	No	Yes	No	No	No
Edgren 2010 (32)	No	Yes	No	No	No
Engoren 2009 (5)	No	Yes	No	No	No
Engoren 2009 (6)	No	Yes	No	No	No
Garty 2009 (7)	No	Yes	Yes	Yes	Yes
Jani 2007 (8)	No	No (>60 years)	Yes	Yes	Yes
Johnson 2006 (9)	No	Unclear	No	No	No
Khorana 2008 (10)	No	Yes	No	No	No
Koch 2006 (11,12)	Yes	Yes	Yes	Yes	Yes
Koch 2008 (33)	No	Yes	Yes	Yes	Yes
Murphy 2007 (13)	No	Yes	Yes	Yes	Yes
Nikolsky 2009 (14)	Yes	Yes	Yes	Yes	Yes
O'Keefe 2010 (29)	Yes	Yes	No	No	No
Pederson 2009 (15)	No	Yes	No	No	No
Rogers 2006 (16)	No	No (>65 years)	No	No	No
Rogers 2009 (17)	No	No (> 65 years)	No	No	No
Ruttinger 2007 (30)	No	Yes	No	No	No
Salehiomran 2009 (18)	No	Yes	Yes	Yes	Yes
Stone 2008 (19)	No	No (< 16 years))	No	No	No
Surgenor 2009 (20)	Yes	Yes	No	No	No
Taylor 2006 (21)	Yes	Yes	No	No	No
van de Watering 2006 (34)	No	Yes	No	No	No
van Straten 2010 (22)	Yes	Yes	No	No	No
Vincent 2008 (23)	Yes	Yes	No	No	No
Weightman 2009 (31)	Yes	Yes	No	No	No
Weinburg 2008 (24)	No	Yes	No	No	No
Weinburg 2008 (35)	No	Yes	No	No	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Wu 2010 (25)	No	No (> 65 years)	Yes	Yes	Yes
Zilberberg 2008 (26)	No	Yes	No	No	No

*The method of dealing with confounding was deemed adequate if important covariates were measured and adjusted for in the analysis.

For peer review only

APPENDIX 1: Search strategies**MEDLINE (Ovid)**

1. ERYTHROCYTE TRANSFUSION/
2. *BLOOD TRANSFUSION/
3. (hemotransfus* or haemotransfus*).tw.
4. ((transfus* or retransfus*) adj1 (trigger* or level* or threshold* or rule* or restrict* or limit*)).tw.
5. (transfusion* adj1 (management or practice* or polic* or strateg* or guideline* or indication* or protocol* or criteri*)).tw.
6. ((blood adj1 management) or (management adj1 blood) or (blood adj1 support) or (blood adj1 requirement*)).tw.
7. ((red cell* adj1 management) or (red cell* adj1 support) or (red cell adj1 requirement*)).tw.
8. (blood adj1 need*).tw. or transfus*.ti.
9. or/1-8
10. BLOOD TRANSFUSION/
11. ERYTHROCYTES/
12. (red cell* or red blood cell* or erythrocyte* or RBC*).tw.
13. 11 or 12
14. 10 and 13
15. (critical* or intensive or trauma or surg* or injur* or postinjur* OR organ failure* OR sepsis or septic OR infection* OR infectious OR ARDS OR acute respiratory distress OR multiorgan).ti. and transfus*.ab.
16. 9 or 14 or 15
17. BLOOD PRESERVATION/
18. transfus*.mp.
19. 17 and 18
20. ((storage or stored or storing or age* or aging or old or older or duration or fresh* or preserv* or conserv*) adj2 (whole blood or red blood cell* or red cell* or RBC*)).tw. and transfus*.mp.
21. (fresh blood or new blood or old* blood or fresh red blood cells or new red blood cells or old* red blood cells or fresh red cells or new red cells or old* red cells).tw.
22. 16 or 19 or 20 or 21
23. PROGNOSIS/
24. DISEASE FREE SURVIVAL/
25. exp CRITICAL CARE/
26. TREATMENT FAILURE/
27. exp MORTALITY/
28. SURVIVAL/
29. SURVIVAL ANALYSIS/
30. RISK ASSESSMENT/ or RISK FACTORS/
31. TREATMENT OUTCOME/
32. (survival* or survivor* or nonsurvivor* or survived or surviving).ti,ab.
33. ((predictor* or prediction*) adj1 death).tw.
34. (prognos* or mortality).tw.
35. (outcome* adj2 (therap* or treatment*)).ti,ab.
36. ((risk adj assessment) or (associated adj risk)).tw.
37. (risk* or association* or causalit* or causation or cause*).ti.
38. exp POSTOPERATIVE COMPLICATIONS/
39. exp INTRAOPERATIVE COMPLICATIONS/

40. or/23- 39
41. 22 and 40
42. BLOOD TRANSFUSION/ae, co, mo, ut or ERYTHROCYTE TRANSFUSION/ae, co, mo, ut
43. ((reaction* or effect* or efficac* or complication* or risk* or adverse* or hazard* or accident* or incident* or morbid* or death* or mortalit* or outcome*) adj3 (transfus* or postransfus* or RBC* or red cell* or erythrocyte*)).tw.
44. (transfus* or posttransfus*).ti.
45. or/41-44
46. EPIDEMIOLOGIC STUDIES/
47. exp CASE CONTROL STUDIES/
48. exp COHORT STUDIES/
49. (case* adj2 control*).tw.
50. cohort*.ti,ab.
51. (follow up adj (study or studies)).tw.
52. (observational adj2 (study or studies)).tw.
53. ((controlled adj2 trial*1) or (controlled adj2 stud*) or (comparative adj trial*) or (comparative adj stud*) or (comparison adj group*) or (comparator adj group*)).tw.
54. longitudinal.tw.
55. retrospective*.tw.
56. cross sectional.tw.
57. CROSS-SECTIONAL STUDIES/
58. Controlled clinical trial.pt.
59. CROSSOVER STUDIES/
60. Comparative study.pt.
61. CLINICAL TRIALS AS TOPIC/
62. exp CONTROLLED CLINICAL TRIALS AS TOPIC/
63. (nonrandomi* or (non adj randomi*)).tw.
64. or/46-63
65. 45 and 64

EMBASE (Ovid)

1. ERYTHROCYTE TRANSFUSION/
2. *BLOOD TRANSFUSION/ or *BLOOD COMPONENT THERAPY/
3. (hemotransfus* or haemotransfus*).tw.
4. ((transfus* or retransfus*) adj1 (trigger* or level* or threshold* or rule* or restrict* or limit*)).tw.
5. (transfusion* adj1 (management or practice* or polic* or strateg* or guideline* or indication* or protocol* or criteri*)).tw.
6. ((blood adj1 management) or (management adj1 blood) or (blood adj1 support) or (blood adj1 requirement*)).tw.
7. ((red cell* adj1 management) or (red cell* adj1 support) or (red cell adj1 requirement*)).tw.
8. (blood adj1 need*).tw. or transfus*.ti.
9. or/1-8
10. BLOOD TRANSFUSION/
11. ERYTHROCYTE/
12. (red cell* or red blood cell* or erythrocyte* or RBC*).tw.
13. 11 or 12
14. 10 and 13

15. (critical* or intensive or trauma or surg* or injur* or postinjur* OR organ failure* OR sepsis or septic OR infection* OR infectious OR ARDS OR acute respiratory distress OR multiorgan).ti. and transfus*.ab.
16. 9 or 14 or 15
17. BLOOD STORAGE/ or ERYTHROCYTE PRESERVATION/
18. transfus*.mp.
19. 17 and 18
20. ((storage or stored or storing or age* or aging or old or older or duration or fresh* or preserv* or conserv*) adj2 (whole blood or red blood cell* or red cell* or RBC*)).tw. and transfus*.mp.
21. (fresh blood or new blood or old* blood or fresh red blood cells or new red blood cells or old* red blood cells or fresh red cells or new red cells or old* red cells).tw.
22. 16 or 19 or 20 or 21
23. PROGNOSIS/
24. exp SURVIVAL/
25. exp INTENSIVE CARE/
26. exp TREATMENT OUTCOME/
27. exp EPIDEMIOLOGY/
28. RISK ASSESSMENT/ or
29. RISK BENEFIT ANALYSIS/ or RISK FACTOR/
30. RISK MANAGEMENT/
31. RISK REDUCTION/
32. (survival* or survivor* or nonsurvivor* or survived or surviving).ti,ab.
33. ((predictor* or prediction*) adj1 death).tw.
34. (prognos* or mortality).tw.
35. (outcome* adj2 (therap* or treatment*)).ti,ab.
36. (risk assessment or associated risk).tw.
37. (risk* or association* or causalit* or causation or cause*).ti.
38. exp POSTOPERATIVE COMPLICATION/
39. PEROPERATIVE COMPLICATION/
40. or/23-39
41. 22 and 40
42. ((reaction* or effect* or efficac* or complication* or risk* or adverse* or hazard* or accident* or incident* or morbid* or death* or mortalit* or outcome*) adj3 (transfus* or postransfus* or RBC* or red cell* or erythrocyte*)).tw.
43. (transfus* and posttransfus*).ti.
44. or/41-43
45. Clinical Study/
46. exp Case Control Study/
47. Family Study/
48. Longitudinal Study/
49. Retrospective Study/
50. Prospective Study/
51. Randomized Controlled Trials/
52. 50 not 51
53. Cohort Analysis/
54. Comparative Study/
55. cohort*.ti,ab.
56. (case* adj2 control*).tw.
57. (follow up adj (study or studies)).tw.
58. (observational adj2 (study or studies)).tw.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 59. (epidemiologic* adj (study or studies)).tw.
- 60. (cross sectional adj (study or studies)).tw.
- 61. (retrospective* or longitudinal*).tw.
- 62. ((controlled adj2 trial*1) or (controlled adj2 stud*) or (comparative adj trial*) or (comparative adj stud*) or (comparison adj group*) or (comparator adj group*)).tw.
- 63. (nonrandomi* or (non adj randomi*)).tw.
- 64. or/45-49, 52-63
- 65. 44 and 64

For peer review only

APPENDIX 2: Characteristics of included studies

Study ID	Design	Objective	Participants	Intervention (exposure)	Comparator (control)	Outcome
Red blood cells versus no red blood cells – prospective studies						
Aronson 2008 (3)	Design: prospective cohort How pts recruited: admitted to intensive care unit Country: Israel Year: 2000 to 2006 Funding: not reported	Effects of RBCT in patients with acute myocardial infarction	Adults with acute MI in an intensive coronary care unit (n=2358)	RBCT (n=192) Prescribing guidance: not reported	No RBCT(n=2134)	Mortality at 6 months #
Bochicchio 2008 (4)	Design: prospective cohort How pts recruited: admitted to Adams Cowley Shock Trauma Centre Country: USA Year: 2002 to 2004 Funding: not reported	Effects of RBC and other blood product transfusion (RBC and FFP) on outcome in trauma patients	Adults admitted to intensive care unit (n=1172)	RBC and other blood product transfusion (n=786); RBC only (n=246) Prescribing guidance: no formal protocol used	No RBC or other blood product transfusion (n=386).	Mortality (time period not specified)
Koch 2006 (11,12)	Design: prospective cohort How pts recruited: admitted to large tertiary hospital (Cleveland Clinic) Country: USA Year: 1995 to 2002 Funding: Non industry funded	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass grafting (n=11963)	RBCT (n=5812) Prescribing guidance: not reported	No RBCT(n=6151)	Mortality in-hospital
Nikolsky 2009 (14)	Design: prospective cohort How pts recruited: part of CADILLAC randomized trial comparing different mechanical reperfusion strategies Country: multi centre Year: 1997 to 1999 Funding: not reported	Effect of RBCT in patients undergoing angioplasty for acute myocardial infarction	Adults undergoing angioplasty for acute myocardial infarction (n=2060)	RBCT (n=82) Prescribing guidance: not reported	No RBCT (n=1978)	Mortality at 30 days and 1 year #
Surgenor 2009 (20)	Design: prospective cohort How pts recruited: admitted to one of eight medical centres as part of the Northern New	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass surgery (n=9079)	RBCT (n=3254) Prescribing guidance: reported as at the	No RBCT (n=5825)	Mortality over 5 years #

	England Cardiovascular Disease Study Group Country: USA Year: 2001 to 2004 Funding: not reported			discretion of the patient care team		
Taylor 2006 (21)	Design: prospective cohort How pts recruited: admitted to intensive care unit at the St John's Mercy Medical Centre Country: USA Year: 2001 to 2003 Funding: not reported	Effect of RBCT on nosocomial infection and mortality in critically ill patients	Adults admitted to critical care unit (n=2085)	RBCT (n=449) Prescribing guidance: reported as at the discretion of the patient care team	No RBCT (n=1636)	Mortality (time period not specified)
Van Straten 2010 (22)	Design: prospective cohort How pts recruited: admitted to hospital (centre not specified) Country: Netherlands Year: 1998 to 2007 Funding: not reported	Effect of RBCT on long and short term survival in patients undergoing coronary artery bypass grafting	Patients undergoing coronary artery bypass grafting (n=10425)	RBCT (n=3597) Prescribing guidance: not reported	No RBCT (n=6828)	Mortality ≤ 30 days and mortality > 30 days #
Vincent 2008 (23)	Design: prospective cohort How pts recruited: admitted to European intensive care unit (n=198 units) Country: Belgium Year: 1 May to 15 May 2002 Funding: industry supported	Effect of RBCT on mortality in European intensive care units	Adults admitted intensive care unit (n=3147)	RBCT (n=1040) Prescribing guidance: not reported	No RBCT (n=2107)	Mortality in hospital at 30 days #
Red blood cells versus no red blood cells – retrospective studies						
Engoren 2009 (5)	Design: retrospective database How pts recruited: admitted to St Vincent Mercy Medical Centre intensive care unit Country: USA Year: 2001 to 2002 Funding: not reported	Effects of RBCT in critically ill patients (excluded cardiac surgery patients)	Adults admitted to intensive care unit (n=2213)	RBCT (n=404) Prescribing guidance: haemoglobin <8 g/dl	No RBCT (n=1809)	Mortality at 30 days and 180 days #
Engoren 2009 (6)	Design: retrospective database How pts recruited: admitted to St Vincent Mercy Medical Centre	Effects of RBCT in cardiac surgery patients	Adults admitted for cardiac surgery (n=1823)	RBCT (n=378) CABG and value	No RBCT (n=615) CABG and value	Mortality within 30 days >30 days

	for cardiac surgery Country: USA Year: 1991 to 2007 Funding: not reported			RBCT (n=534) Prescribing guidance: not reported	No RBCT (n=296)	
Garty 2009 (7)	Design: retrospective database How pts recruited: admitted to cardiac or internal medicine ward in 25 public hospitals Country: Israel Year: 2003 Funding: Non industry funded	Effect of RBCT (unclear if included other blood products) on patients with acute decompressed heart failure	Adults with acute decompressed heart failure (n=2335)	RBCT (n=166) Prescribing guidance: not reported	No RBCT(n=2169)	Mortality in-hospital, 30 days, 1 year and 4 years #
Jani 2007 (8)	Design: retrospective database (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) How pts recruited: admitted to academic medical centres Country: USA Year: 1997 to 2004 Funding: Blue Cross Blue Shield of Michigan	Effect of RBCT and other blood product on in-patient mortality in anaemic patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI)	Adults (>60 years) with anaemia undergoing PCI within 7 days for having a MI (n=4623).	RBCT and other blood product (n=1033) Prescribing guidance: no formal protocol used	No RBCT or other blood product (n=3590).	Mortality in-hospital
Johnson 2006 (9)	Design: retrospective database How pts recruited: admitted to orthopaedic unit (District General Hospital, Peterborough) Country: UK Year: 1989 to 2002 Funding: Non industry funded	Effect of RBCT (unclear if included other blood products) on mortality in patients with hip fracture	Adults admitted to orthopaedic unit with hip fracture (n=3625)	RBCT (n=1068) Prescribing guidance: haemoglobin <8 g/dl	No RBCT (n=2503)	Mortality at 30, 120 and 365 days #
Khorana 2008 (10)	Design: retrospective database (University Health System Consortium) How pts recruited: admitted to academic medical centres Country: USA Year: 1995 to 2003 Funding: National Cancer Institute and National Heart, Lung and Blood Institute	Effect of RBCT and other blood product on thrombosis and mortality in hospitalised patients with cancer	Adults with cancer admitted to hospital (n=504208)	RBCT and other blood product (n=74051); RBC only (n=58814) Prescribing guidance: not reported	No RBCT or other blood product (n=430157)	Mortality in-hospital

Murphy 2007 (13)	Design: 3 retrospective databases (PATS (Patient analysis and Tracking System), haematological and blood bank studys) How pts recruited: admitted to Bristol Royal Infirmary for adult cardiac surgery Country: UK Year: 1996 to 2003 Funding: British Heart Foundation	Effect of RBCT on mortality, post operative morbidity and cost in patients undergoing cardiac surgery	Adults > 16 years undergoing cardiac surgery (n=8598)	RBCT (n=4909) Prescribing guidance: not reported	No RBCT (n=3689)	Mortality up to 7 years post surgery (median 4.15 years) #
Pederson 2009 (15)	Design: retrospective database (Danish Hip Arthroplasty Registry) How pts recruited: admitted from 20 orthopaedic departments Country: Denmark Year: 1999 to 2007 Funding: not reported	Effect of RBCT on mortality in patients undergoing total hip replacement	Adults undergoing surgery for total hip replacement (n=28087)	RBCT (n=9063) Prescribing guidance: not reported	No RBCT (n=19024)	Mortality at 90 days
Rogers 2006 (16)	Design: retrospective database (Center for Medicare and Medicaid Services) How pts recruited: Medicare beneficiaries hospitalised for coronary artery bypass surgery Country: USA Year: 1997 to 1998 Funding: non industry funded	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Older adults (> 65 Years) undergoing coronary artery bypass surgery (n=9218)	RBCT (n=6893) Prescribing guidance: not reported	No RBCT (n=2325)	Mortality within 100 days
Rogers 2009 (17)	Design: retrospective database How pts recruited: Medicare beneficiaries who received coronary artery bypass surgery Country: USA Year: 2003 to 2006 Funding: Michigan Foundation	Effect of RBCT and other blood product on infection and mortality in patients undergoing coronary artery bypass surgery	Older adults (> 65 years) undergoing coronary artery bypass surgery (n=24789)	RBCT and other blood product (n=20789) Prescribing guidance: not reported	No RBCT or other blood product (n=4000)	Mortality in hospital and at 30 days post discharge

Salehiomran 2009 (18)	Design: retrospective database How pts recruited: patients admitted to Tehran Heart Centre who received coronary artery bypass surgery Country: Iran Year: 2002 to 2008 Funding: not reported	Effect of RBCT (unclear if included other blood products) on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass surgery (n=14152)	RBCT (n=2333) Prescribing guidance: hematocrit <25-26%	No RBCT (n=11773)	Mortality at 30 days
Stone 2008 (19)	Design: retrospective database How pts recruited: admitted to paediatric trauma centre Country: USA Year: 1998 to 2006 Funding: not reported	Effect of RBCT on mortality in paediatric trauma patients	Children with blunt or penetrating injury admitted to trauma centre (n=1639)	RBCT (n=106) Prescribing guidance: reported no specific transfusion protocol was used	No RBCT (n=1533)	Mortality in-hospital
Weinberg 2008 (24)	Design: retrospective database How pts recruited: admitted to trauma centre at University of Alabama Country: USA Year: 2000 to 2007 Funding: not reported	Effect of RBCT on mortality in trauma patients	Less severely injured adults admitted to trauma centre (n=1624)	RBCT (n=430) Prescribing guidance: not reported	No RBCT (n=1194)	Mortality in hospital
Wu 2010 (25)	Design: retrospective database (Department of Veteran Affairs and National Surgical Quality Improvement Program) How pts recruited: admitted to one of 142 veteran hospitals and requiring major non cardiac surgery Country: USA Year: 1997 to 2004 Funding: not reported	Effect of RBCT on mortality in older adults after major non cardiac surgery	Older adults (>65 years) undergoing major non cardiac surgery (n=239286)	RBCT(n=22515) Prescribing guidance: not reported	No RBCT (n=216771)	Mortality at 30 days
Zilberberg 2008 (26)	Design: retrospective database (Henry Ford Health System includes data from 7 hospitals in USA) How pts recruited: admitted to hospital and requiring	Effect of RBCT on mortality in critically ill patients requiring prolonged ventilation	Adults critically ill and requiring prolonged ventilation 96 ≥hours (n=4344)	RBCT (n=2912) Prescribing guidance: not reported	No RBCT (n=1432)	Mortality in-hospital

	ventilation Country: USA Year: 2000 to 2005 Funding: industry supported					
Volume 'A' red blood cells versus volume 'B' red blood cells						
Bernard 2009 (27)	Design: retrospective database How pts recruited: admitted to hospital and requiring major surgery Country: USA Year: 2005 to 2006 Funding: industry supported	Effect of RBCT and volume of blood in patients undergoing major surgery	Adults undergoing major surgery (n=125177)	Volume of RBCT (classified as: 0 units RBC, 1 unit, 2 units, 3-4 units, 5-9 units >10 units intra operative and >4 units post operative) Prescribing guidance: no formal protocol used	Another volume of RBCT (classified as: 0 units RBC, 1 unit, 2 units, 3-4 units, 5-9 units >10 units intra operative and >4 units post operative) Prescribing guidance: no formal protocol used	Mortality at 30 days
Charles 2007 (28)	Design: retrospective database (NTRACS trauma registry) How pts recruited: admitted to Level 2 trauma centre Country: USA Year: 1994 to 2004 Funding: not reported	Effect of RBCT and volume of blood in patients with blunt trauma injuries	Adults >18 yrs with blunt trauma injuries admitted to trauma centre (n=8215)	Volume of RBCT (classified as: 0 units RBC, 1-2 units, 3-5 units, >6 units) Prescribing guidance: no formal protocol used	Another volume of RBCT (classified as: 0 units RBC, 1-2 units, 3-5 units, >6 units) Prescribing guidance: no formal protocol used	Mortality at 24 hours
O'Keefle 2010 (29)	Design: retrospective database (American College of Surgeons National Quality Improvement Program) How pts recruited: admitted from 173 hospitals and undergoing vascular surgery Country: USA Year: 2005 to 2007 Funding: not reported	Effect of RBCT on mortality in patients undergoing lower extremity revascularization	Adults with peripheral arterial disease (n=8799)	Volume of RBCT (classified as: 0 units RBC, 1 to 2 and >3 units) Prescribing guidance: not reported	Another volume of RBCT (classified as: 0 units RBC, 1 to 2 and >3 units) Prescribing guidance: not reported	Mortality at 30 days
Ruttinger 2007 (30)	Design: retrospective database How pts recruited: admitted to surgical intensive care unit LMU University Hospital., Munich Country: Germany	Effect of RBCT on mortality in critically ill patients	Patients admitted to intensive care unit (n=3037)	Volume of RBCT (classified as: 1 to 2 units (n=676) RBC, 3 to 4 (n=345), 5 to 8 (n=301) and >8 units	Another volume of RBCT (classified as: 1 to 2 units RBC, 3 to 4, 5 to 8 and >8 units)	Mortality in-hospital

	Year: 1993 to 2005 Funding: not reported			(n=471) Prescribing guidance: haemoglobin <8-9 g/dl	Prescribing guidance: haemoglobin <8-9 g/dl	
Weightman 2009 (31)	Design: prospective cohort How pts recruited: admitted to Sir Charles Gairdner hospital Country: Australia Year: 1993 to 2000 Funding: not reported	Effect of RBCT and other blood product on long term survival in patients undergoing coronary artery bypass grafting	Patients undergoing coronary artery bypass grafting (n=1841) and survived longer than 60 days	Volume of RBCT and other blood product (classified as: 0 units (n=779), 1-2 units (n=402), 3-6 units (n=333) and > 6units (n=327)) Prescribing guidance: not reported	Another volume of RBCT and other blood product (classified as: 0 units, 1-2 units, 3-6 units and > 6units) Prescribing guidance: not reported	Mortality (mean follow up 8.1 years)#
'Older' red blood cells versus 'newer' red blood cell						
Edgren 2010 (32)	Design: retrospective database How pts recruited: received blood transfusion as recorded in Scandinavian Donations and Transfusion Study Country: Sweden and Denmark Year: 1995 to 2002 Funding: National Heart, Lung and Blood Institute of NIH	Effect of RBCT duration of storage on mortality	Adults receiving ≥ 1 RBC transfusion (n=364037)	RBCT stored for 0-9 days, 10-19 days, 20-29 days, 30-42 days Prescribing guidance: no formal protocol used	RBCT stored for 0-9 days, 10-19 days, 20- 29 days, 30-42 days Prescribing guidance: no formal protocol used	Mortality ≤ 7 days and mortality 8 to 730 days#
Koch 2008 (33)	Design: retrospective database (Cleveland clinic blood bank and cardiac registries) How pts recruited: admitted to Cleveland Clinic Country: USA Year: 1998 to 2006 Funding: National Institute for Health Research and Joseph Drown Foundation	Effect of RBCT duration of storage on mortality and serious complication in patients undergoing cardiac surgery	Adults >18 years undergoing coronary- artery bypass grafting, cardiac-valve surgery, or both (n=6002)	RBCT stored for ≤ 14 days (n=2872) Prescribing guidance: no formal protocol used	RBCT stored for >14 days (n=3130) Prescribing guidance: no formal protocol used	Mortality in-hospital and at 1 year
Van de Watering 2006 (34)	Design: retrospective database (Leiden University Medical Centre)	Effect of RBCT duration of storage on mortality in	Adults undergoing cardiothoracic surgery (n=2715)	RBCT stored for <18 days (n=942)	RBCT stored for >18 days (n=941)	Mortality at 30 days#

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	How pts recruited: admitted to cardiothoracic surgery unit Country: Netherlands Year: 1993 to 1999 Funding: none industry	cardiac patients		Prescribing guidance: no formal protocol used	Prescribing guidance: no formal protocol used	
Weinberg 2008 (35)	Design: retrospective database How pts recruited: admitted to trauma centre at University of Alabama Country: USA Year: 2000 to 2007 Funding: not reported	Effect of leukodepleted RBCT transfusion and duration of storage on mortality in trauma patients	Severely injured adults admitted to trauma centre (n=1813)	RBCT stored for <14 days Prescribing guidance: no formal protocol used	RBCT stored for ≥14 days Prescribing guidance: no formal protocol used	Mortality (time period not specified)

RBCT=red blood cell transfusion; NR: not reported; #time-to-event outcome

Peer review only

APPENDIX 3: Statistical methods and presentation of unadjusted and adjusted results of the included studies

Study ID	Study covariates	Comparison	Unadjusted results	Adjusted results	Method of adjustment
Red blood cells versus no red blood cells – prospective studies					
Aronson 2008 (3)	Number covariates: 16 Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality at 6 months#	RBCT (n): NR No RBCT (n): NR Hazard ratio 4.4 (95% CI 3.2 to 5.9)	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.9 (95% CI 1.3 to 2.9)	Nature of adjustment: transfusion propensity, baseline characteristics, nadir haemoglobin Type of model used: logistic regression Number covariates in model: 16
Bochicchio 2008 (4)	Number covariates: 5 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT or other blood products Mortality (time period not specified)	RBCT: 147/786 No RBCT: 32/386 p<0.001 (Odds ratio not reported)	RBCT: 147/786 No RBCT: 32/386 Odds ratio 1.05 (95% CI 1.03 to 1.07)	Nature of adjustment: age, ISS, admission GCS Type of model used: logistic regression Number covariates in model: 3
Koch 2006 (11,12)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates were pre-specified	RBCT versus no RBCT Mortality in hospital	RBCT (n): NR No RBCT (n): NR Odds ratio 1.78 (95% CI 1.70 to 1.87)	RBCT (n): NR No RBCT (n): NR Odds ratio 1.77 (1.67 to 1.87)	Nature of adjustment: multiple covariates Type of model used: logistic regression Number covariate in model: multiple covariates
Nikolsky 2009 (14)	Number covariates: 25 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days and 1 year#	Not reported	Mortality at 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 4.71(95% CI 1.97 to 11.26) Mortality at 1 year RBCT (n): NR	Nature of adjustment: transfusion propensity Type of model used: Cox proportional hazards model Number covariate in model: 19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

				No RBCT (n): NR Hazard ratio 3.16 (95% CI 1.66 to 6.03)	
Surgenor 2009 (20)	Number covariates: multiple Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT versus no RBCT Mortality within 5 years#	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.94 (95% CI 1.71 to 2.20)	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.16 (95% CI 1.01 to 1.33)	Nature of adjustment: propensity model Type of model used: Cox proportion hazard model Number covariates in model: 13
Taylor 2006 (21)	Number covariates: 5 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: no Covariates pre-specified	RBCT versus no RBCT Mortality (time period not specified)	RBCT: 98/449 No RBCT: 166/1636 p<0.001 (only p value reported)	POS ≤ 25% RBCT: 47/147 No RBCT: 105/336 p=0.88 POS 25% ≤ 50% RBCT: 17/126 No RBCT: 23/358 p=0.013 POS 50% ≤ 75% RBCT: 14/94 No RBCT: 100/390 P<0.0001 POS >75% RBCT: 3/39 No RBCT: 4/444 p=0.14 (only p value reported)	Nature of adjustment: mortality predication model (POS) Type of model used: logistic regression Number covariates in model: NR
Van Straten 2010 (22)	Number covariates: 16 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: no Unclear if covariates pre-	RBCT versus no RBCT Mortality ≤ 30 days and mortality > 30 days#	Mortality ≤ 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 1.31 (95% CI 1.27 to 1.35) Mortality > 30 days	Mortality ≤ 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 1.21 (95% CI 1.13 to 1.30) Mortality > 30 days	Nature of adjustment: unclear Type of model used: Cox proportional hazards model Number covariates in model: NR

	specified or data driven		Hazard ratio 1.16 (95% CI 1.13 to 1.20)	Hazard ratio 1.04 (95% CI 0.99 to 1.07)	
Vincent 2008 (23)	Number covariates: 8 Age: yes Sex: yes Smoking :no Co-morbidity: yes Hb level: no Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days in hospital#	RBCT: 311/1040 No RBCT: 436/2107 p<0.001 (only p value reported)	RBCT: NR No RBCT: NR Hazard ratio 0.89 (95% CI 0.76 to 1.05) p=0.16	Nature of adjustment: multiple covariates Type of model used: Cox proportional hazards model Number covariates in model: 8
Red blood cells versus no red blood cells – retrospective studies					
Engoren 2009 (5)	Number covariates: 25 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days and 180 days#	Mortality 30 days RBCT: 101/404 No RBCT: 265/1809 Mortality 180 days RBCT: 150/404 No RBCT: 414/1809 p<0.01 (Hazard ratios not reported)	Mortality 30 days RBCT: NR No RBCT: NR Hazard ratio 1.11 (95% CI 0.86 to 1.42) Mortality 180 days RBCT: NR No RBCT: NR Hazard ratio 1.14 (95% CI 0.83 to 1.58)	Nature of adjustment: multiple variables Type of model used: Cox proportional hazard modelling Number covariates in model: NR
Engoren 2009 (6)	Number covariates: multiple Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality within 30 days and >30 days	Mortality within 30 days Value only: RBCT: 26/993 No RBCT: 16/993 CABG and value: RBCT: 69/830 No RBCT: 14/830 Mortality >30 days Value only: RBCT: 160/993 No RBCT: 165/993 CABG and value: RBCT: 279/830 No RBCT: 113/830	Mortality within 30 days Value only: Odds ratio 1.95 (95% CI 0.97 to 3.91) CABG and value: Odds ratio 2.23 (95% CI 1.12 to 4.46) Mortality >30 days Value only: Risk ratio 1.25 (95% CI 0.97 to 1.61) CABG and value: Risk ratio 1.44 (95% CI 1.13 to 1.84)	Nature of adjustment: propensity score Type of model used: Cox proportional hazard modelling (mortality >30 days) and logistic regression (mortality within 30 days) Number covariates in model: NR
Garty 2009	Number covariates:	RBCT (unclear if included)	Mortality in hospital	Mortality in hospital	Nature of adjustment: propensity

(7)	unclear Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Unclear if covariates pre-specified or data driven	other blood product) versus no RBCT Mortality in hospital, 30 days, 1 year and 4 years#	RBCT: 18/166 (10.8%) No RBCT: 113/2169 (5.2%) Mortality 30 days RBCT: 18/166 (11%) No RBCT: 183/2169 (8.5%) Mortality 1 year RBCT: 65/166 (39.6%) No RBCT: 616/2169 (28.5%) Mortality 4 years RBCT: 114/166 (69.5%) No RBCT: 1284/2169 (59.5%)	RBCT: 9/103 (8.7%) No RBCT: 15/103 (14.6%) Hazard ratio: 0.48 (95% CI 0.21 to 1.11) Mortality 30 days RBCT: 10/103 (9.7%) No RBCT: 19/103 (18.4%) Hazard ratio: 0.29 (95% CI 0.13 to 0.64) Mortality 1 year RBCT: 40/103 (38.8%) No RBCT: 44/103 (42.7%) Hazard ratio: 0.74 (95% CI 0.50 to 1.09) Mortality 4 years RBCT: 75/103 (72.8%) No RBCT: 79/103 (76.7%) Hazard ratio: 0.86 (95% CI 0.64 to 1.14)	score Type of model used: Cox proportional hazard modelling (1-4 year mortality) and logistic regression (mortality up to 30 days) Number covariates in model: 9
Jani 2007 (8)	Number covariates: 31 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT Mortality in hospital	RBCT: 150/1033 No RBCT: 108/3590 p<0.001 (only p value reported)	RBCT: 76/598 No RBCT: 44/598 Odds ratio 2.02 (95% CI 1.47 to 2.79)	Nature of adjustment: transfusion propensity and co morbidities Type of model used: logistic regression Number covariate in model: 10
Johnson 2006 (9)	Number covariates: 7 Age: yes Sex: yes Smoking: no Co-morbidity: no HB level: yes Unclear if covariates pre-specified or data driven	RBCT (unclear if included other blood product) versus no RBCT Mortality at 30, 120, 365 days#	Mortality 30 days RBCT: 95/1068 No RBCT: 181/2503 p=0.10 Mortality 120 days RBCT: 247/1068 No RBCT: 374/2503 p<0.0001 Mortality 365 days	Mortality 30 days (not reported) Mortality 120 days (not reported) Mortality 365 days	Nature of adjustment: age, sex, ASA grade, preoperative haemoglobin, residential status, mobility score Type of model used: Cox regression Number covariate in model: 7

			RBCT : 381/1068 No RBCT: 626/2503 p<0.001 (only p values reported)	RBCT: 381/1068 No RBCT: 626/2503 Hazard ratio 1.11 (95% CI 0.96 to 1.29)	
Khorana 2008 (10)	Number covariates: Unclear Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: no Covariates pre-specified	RBCT and other blood product versus no RBCT Mortality in hospital	RBCT (n): 11.9% No RBCT (n): NR	RBCT (n): NR No RBCT (n): NR Odds ratio 1.34 (95% 1.29 to 1.38)	Nature of adjustment: NR Type of model used: multivariate logistic regression Number covariate in model: NR
Murphy 2007 (13)	Number covariates: 21 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality up to 7 years post surgery#	Not reported	Mortality 0 - 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 6.69(95% CI 3.66 to 15.1) Mortality 31 days to 1 year Hazard ratio 2.59 (95% CI 1.68 to 4.18) Mortality > 1 year Hazard ratio 1.32 (95% CI 1.08 to 1.64)	Nature of adjustment: transfusion propensity Type of model used: logistic regression and Cox proportional hazards regression Number covariate in model: NR
Pederson 2009 (15)	Number covariates: 69 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality at 90 day	RBCT (n): NR No RBCT (n): NR Odds ratio 2.17 (95% CI 1.24 to 3.79)	RBCT: 39/2254 No RBCT: 18/2254 Odds ratio 2.17 (95% CI 1.24 to 3.80)	Nature of adjustment: transfusion propensity Type of model used: multivariate logistic regression Number covariate in model: NR
Rogers 2006 (16)	Number covariates: 33 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: unclear	RBCT versus no RBCT Mortality within 100 days	RBCT: 648/6893 No RBCT: 44/2325 Odds ratio 6.6 (95% CI 4.4 to 9.9)	RBCT: 648/6893 No RBCT: 44/2325 Odds ratio 5.6 (95% CI 3.7 to 8.6)	Nature of adjustment: sex, age, race, co morbidity, urgency of admission Type of model used: generalised linear regression Number covariate in model: 5

	Unclear if covariates pre-specified or data driven				
Rogers 2009 (17)	Number covariates: 13 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: no Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT Mortality in hospital and at 30 days	Not reported	Mortality in hospital RBCT (n): NR No RBCT (n): NR Elective surgery: Odds ratio 4.67 (95% CI 2.38 to 9.18) Urgent surgery: Odds ratio 1.82 (95% CI 1.51 to 2.20) Mortality 30 days post discharge Elective surgery: Odds ratio 2.88 (95% CI 1.38 to 5.98) Urgent surgery: Odds ratio 4.65 (95% CI 1.90 to 11.39)	Nature of adjustment: propensity score, surgical volume, hospital volume Type of model used: multivariate mixed effect logistic regression Number covariate in model: 3
Salehiomran 2009 (18)	Number covariates: 31 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT (unclear if included other blood products) versus no RBCT Mortality at 30 days	RBCT: 60/2333 No RBCT: 42/11773 p<0.001 (Odds ratio not reported)	RBCT: 60/2333 No RBCT: 42/11773 Odds ratio 3.98 (95% CI 2.44 to 6.47)	Nature of adjustment: not reported Type of model used: multivariate logistic regression Number covariate in model: 13
Stone 2008 (19)	Number covariates: 7 Age: yes Sex: yes Smoking: N/A Co-morbidity: yes Hb level: no Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality in hospital	RBCT: 31/106 No RBCT: 42/1533 Odds ratio 14.67 (95% CI not reported)	Not reported (authors said statistical model was to unreliable to provide reliable conclusions)	Nature of adjustment: injury severity Type of model used: logistic regression Number covariate in model: NR
Weinberg 2008 (24)	Number covariates: 9 Age: yes Sex: yes Smoking: no Co-morbidity: no Hb level: no Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality in hospital	RBCT (n): 4.2% No RBCT (n): 2.3% p=0.04	RBCT (n): NR No RBCT (n): NR Odds ratio 0.96 (95% CI 0.48 to 1.94)	Nature of adjustment: age, gender, ISS, injury, ventilation, transfusion volume Type of model used: logistic regression Number of covariates in model: 5

Wu 2010 (25)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes Hb level: yes Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality at 30 days	Not reported	RBCT (n): NR No RBCT (n): NR Odds ratio 1.37 (95% CI 1.27 to 1.48)	Nature of adjustment: mean operative time, ASA classification, rate of general anaesthesia Type of model used: logistic regression Number covariates in model: NR
Zilberberg 2008 (26)	Number covariates: multiple Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT versus no RBCT Mortality in hospital	RBCT: 938/2912 No RBCT: 342/1432 Odds ratio 1.51 (95% CI 1.31 to 1.75)	RBCT : 938/2912 No RBCT: 342/1432 Odds ratio 1.21 (95% CI 1.00 to 1.48)	Nature of adjustment: multiple variables Type of model used: logistic regression Number covariates in model: 13
Volume 'A' red blood cells versus volume 'B' red blood cells					
Bernard 2009 (27)	Number covariates: multiple Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 30 days	Intra operative 1 unit: 136/1343 2 units: 194/1903 3-4 units: 151/977 5-9 units: 67/412 >10 units: 45/153 Post operative >4 units: 153/575 (Odds ratios not reported)	Intra operative 1 unit: Odds ratio 1.32 2 units: Odds ratio 1.38 3-4 units: Odds ratio 1.97 5-9 units: Odds ratio 2.17 >10 units: Odds ratio 9.83 Post operative >4 units: Odds ratio 2.65 (95% CI not reported)	Nature of adjustment: transfusion propensity, type of procedure, wound class, operative duration Type of model used: logistic regression Number covariates in model: multiple
Charles 2007 (28)	Number covariates: 7 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 24 hours	0 RBCT: 1.8% 1-2 units: 6.5% 3-5 units: 16.1% ≥6 units: 29.8% (Odds ratios not reported)	1-2 units: p=0.18 3-5 units: Odds ratio 3.22 p=0.002 ≥6 units: Odds ratio 4.87 p=0.000 (95% CI not reported)	Nature of adjustment: age, gender, ISS score, SI Type of model used: logistic regression Number covariates in model: 4

O'Keeffe 2010 (29)	Number covariates: 23 Age: yes Sex: yes Smoking: unclear Co-morbidity: yes HB level: yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 30 days	Not reported	1-2 units: Odds ratio 1.92 (95% CI 1.36 to 2.70) >3 units: Odds ratio 2.48 (95% CI 1.55 to 3.98)	Nature of adjustment: transfusion propensity Type of model used: logistic regression Number covariate in model: 19
Ruttinger 2007 (30)	Number covariates: 14 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality in hospital	% reported in figure only (Odds ratios not reported)	1-2 units: Odds ratio 0.68 (95% CI 0.35 to 1.28) 3-4 units: Odds ratio 1.11 (95% CI 0.52 to 2.39) 5-8 units: Odds ratio 1.16 (95% CI 0.60 to 2.26) 8 units: Odds ratio 0.74 (95% CI 0.36 to 1.51)	Nature of adjustment: extended analysis Type of model used: logistic regression Number covariate in model: NR
Weightman 2009 (31)	Number covariates: 16 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	Volume of RBCT and other blood product (classified as: 0 units, 1-2 units, 3-6 units and > 6units) Mortality (mean follow up 8.1 years)	0 units: 80/779 1-2 units: 56/402 3-6 units: 58/333 > 6 units: 72/327	1-2 units: Hazard ratio 1.00 (95% CI 0.70 to 1.44) 3-6 units: Hazard ratio 0.98 (95% CI 0.67 to 1.41) > 6 units: Hazard ratio 1.25 (95% CI 0.87 to 1.79)	Nature of adjustment: multiple measures Type of model used: Cox proportional hazard model Number covariates in model: 12
'Older red blood cells versus 'newer' red blood cells					
Edgren 2010 (32)	Number covariates: unclear Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Covariates pre-specified	RBCT storage for 0- days, 10-19 days, 20-29 and 30-42 days Mortality ≤ 7 days and mortality 8 to 730 days#	Not reported	Mortality 1 to 7 days Stored 0- 9 days: Hazard ratio 0.96 (95% CI 0.91 to 1.00) Stored 10-19 days: Hazard ratio 1.00 (95% CI not reported) Stored 20-29 days: Hazard ratio 1.06 (95% CI 0.96 to 1.06) Stored 30-42 days: Hazard ratio 1.05 (95% CI 0.97 to 1.12) Mortality 8 to 730 days Stored 0- 9 days: Hazard ratio 1.01 (95% CI 0.99 to 1.02) Stored 10-19 days: Hazard ratio 1.00 (95% CI not reported)	Nature of adjustment: number transfusions, age, sex, blood group, calendar period, season, weekday, hospital, indication Type of model used: Cox proportional hazards regression Number covariates in model: 9

				Stored 20-29 days: Hazard ratio 0.99 (95% CI 0.97 to 1.01) Stored 30-42 days: Hazard ratio 1.05 (95% CI 1.02 to 1.08)	
Koch 2008 (33)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT stored for ≤ 14 days versus RBCT stored for > 14 days Mortality in hospital and at 1 year	Mortality in hospital Stored ≤ 14 days: 49/2872 Stored > 14 days: 88/3130 p=0.004 (only p value reported)	Mortality at 1 year Stored ≤ 14 days: 7.4% Stored > 14 days: 11% p<0.001 (only p value reported)	Nature of adjustment: transfusion propensity Type of model used: logistic regression Number covariate in model: NR
Van de Watering 2006 (34)	Number covariates: 7 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT stored for <18 days versus RBCT stored for >18 days Mortality at 30 days#	Stored <18 days (n): NR Hazard ratio 1.33 (95% CI 1.04 to 1.68) Stored > 18 days (n): NR Hazard ratio: 0.85 (95% CI 0.69 to 1.05)	Stored <18 days (n): NR Hazard ratio 0.93 (95% CI 0.71 to 1.23) Stored > 18 days (n): NR Hazard ratio 0.98 (95% CI 0.76 to 1.25)	Nature of adjustment: number of transfusions, duration of surgery, previous CABG, number of distal anatomises, age, sex, Hb level Type of model used: NR Number covariates in model: 7
Weinberg 2008 (35)	Number covariates: 6 Age: yes Sex: yes Smoking: no Co-morbidity: no Hb level: no Covariates pre-specified	RBCT stored for <14 days versus RBCT stored for >14 days Mortality (time period not specified)	Not reported	Stored <14 days: 1-2 units: Odds ratio 1.65 (95% CI 1.01 to 2.70) ≥ 3 units: Odds ratio 1.70 (95% CI 0.96 to 2.99) Stored ≥ 14 days: 1-2 units: Odds ratio 1.78 (95% CI 1.06 to 2.98) ≥ 3 units: Odds ratio 2.78 (95% CI 1.58 to 4.88)	Nature of adjustment: age, gender, ISS, type injury, number units transfused first 24 hours, length of hospital stay Type of model used: logistic regression Number covariates in model: 6

RBCT=red blood cell transfusion; NR: not reported; OR = odds ratio; RR = risk ratio; HR = hazard ratio; #time-to-event outcome

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

APPENDIX 4: Summary of unadjusted and adjusted results of the included studies

Study ID	Disease area	Comparison	Mortality	Unadjusted results	Adjusted result
Red blood cells versus no red blood cells – prospective studies					
Aronson 2008 (3)	Cardiac surgery	RBCT versus no RBCT	6 months	HR 4.4 (95% CI 3.2 to 5.9)	HR 1.9 (95% CI 1.3 to 2.9)
Bochicchio 2008 (4)	Trauma	RBCT and other blood product versus no RBCT	Time period not specified	OR 2.54 (95% CI 1.70 to 3.81)*	OR 1.05 (95% CI 1.03 to 1.07)
Koch 2006 (11,12)	Cardiac surgery	RBCT versus no RBCT	In hospital	OR 1.78 (95% CI 1.70 to 1.87)	OR 1.77 (1.67 to 1.87)
Nikolsky 2009 (14)	Cardiac surgery	RBCT versus no RBCT	30 days and 1 year	Not reported	Mortality at 30 days HR 4.71(95% CI 1.97 to 11.26) Mortality at 1 year HR 3.16 (95% CI 1.66 to 6.03)
Surgenor 2009 (20)	Cardiac surgery	RBCT versus no RBCT	≤ 5 years	HR 1.94 (95% CI 1.71 to 2.20)	HR 1.16 (95% CI 1.01 to 1.33)
Taylor 2006 (21)	Intensive care	RBCT versus no RBCT	Time period not specified	OR 2.47 (95% CI 1.88 to 3.26)*	POS ≤ 25% p=0.88 POS 25% ≤ 50% p=0.013 POS 50% ≤ 75% p<0.0001 POS >75% p=0.14
Van Straten 2010 (22)	Cardiac surgery	RBCT versus no RBCT	≤ 30 days and > 30 days	Mortality ≤ 30 days HR 1.31 (95% CI 1.27 to 1.35) Mortality > 30 days HR 1.16 (95% CI 1.13 to 1.20)	Mortality ≤ 30 days HR 1.21 (95% CI 1.13 to 1.30) Mortality > 30 days HR 1.04 (95% CI 0.99 to 1.07)
Vincent 2008 (23)	Intensive care	RBCT versus no RBCT	30 days in hospital	OR 1.64 (95% CI 1.38 to 1.94)*	HR 0.89 (95% CI 0.76 to 1.05)

Red blood cells versus no red blood cells – retrospective studies					
Engoren 2009 (5)	Intensive care	RBCT versus no RBCT	30 and 180 days	Mortality 30 days OR 1.94 (95% CI 1.50 to 2.52)* Mortality 180 days OR 1.99 (95% CI 1.58 to 2.50)*	Mortality 30 days HR 1.11 (95% CI 0.86 to 1.42) Mortality 180 days HR 1.14 (95% CI 0.83 to 1.58)
Engoren 2009 (6)	Cardiac surgery	RBCT versus no RBCT	≤ 30 days and >30 days	Mortality ≤30 days Valve only: OR 1.65 (95% CI 0.88 to 3.08)* CABG and valve: OR 5.28 (95% CI 2.95 to 9.47)* Mortality >30 days Valve only: RR 0.97 (95% CI 0.79 to 1.18)* CABG and valve: RR 2.47 (95% CI 2.03 to 3.00)*	Mortality ≤30 days Valve only: OR 1.95 (95% CI 0.97 to 3.91) CABG and valve: OR 2.23 (95% CI 1.12 to 4.46) Mortality >30 days Valve only: RR 1.25 (95% CI 0.97 to 1.61) CABG and valve: RR 1.44 (95% CI 1.13 to 1.84)
Garty 2009 (7)	Cardiac surgery	RBCT (unclear if other blood product) versus no RBCT	In hospital, 30 days, 1 year and 4 years	Mortality in hospital OR 0.77 (95% CI 0.46 to 1.31)* Mortality 30 days OR 2.21 (95% CI 1.31 to 3.74)* Mortality 1 year OR 1.62 (95% CI 1.17 to 2.25)* Mortality 4 years OR 1.51 (95% CI 1.08 to 2.12)*	Mortality in hospital HR 0.48 (95% CI 0.21 to 1.11) Mortality 30 days HR 0.29 (95% CI 0.13 to 0.64) Mortality 1 year HR 0.74 (95% CI 0.50 to 1.09) Mortality 4 years HR 0.86 (95% CI 0.64 to 1.14)
Jani 2007 (8)	Cardiac surgery	RBCT and other blood product versus no RBCT	In hospital	OR 5.48 (95% CI 4.23 to 7.09)*	OR 2.02 (95% CI 1.47 to 2.79)
Johnson 2006 (9)	Hip fracture and replacement	RBCT (unclear if other blood product) versus no RBCT	30 days, 120 days, 365 days	Mortality 30 days OR 1.84 (95% CI 1.42 to 2.38)* Mortality 120 days OR 1.71 (95% CI 1.43 to 2.05)*	Mortality 365 days HR 1.11 (95% CI 0.96 to 1.29)

				Mortality 365 days OR 1.66 (95% CI 1.42 to 1.94)*	
Khorana 2008 (10)	Oncology	RBCT and other blood product versus no RBCT	In hospital	Not reported	OR 1.34 (95% 1.29 to 1.38)
Murphy 2007 (13)	Cardiac surgery	RBCT versus no RBCT	≤7 years	Not reported	Mortality 0 - 30 days HR 6.69 (95% CI 3.66 to 15.1) Mortality 31 days to 1 year HR 2.59 (95% CI 1.68 to 4.18) Mortality > 1 year HR 1.32 (95% CI 1.08 to 1.64)
Pederson 2009 (15)	Hip fracture and replacement	RBCT versus no RBCT	90 day	OR 2.17 (95% CI 1.24 to 3.79)	OR 2.17 (95% CI 1.24 to 3.80)
Rogers 2006 (16)	Cardiac surgery	RBCT versus no RBCT	≤100 days	OR 6.6 (95% CI 4.4 to 9.9)	OR 5.6 (95% CI 3.7 to 8.6)
Rogers 2009 (17)	Cardiac surgery	RBCT and other blood product versus no RBCT	In hospital and 30 days	Not reported	Mortality in hospital Elective surgery: OR 4.67 (95% CI 2.38 to 9.18) Urgent surgery: OR 1.82 (95% CI 1.51 to 2.20) Mortality 30 days post discharge Elective surgery: OR 2.88 (95% CI 1.38 to 5.98) Urgent surgery: OR 4.65 (95% CI 1.90 to 11.39)
Salehiomran 2009 (18)	Cardiac surgery	RBCT (unclear if other blood product) versus no RBCT	30 days	OR 1.55 (95% CI 1.04 to 2.30)*	OR 3.98 (95% CI 2.44 to 6.47)
Stone 2008 (19)	Paediatric trauma	RBCT versus no RBCT	In hospital	OR 14.67 (95% CI not reported)	Not reported
Weinberg 2008 (24)	Adult trauma	RBCT versus no RBCT	In hospital	OR 1.89 (95% CI 0.97 to 3.60)*	OR 0.96 (95% CI 0.48 to 1.94)
Wu 2010 (25)	Intensive care	RBCT versus no RBCT	30 days	Not reported	OR 1.37 (95% CI 1.27 to 1.48)

Zilberberg 2008 (26)	Intensive care	RBCT versus no RBCT	In hospital	OR 1.51 (95% CI 1.31 to 1.75)	OR 1.21 (95% CI 1.00 to 1.48)
Volume 'A' red blood cells versus volume 'B' red blood cells					
Bernard 2009 (27)	Surgery	Volume RBCT versus another volume RBCT	30 days	Not reported	Intra operative 1 unit: OR 1.32(95% CI not reported) 2 units: OR 1.38(95% CI not reported) 3-4 units: OR 1.97(95% CI not reported) 5-10 units: OR 2.17(95% CI not reported) >10 units: OR 9.83(95% CI not reported) Post operative >4 units: OR 2.65 (95% CI not reported)
Charles 2007 (28)	Trauma	Volume RBCT versus another volume RBCT	24 hours	Not reported	3-5 units: OR 3.22 (95% CI not reported) ≥6 units: OR 4.87 (95% CI not reported)
O'Keeffe 2010 (29)	Cardiac surgery	Volume RBCT versus another volume RBCT	30 days	Not reported	1-2 units: OR 1.92 (95% CI 1.36 to 2.70) >3 units: OR 2.48 (95% CI 1.55 to 3.98)
Ruttinger 2007 (30)	Intensive care	Volume RBCT versus another volume of RBCT	In hospital	Not reported	1-2 units: OR 0.68 (95% CI 0.35 to 1.28) 3-4 units: OR 1.11 (95% CI 0.52 to 2.39) 5-8 units: OR 1.16 (95% CI 0.60 to 2.26) 8 units: OR 0.74 (95% CI 0.36 to 1.51)
Weightman	Cardiac surgery	Volume RBCT and other blood	Mean 8.1 year follow up	Not reported	1-2 units:

2009 (31)		product versus another volume RBCT			HR 1.00 (95% CI 0.70 to 1.44) 3-6 units: HR 0.98 (95% CI 0.67 to 1.41) > 6 units: HR 1.25 (95% CI 0.87 to 1.79)
'Older red blood cells versus 'newer' red blood cells					
Edgren 2010 (32)	Not specified	RBCT stored for 0- days, 10-19 days, 20-29 and 30-42 days	≤ 7 days and 8 to 730 days	Not reported	Mortality 1 to 7 days Stored 0- 9 days: HR 0.96 (95% CI 0.91 to 1.00) Stored 10-19 days: HR 1.00 (95% CI not reported) Stored 20-29 days: HR 1.06 (95% CI 0.96 to 1.06) Stored 30-42 days: HR 1.05 (95% CI 0.97 to 1.12) Mortality 8 to 730 days Stored 0- 9 days: HR 1.01 (95% CI 0.99 to 1.02) Stored 10-19 days: HR 1.00 (95% CI not reported) Stored 20-29 days: HR 0.99 (95% CI 0.97 to 1.01) Stored 30-42 days: HR 1.05 (95% CI 1.02 to 1.08)
Koch 2008 (33)	Cardiac surgery	RBCT stored for ≤ 14 days versus RBCT stored for > 14 days	In hospital and 1 year	Mortality in hospital OR 0.60 (95% CI 0.42 to 0.85)*	Mortality at 1 year p<0.001
Van de Watering 2006 (34)	Cardiac surgery	RBCT stored for <18 days versus RBCT stored for >18 days	30 days	Stored <18 days HR 1.33 (95% CI 1.04 to 1.68) Stored > 18 days HR 0.85 (95% CI 0.69 to 1.05)	Stored <18 days HR 0.93 (95% CI 0.71 to 1.23) Stored > 18 days HR 0.98 (95% CI 0.76 to 1.25)
Weinberg 2008 (35)	Trauma	RBCT stored for <14 days versus RBCT stored for >14 days	Time period not specified	Not reported	Stored <14 days 1-2 units: OR 1.65 (95% CI 1.01 to 2.70)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

					≥ 3 units: OR 1.70 (95% CI 0.96 to 2.99)
					Stored ≥ 14 days 1-2 units: OR 1.78 (95% CI 1.06 to 2.98)
					≥ 3 units: OR 2.78 (95% CI 1.58 to 4.88)

RBCT=red blood cell transfusion; *calculated from raw data; OR = odds ratio; RR = risk ratio; HR = hazard ratio

For peer review only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7-8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Appendix 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14 & table 4
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-14 & figure 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Figure 2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8-14 & table 4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
For more information, visit: www.prisma-statement.org.



PRISMA 2009 Checklist

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49

For peer review only



A systematic review of the effect of red blood cell transfusion on mortality: evidence from large scale observational studies published between 2006 and 2010

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-002154.R1
Article Type:	Research
Date Submitted by the Author:	11-Mar-2013
Complete List of Authors:	Hopewell, Sally; University of Oxford, Centre for Statistics in Medicine Omar, Omar; University of Oxford, Centre for Statistics in Medicine Yu, Ly-Mee; University of Oxford, Centre for Statistics in Medicine Hyde, Chris; University of Exeter, Peninsula College of Medicine & Dentistry Doree, Carolyn; John Radcliffe Hospital, NHS Blood and Transplant Murphy, Mike; John Radcliffe Hospital, NHS Blood and Transplant
Primary Subject Heading:	Evidence based practice
Secondary Subject Heading:	Haematology (incl blood transfusion)
Keywords:	EPIDEMIOLOGY, Blood bank & transfusion medicine < HAEMATOLOGY, INTENSIVE & CRITICAL CARE

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8 **A systematic review of the effect of red blood cell transfusion on**
9
10 **mortality: evidence from large scale observational studies published**
11
12 **between 2006 and 2010**
13
14
15
16
17
18
19

20 Sally Hopewell^{1,2}, Omar Omar², Chris Hyde³, Ly-Mee Yu², Carolyn Doree¹, Mike F. Murphy¹
21
22
23

- 24
25 1. Systematic Review Initiative, NHS Blood and Transplant, Department of
26 Haematology, Oxford University Hospitals and University of Oxford, UK.
27
28 2. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
29
30 3. PenTAG, Peninsula College of Medicine and Dentistry, Exeter, UK
31
32
33
34

35 Correspondence to:

36
37 Dr Sally Hopewell, Centre for Statistics in Medicine, University of Oxford, Wolfson College,
38 Linton Road, Oxford, OX2 6UD, UK. Tel: +44 1865 284400; Fax: +44 1865 284424; Email:
39 sally.hopewell@csm.ox.ac.uk
40
41
42
43

44 **Keywords**

45
46 Systematic review, observational studies, transfusion, mortality.
47

48 Word count 4324
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective: To carry out a systematic review of recently published large scale observational studies assessing the effect of red blood cell transfusion (RBCT) on mortality , with particular emphasis on the statistical methods used to adjust for confounding. Given the limited number of randomized trials of the efficacy of RBCT, clinicians often use evidence from observational studies. However, confounding factors, for example individuals receiving blood generally being sicker than those who do not, makes their interpretation challenging.

Design: Systematic review.

Information sources: We searched MEDLINE and EMBASE for studies published from 1 January 2006 to 31 December 2010.

Eligibility criteria for included studies: We included prospective cohort, case control studies or retrospective analyses of databases or disease registers where the effect of risk factors for mortality or survival was examined. Studies must have included more than 1000 participants receiving RBCT for any cause. We assessed the effects of RBCT versus no RBCT and different volumes and age of RBCT.

Results: Thirty two studies were included in the review; 23 assessed the effects of RBCT versus no RBCT; five assessed different volumes and four older versus newer RBCT. There was considerable variability in the patient populations, study designs and level of statistical adjustment. Overall, most studies showed a higher rate of mortality when comparing patients who received RBCT with those who did not, even when these rates were adjusted for confounding; the majority of these increases were statistically significant. The same pattern was observed in studies where protection from bias was likely to be greater, such as prospective studies.

Conclusion: Recent observational studies do show a consistent adverse effect of RBCT on mortality. Whether this is a true effect remains uncertain as it is possible that even the best conducted adjustments cannot completely eliminate the impact of confounding.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ARTICLE SUMMARY**Article focus**

- Given the limited number of randomized trials of the efficacy of red blood cell transfusion (RBCT), clinicians often use evidence from observational studies.
- Confounding factors, for example individuals receiving blood generally being sicker than those who do not, can make their interpretation challenging.
- Our objective was to systematically review large observational studies (n>1000 patients) published in the last five years assessing the effect of RBCT on mortality, with particular emphasis on the statistical methods used to adjust for confounding.

Key messages

- We identified considerable variability in the patient populations, study designs and level of statistical adjustment.
- Most studies showed higher mortality rates when comparing patients who received RBCT with those who did not, even when adjusting for confounding. We identified similar patterns in studies where protection from bias was likely to be greatest.

Strengths and limitations of this study

- Overall, observational studies do show a consistent adverse effect of RBCT on mortality.
- However, even the best conducted adjustments for confounding cannot completely eliminate its impact, particularly when investigating the effect of RBCT on mortality.

Introduction

Randomized controlled trials are considered the gold standard with which to evaluate the efficacy of a particular health care intervention. In 2005, Blajchman (1) published a study that explored the impact that ten landmark randomized controlled trials have had on the practice of transfusion medicine. The use of randomized trials to evaluate transfusion medicine has only been established since the 1980s (1). Given the limited number of high quality randomized trials of the efficacy of blood transfusion and the challenges of conducting new trials, clinicians often rely on evidence from observational studies. In a randomized trial patients are allocated to comparison groups at random, so the level of disease is likely to be similar in each group and differences in disease severity unlikely to be the explanation for any differences in outcome seen. In an observational study, the groups of patients being compared are not likely to be comparable and the differences in prognostic factors may of themselves lead to difference in outcome. The impact of such “confounding” can be reduced by adjustment in the statistical analysis, but the success of this is dependent on the technique used, complete identification of the factors which might influence outcome and their accurate measurement in the patients in the study (2). As all the factors influencing outcome may never be known, adjustment is unlikely to ever completely account for the confounding occurring in observational studies. The unknown inter-dependence of multiple factors is also a major challenge.

There is increasing implementation of restrictive policies for transfusion, and evidence of reduction in blood use in several countries such as the United Kingdom (UK) and the United States of America (USA) with no evidence of poorer clinical outcomes(3;4). However, there remains considerable variation between hospitals in blood reduction in the UK (5) and elsewhere (6) suggesting that overall blood usage could be further reduced without compromising patient safety. Observational studies may have influenced these changes in transfusion practice along with evidence from randomized controlled trials, national

1
2
3 guidelines, and process driven initiatives, but the impact that the contribution of data from
4
5 observational studies has made to the practice of transfusion medicine has not been
6
7 systematically explored. The aims of this systematic review were therefore to identify
8
9 recently published (2006 to 2010), large scale observational studies assessing the effects of
10
11 red blood cell transfusion (RBCT) on mortality. In particular we aimed to critique the
12
13 statistical methods, and the assumptions made in the analyses of the observational data,
14
15 and to consider the validity of these data as an evidence base for the practice of transfusion
16
17 medicine and to inform future research in this field.
18
19

20 21 22 **Methods**

23 24 **Criteria for selecting studies**

25 26 Type of participants

27
28 We included both adults and children receiving RBCT for any cause. We also included studies
29
30 which stated that patients received red blood cells and other blood products. When
31
32 reported by the primary studies we assessed the effects of RBCT separately from other
33
34 blood products.
35
36

37 38 39 Type of intervention and comparator

40
41 We included the following risk factors:

- 42
43 • RBCT versus no RBCT
- 44
45 • Volume 'A' of RBCT versus volume 'B' of RBCT (as defined by the primary studies)
- 46
47 • 'Older' RBCT versus 'newer' RBCT (as defined by the primary studies)
- 48
49

50 51 52 Type of outcome measure

53
54 Our primary outcome measure was death, mortality or survival measured at any time point.
55
56
57
58
59
60

Type of studies

We included prospective cohort, case control studies or retrospective analyses of databases or disease registers where the effect of the above risk factors on death, mortality or survival is examined. Studies must have included more than 1000 participants. This was a pragmatic limit designed to focus attention on studies most likely to have had an impact and least likely to have been affected by chance.

Search strategy

We carried out a comprehensive search (21 January 2011) of MEDLINE and EMBASE for studies published from 1 January 2006 to 31 December 2010 using the strategies in Appendix 1. Again we chose to use a pragmatic approach and limited our search to studies published in the last five years. We also excluded conference abstracts unless they had subsequently been published as full articles.

Data collection and analysis

One review author (CD) initially screened all search results for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, another author (SH) independently screened all remaining hits. We retrieved full text articles for all those references where we are unable to decide on eligibility based on the title and abstract alone. All full text articles were independently screened by two review authors (SH, MM) to ensure that they met the eligibility criteria.

Data extraction and management

Two review authors (SH, OO) independently extracted data from all included studies. Any disagreements were resolved by discussion or by consulting a third author if there was still uncertainty. We extracted data on the following study characteristics: the study design, how

1
2
3 patients were recruited, the country where the study was conducted, the source of funding,
4
5 the type of participants, their age, disease area, setting, the type of intervention /
6
7 comparator and nature of the exposure, the number of participants in each group, whether
8
9 any formal prescribing guidance was reported, the type of outcome measure (i.e. mortality)
10
11 and the time point at which it was measured.
12
13

14
15
16 We also extracted information on the statistical methods used to adjust for differences
17
18 between study groups, in particular the number of study covariates measured, whether
19
20 important covariates relating to red cell transfusion were assessed (i.e. age, sex, co-
21
22 morbidity, hemoglobin) and whether these were incorporated into the analysis, whether the
23
24 choice of covariates were pre-specified or data driven and the statistical model used for the
25
26 statistical adjustment. We also assessed the effects of smoking as a study covariate in
27
28 relation to blood transfusion and its effect on mortality. In terms of the study results we
29
30 extracted data on the presentation of both the unadjusted and adjusted result for the effect
31
32 of red cell transfusion on mortality as reported by each study. If not reported by the primary
33
34 study we calculated (where there were sufficient data) the odds ratio for the effect of blood
35
36 transfusion on mortality for unadjusted analyses using STATA (version 11). We assessed, for
37
38 the unadjusted and adjusted result, whether the study reported summary statistics for each
39
40 comparison group, the treatment effect, confidence interval, p value and whether the result
41
42 was statistically significant. If a study reported more than one adjusted analysis we selected
43
44 in order of preference (i) the main adjusted analysis mentioned in the abstract, (ii) the main
45
46 adjusted analysis mentioned in the conclusions, (iii) the main adjusted analysis mentioned in
47
48 the results section. If mortality was assessed for more than one time point (i.e. at 30 days
49
50 and 1 year) then we used the shorter time point in our analysis.
51
52
53
54
55

56 57 **Assessment of methodological quality** 58 59 60

1
2
3 We also assessed whether studies met important methodological criteria for the reporting
4 of observational studies (2): whether the samples were representative of those to whom the
5 results might be generalised, whether important covariates in relation to RBCT and mortality
6 (e.g. sex, age, smoking, co-morbidity, hemoglobin level) were measured and incorporated
7 into the analysis, whether the method of dealing with confounding between patient groups
8 was adequate, whether a statistician was listed as an author of the study and whether the
9 data were collected prospectively following an agreed study design. We included smoking as
10 a covariate as, while not directly correlated with transfusion, it is considered important
11 when assessing mortality.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Method of analysis**

26 We have presented the results separately for the three different types of comparisons.
27 Within each, due to the varied nature of the clinical conditions, study designs and level of
28 statistical adjustment, we decided a priori not to combine the results of individual studies in
29 a meta-analysis and instead present the results of the individual studies descriptively in the
30 text, tables and figures.
31
32
33
34
35
36
37
38
39

40 **Results**

41 Searches of MEDLINE and EMBASE identified 4318 possible records. 4272 did not meet the
42 eligibility criteria for this study. Full articles were retrieved for 45 studies; 13 further studies
43 were excluded as they did not fulfil our eligibility criteria (see Appendix 2 for list of excluded
44 studies). Thirty two studies were included in the review; 23 (7-30) studies assessed the
45 effects of RBCT versus no RBCT, five studies (31-35) assessed different volumes of RBCT and
46 four (36-39) assessed giving older versus newer RBCT (see Figure 1).
47
48
49
50
51
52
53
54
55
56

57 **Red blood cell transfusion versus no red blood cell transfusion**

1
2
3 Twenty three studies (7-30) assessed the effects of RBCT versus no RBCT on mortality. Four
4
5 of these studies (8;12;14;21) included both red cell transfusion and other blood products
6
7 (e.g. platelets, plasma, cryoprecipitate); for one study, data were available separately for
8
9 RBCT and mortality (14). For three studies it was unclear if other blood products were
10
11 transfused along with red blood cells (11;13;22).
12
13

14 15 16 *Study characteristics (Table 1)*

17
18 Eight studies were prospective cohort studies following up a planned group of patients
19
20 (7;8;15;16;18;24-27), the other 15 studies assessed data from a retrospective patient
21
22 registry or database. Fourteen studies were conducted in the USA, two in the UK, two in
23
24 Israel and the remainder in Belgium, the Netherlands, Iran and Denmark; one study was
25
26 conducted in multiple countries. The time period assessed was between 1989 and 2008.
27
28 Twelve of the studies (7;9;11;12;15-18;20-22;24;26) specifically looked at adults undergoing
29
30 cardiac surgery, five were in patients in the intensive care unit (10;25;27;29;30), two were in
31
32 adults trauma patients (8;28), two were in patients following hip fracture/replacement
33
34 (13;19) one was in oncology patients (14) and the other in pediatric trauma patients (23).
35
36 Three of the studies (12;20;21) specifically looked at the effects of RBCT in older adults (e.g.
37
38 > 60 years). The size of the studies varied from 1,624 participants to 504,208 participants
39
40 with an overall median sample size of 4344 (IQR 2085 to 11963); median 1068 (IQR 430 to
41
42 5812) for patients undergoing RBCT compared to median 2325 (IQR 1636 to 6151) for
43
44 patient with no RBCT. The time period at which mortality was assessed also varied across
45
46 studies from in-hospital to mortality at seven years; the most common time point being
47
48 mortality at or within 30 days. Several studies reported mortality for more than one time
49
50 period. Only seven of the 23 studies provided any mention of guidelines for the prescription
51
52 of RBCT; two studies said no formal protocol was used (8;23), two studies stated a
53
54 hemoglobin of <8g/dl (10;13), one study stated a hematocrit of less than 25-26% (22) and
55
56
57
58
59
60

1
2
3 two studies said prescription was at the discretion of the patient care team (24;25). For full
4
5 details of the characteristics of the included studies see Appendix 3.
6
7

8
9
10 *Statistical methods (Table 2)*

11 All 23 studies provided information on the statistical methods used to adjust for differences
12
13 in the baseline characteristics of patients who received RBCT and those who did not.
14
15 However, the amount of detail and appropriateness of the method used varied across
16
17 studies. In 13 studies (7;9;10;14-19;22;24;25;27;30) the choices of covariates measured
18
19 were reported as pre-specified and not data driven, but this was unclear for the remaining
20
21 10 studies. The number of covariates measured and incorporated in the analysis also varied
22
23 across studies with half the studies reported to assess more than 20 different covariates.
24
25 Despite the high number of covariates assessed in these studies, not all measured covariates
26
27 which appeared to be of specific importance in relation to RBCT. All of the 23 studies did
28
29 report measuring the age and sex of the patients and 21 reported measuring patient co-
30
31 morbidity. Overall, only eight (7;11;12;15-18;22;29) studies measured and incorporated the
32
33 covariates age, sex, smoking, co-morbidity and haemoglobin level into the adjusted analysis..
34
35 Fourteen of the 23 studies reported using logistic regression (i.e. mortality was reported as a
36
37 binary outcome) as the method of adjusting for differences in the baseline characteristics
38
39 between the two patients groups; six studies reported using Cox proportional hazard (i.e.
40
41 mortality was reported as a time to event outcome) and three studies reporting using both
42
43 methods; in these three studies mortality was assessed for more than one time period. Nine
44
45 studies (7;12;17-19;21;27;29) reported using propensity scores prior to adjusting for
46
47 confounders, however, sometimes this matching was only using a much smaller subgroup of
48
49 patients. For full details of the statistical methods see Appendix 4.
50
51
52
53
54

55
56
57 *Presentation of adjusted and unadjusted results (Table 3)*
58
59
60

1
2
3 There were marked differences in the presentation and reporting of the unadjusted and
4
5 adjusted results when comparing the effects of RBCT versus no RBCT on mortality. Seven of
6
7 the 23 studies reported a summary statistic for each group for both the unadjusted and
8
9 adjusted analysis. Five studies reported a summary statistics for only the unadjusted analysis
10
11 and one study for the adjusted analysis only; no summary statistic comparing the effects of
12
13 RBCT versus no RBCT on mortality was reported in the remained 10 studies. Eight studies
14
15 reported the treatment effect (e.g. odds ratio, risk ratio, hazard ratio) and the corresponding
16
17 confident interval (six studies) for both the unadjusted and adjusted analysis (7;15;16;18-
18
19 20;24;26;30), whereas 12 studies reported the treatment effect and confident interval (10
20
21 studies) for adjusted analysis only and one study for the unadjusted analysis only. Where
22
23 possible we calculated the odds ratio for the effect of RBCT on mortality for unadjusted
24
25 analyses if it was not reported in the published article.
26
27
28
29
30

31
32 Seventeen of the 23 studies reported a statistically significant result for the unadjusted
33
34 analysis, and 15 for the adjusted analysis (Figure 2), when comparing the effect of RBCT
35
36 versus no RBCT on mortality, with more deaths occurring in patients receiving transfusion.
37
38 This effect was statistically non-significant in seven studies based on the result of the
39
40 adjusted analysis. Prospective studies were more likely to show a statistically significant
41
42 effect for blood transfusion on mortality compared to retrospective studies for both the
43
44 unadjusted and adjusted analysis. For full details see Appendix 5.
45
46
47

48 **Volume 'A' red blood versus volume 'B' red blood cells**

49
50 Five studies (31-35) assessed the effect of different volumes of RBCT on mortality. One of
51
52 these studies (35) included both RBCT and other blood products.
53
54
55

56
57 *Study characteristics (Table 1)*
58
59
60

1
2
3 One study assessed a prospective cohort and followed up a planned group of patients (35),
4
5 the other four studies assessed data from a retrospective patient registry or database. Two
6
7 of the studies (33;35) specifically looked at adults undergoing cardiac surgery, one was in
8
9 trauma patients (32), one was in patients undergoing major surgery (31) and one in patients
10
11 in the intensive care unit (34). The size of the studies varied from 1,841 participants to
12
13 125,177 participants, with an overall median sample size of 8215 (IQR 3037 to 8799). The
14
15 volume of RBCT varied considerably across studies from 1-2 units to more than eight units.
16
17 The time period at which mortality was assessed also varied across studies from in-hospital
18
19 to mortality at eight years. Three of the five studies provided any mention of guidelines for
20
21 the prescription of red blood cells, however only one gave any specific requirement stating a
22
23 hemoglobin of <8g/dl (34) (See Appendix 3).
24
25
26
27
28

29 *Statistical methods (Table 2)*

30
31 All five studies provided information on the statistical methods used to adjust for differences
32
33 in the baseline characteristics of patients who received different volumes of red blood
34
35 transfusion, however, as with the studies of RBCT versus no RBCT, the amount of detail and
36
37 appropriateness of the method used varied across studies. In all five studies (31-35) the
38
39 choices of covariates measured were reported as pre-specified. The number of covariates
40
41 measured and incorporated in the analysis varied across studies with two the studies
42
43 reported to assess more than 20 different covariates. Once again, despite the high number
44
45 of covariates assessed in these studies, not all measured covariates seem to be of specific
46
47 importance in relation to RBCT. All five studies reported measuring age and sex and patient
48
49 co-morbidity, however, one (31) measured and incorporated the covariates age, sex,
50
51 smoking, co-morbidity and hemoglobin level into the adjusted analysis.
52
53
54
55
56

57 *Presentation of adjusted and unadjusted results (Table 3)*

1
2
3 As with the studies of RBCT versus no RBCT, there were marked difference in the
4 presentation and reporting of the unadjusted and adjusted results when comparing the
5 effects of different volumes of RBCT on mortality. Two studies reported a statistically
6 significant result for the adjusted analysis with more deaths occurring in patients receiving
7 larger volumes of RBCT. This effect was statistically non significant in two studies based on
8 the result for adjusted analysis and was not reported for the remaining one study. No
9 studies reported on the statistical significance of the result of the unadjusted analysis (See
10 Appendix 4 and 5).
11
12
13
14
15
16
17
18
19

20 21 22 **'Older' red blood cells versus 'newer' red blood cells**

23
24 Four (36-39) studies assessed the effects of age of RBCT on mortality, one of which
25 specifically looked at leukodepleted RBCT (39).
26
27
28
29
30

31 *Study characteristics (Table 1)*

32
33 All four studies assessed data from a retrospective patient registry or database. Two of the
34 studies (37;38) specifically looked at adults undergoing cardiac surgery, one was in trauma
35 patients (39), while the other did not mention a specific patient group. The size of the
36 studies varied from 1,813 participants to 364,037 participants, with an overall median
37 sample size of 4358 (IQR 2264 to 185019). The period of time in which the blood was stored
38 varied considerably across studies. Two studies (37;39) assessed RBCT stored for less than 14
39 days compared to those stored for more than 14 days, one study (38) compared blood
40 stored for less than 18 days and with blood stored for more than 18 days and one study (36)
41 looked at multiple storage periods ranging from 1 to 42 days. None of the studies provided
42 any mention of guidelines for the prescription of red blood cells (See Appendix 2).
43
44
45
46
47
48
49
50
51
52
53
54

55 56 57 *Statistical methods (Table 2)*

1
2
3 All four studies provided information on the statistical methods used to adjust for
4 differences in the baseline characteristics of patients who received RBCT stored for different
5 time periods, however, once again the amount of detail and appropriateness of the method
6 used varied across studies. The number of covariates measured and incorporated in the
7 analysis also varied across studies. All of the four studies reported measuring the age and
8 sex of the participants. Only two studies reported measuring patient hemoglobin levels and
9 three studies reported assessing patient co-morbidities. Only one (37) of the four studies
10 measured and incorporated the covariates age, sex, smoking, co-morbidity and haemoglobin
11 level into the adjusted analysis.
12
13
14
15
16
17
18
19
20
21
22
23

24 *Presentation of adjusted and unadjusted results (Table 3)*

25
26 As with the studies of RBCT versus no RBCT and of volume 'A' red blood cells versus volume
27 'B' RBCT, there were marked differences in the presentation and reporting of the unadjusted
28 and adjusted results when comparing the effects of RBCT stored for different time periods
29 on mortality. Two studies reported a statistically significant result for the unadjusted
30 analysis and one study reported a statistically significant result for the adjusted analysis. In
31 two of these three studies there were more deaths occurring in patients receiving older
32 blood and in one study there were more deaths in patients receiving newer blood. This
33 effect was statistically non significant in three studies based on the result for adjusted
34 analysis (See Appendix 4 and 5).
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Assessment of methodological quality (Table 4)**

49
50 Overall the assessment of methodological quality varied across studies and by study group
51 with only 10 of the 32 included studies assessing a prospective cohort following up a
52 planned group of patients over time, the remaining two-third of the studies assessed data
53 from a retrospective patient registry or database. In most studies the sample of patients
54
55
56
57
58
59
60

1
2
3 included in the study was considered representative of those to whom the results might be
4
5 generalised. Four studies (12;20;21;29) specifically focussed on older adults (>60 years) and
6
7 one study (23) on children, so the findings from these studies should only be interpreted in
8
9 relation to these specific patient groups. The baseline characteristics of patients who
10
11 received RBCT compared to those patients who did not receive RBCT (or patients who
12
13 received different volumes or age of blood) were often very different and so we wanted to
14
15 assess whether studies had adjusted for these differences when carrying out their statistical
16
17 analysis. Only 10 studies measured and incorporated in the analysis covariates which we
18
19 deemed of specific importance in relation to RBCT (i.e. age, sex, smoking, co-morbidity and
20
21 haemoglobin level), thus we deemed the method of dealing with confounding between
22
23 patient groups as adequate in only 31% of studies. Critically however, when we restricted
24
25 our analysis of results to studies with adequate methods, the pattern of an increase in
26
27 mortality associated with RBCT remained unchanged.
28
29
30
31
32

33 Discussion

34 *Summary of main findings*

35
36 We identified 32 observational studies of more than 1000 participants published between
37
38 2006 and 2010 assessing the effect of RBCT on mortality. Twenty three studies compared
39
40 RBCT versus no RBCT, five compared different volumes and four compared different storage
41
42 times. Overall there was considerable variability in the characteristics of the observational
43
44 studies. However, the majority, of studies were retrospective designs assessing patients
45
46 from an existing patient register or database.
47
48
49
50
51

52
53 We also identified considerable variability in the statistical methods used to adjust for
54
55 differences in the baseline characteristics of patients who received RBCT and those who did
56
57 not. It was often unclear if the choice of covariates measured and used in the adjusted
58
59
60

1
2
3 analyses were pre-specified at the start of the study or were driven by the underlying data.
4
5 Perhaps most importantly, around half of the 32 studies did not measure and adjust for
6
7 covariates which we deemed of specific importance to blood transfusion..
8
9

10
11 Overall, more studies found a higher rate of mortality in patients receiving RBCT compared
12
13 with those who did not, and this effect was seen in both the adjusted and unadjusted
14
15 results. In general, where measured equivalently within the same study, the unadjusted
16
17 estimate of risk was greater than the adjusted risk, emphasising that adverse prognostic
18
19 factors are more common in patients receiving RBCT and that adjusting for them leads to a
20
21 smaller estimate of risk. Considering the adjusted risks, although the size of the effect was
22
23 not consistent across all studies, the direction of the effect was. Most studies suggest an
24
25 increased risk of mortality associated with RBCT. Further, those studies which were designed
26
27 prospectively and which used better methods of adjusting for differences in the baseline
28
29 characteristics between groups were more likely to show an increase in the risk of mortality
30
31 compared to studies which were based on retrospective registries or databases, although,
32
33 again the size of the effect was not consistent across all studies. However, it is important to
34
35 remember that even with the best methods of adjustment it cannot completely eliminate
36
37 the impact of confounding (2), as the sicker the patients (thus an increased risk of mortality)
38
39 the more likely they are to have received RBCT.
40
41
42
43
44
45

46 *Comparison with other studies*

47

48 We are aware of one other systematic review of observational studies looking at the effects
49
50 of RBCT on mortality, which focussed specifically on critically ill adults in intensive care units
51
52 and adult trauma and surgical patients (40). This systematic review by Marik and colleagues
53
54 included more studies (n=45) than our review as it did not restrict its inclusion criteria to
55
56 studies with >1000 patients; the median number of patients analysed was 687. They also
57
58
59
60

1
2
3 found that RBCT was associated with an increased risk of mortality based on a meta-analysis
4
5 of 12 studies (odds ratio 1.7; 95% CI 1.4 to 1.9). However there was considerable
6
7 heterogeneity in the meta-analysis, suggesting that it might not have been appropriate to
8
9 combine the results of the individual studies and supports our decision not to conduct a
10
11 meta-analysis.
12

13
14
15 In an overview of evidence from randomized controlled trials Wilkinson and colleagues (41)
16
17 identified 142 trials in RBCT. The majority compared the effects of leucoreduced RBCT or
18
19 different transfusion triggers (n=71). However, they did identify 12 trials comparing the
20
21 effects of RBCT versus no transfusion, seven looking at different volumes of RBCT and 11
22
23 different ages of red blood cells. The size of the trials was very small (median 30 to 40
24
25 patients) and the overview did not specifically examine the effect of RBCT on mortality.
26
27 Currently, we are aware of at least 14 ongoing or recently completed randomized controlled
28
29 trials examining the effects of the age of RBCT on clinical outcomes including the ARIPI (Age
30
31 of Red blood cells In Premature Infants) (42) ABLE, (Age of Blood Evaluation trial in the
32
33 resuscitation of critically ill patients) (43), RECESS (REd CELL Storage duration Study) (44) and
34
35 INFORM (Effects of transfusing fresh versus standard-issue red cells on in-hospital mortality)
36
37 trials, for which mortality or survival is a specified outcome measure.
38
39
40
41
42
43

44 *Limitations*

45
46 Our study has several limitations. Firstly, we only included studies published in the last five
47
48 years and which included more than 1,000 patients. This was because we took a pragmatic
49
50 approach as we hypothesised that more recent studies were more likely to use better
51
52 statistical methods and also that studies with a larger sample size were more likely to show a
53
54 truer effect of the intervention (45) . Thus we aimed to provide a “snap shot” of current
55
56 practice rather provide a comprehensive review of all available evidence. It is possible
57
58
59
60

1
2
3 therefore that the overall effect seen here might be different in older studies and/or in
4 those carried out in smaller numbers of patients. Secondly, we decided not to combine the
5 results of individual studies because of the variability in clinical settings and study methods,
6 and instead presented the results of individual studies descriptively in the text and in tables
7 and figures. More formal statistical analysis might have given a more precise indication of
8 the overall effect of red cell transfusion on mortality, but would have ignored the significant
9 amount of clinical and methodological heterogeneity between studies which we identified a
10 priori and which was very apparent in the analysis done by Marik and colleagues (40).
11 However, in the absence of a more formal statistical analysis we have inevitably had to rely
12 on a vote-counting approach which also has great dangers, particularly the assumption that
13 each included study has equal weight. Our main protection against this is the very
14 pronounced nature of the pattern we have observed and the fact that we have limited our
15 conclusions to the direction of effect.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Finally, we limited our inclusion criteria to published articles and excluded unpublished
34 studies or those published only as conference abstracts; thus our study could be subject to
35 publication bias , as studies which did not show a significant effect of red cell transfusion on
36 mortality might be less likely to be published in full (46). Outcome reporting bias may also be
37 a problem, although difficult to combat, in the case where a risk has been measured at
38 different time points but only those time points which are “positive” are reported. However,
39 in the case of both publication and outcome reporting bias, the extreme nature of the
40 pattern makes it relatively implausible that there are sufficient unpublished studies or time
41 points to reverse it.
42
43
44
45
46
47
48
49
50
51
52
53
54

55 *Implications for clinical practice*
56
57
58
59
60

1
2
3 In recent years, many developed countries including the UK, USA and Australia have
4 developed national initiatives for better blood transfusion practice, sometimes called
5 'patient blood management' (4;5). These include the development of guidelines on blood
6 usage promoting restrictive transfusion strategies and initiatives for using alternatives to
7 transfusion (e.g. cell salvage techniques; improvements in the education and training of
8 clinical staff prescribing blood; the provision of mechanisms for reviewing blood use with
9 feedback of data to clinicians). National data on blood usage in the USA suggests an
10 estimated decline of 3% over each of the last two years (2009-2010) (4), and similar data are
11 available in the UK where the demand for red cell units, which steadily increased during the
12 1990s, has decreased by about 20% in the last 10 years. However, there remains
13 considerable variation between hospitals in blood reduction, and national audits of blood
14 components in the UK and elsewhere suggest that overall blood usage could be further
15 reduced without compromising patient safety (3).

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33 It is difficult to assess how observational studies may have influenced these changes in
34 transfusion practice in comparison to evidence from randomized controlled trials, national
35 guidelines, and process driven initiatives. The most likely answer is that they have all played
36 a role in changing practice. Randomized controlled trials have found that 'restrictive'
37 transfusion strategies are associated with similar or improved clinical outcomes compared to
38 'liberal' transfusion strategies (47). Many national guidelines have adopted restrictive
39 transfusion strategies (47), while needing to make assumptions about the generalisability of
40 the findings of randomized controlled trials in specific clinical groups of patients. There have
41 been many smaller observational studies of process initiatives to reduce transfusion that
42 also indicate reductions in the use of blood without any significant impact on clinical
43 outcomes (48-50).

Conclusion

The findings from this systematic review of recent large scale observational studies show considerable variability in the patient populations and study methods when comparing the effects of RBCT on mortality. Overall, observational studies do show a consistent adverse effect of RBCT on mortality. Although it seems unlikely that this can be entirely explained by selective sampling or a predominance of poorer quality observational studies, it remains possible that even the best conducted adjustments cannot completely eliminate the impact of confounding. ...

Author contributions: SH and OO were involved in the design, implementation, and analysis of the study and in writing the final manuscript. CH, MM and LY were involved in the design and analysis of the study and in writing the final manuscript.

Financial disclosures: None reported.

Funding/support: This study was funded by NHS Blood and Transplant, Research and Development, UK.

Additional contributions: We are grateful to Susan Brunskill for her helpful comments on this manuscript.

References

- (1) Blajchman MA. Landmark studies that have changed the practice of transfusion medicine. *Transfusion* 2005 September;45(9):1523-30.
- (2) Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M, Altman DG. Evaluating non-randomised intervention studies. *Health Technol Assess* 2003;7(27):iii-173.
- (3) Murphy MF, Stanworth SJ, Yazer M. Transfusion practice and safety: current status and possibilities for improvement. *Vox Sang* 2011 January;100(1):46-59.
- (4) Goodnough LT, Shander A. Patient blood management. *Anesthesiology* 2012 June;116(6):1367-76.

- 1
2
3 (5) NHS blood transfusion and transplant / Royal College of Physicians national
4 comparative audit of blood transfusion programme. [http://hospital](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp)
5 [blood.co.uk/safe_use/clinical_audit/national_comparative/index](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp)
6 [asp](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp) [accessed 5 March
7 2013] 2013.
- 8
9 (6) Bennett-Guerrero E, Zhao Y, O'Brien SM, Ferguson TB, Jr., Peterson ED, Gammie JS,
10 Song HK. Variation in use of blood transfusion in coronary artery bypass graft
11 surgery. *JAMA* 2010 October 13;304(14):1568-75.
- 12
13 (7) Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, Markiewicz W,
14 Hammerman H. Impact of red blood cell transfusion on clinical outcomes in patients
15 with acute myocardial infarction. *Am J Cardiol* 2008 July 15;102(2):115-9.
- 16
17 (8) Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Meyer W, Scalea TM. Outcome
18 analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted
19 study. *World J Surg* 2008 October;32(10):2185-9.
- 20
21 (9) Engoren M, Habib RH, Hadaway J, Zacharias A, Schwann TA, Riordan CJ, Durham SJ,
22 Shah A. The effect on long-term survival of erythrocyte transfusion given for cardiac
23 valve operations. *Ann Thorac Surg* 2009 July;88(1):95-100, 100.
- 24
25 (10) Engoren M, Arslanian-Engoren C. Long-term survival in the intensive care unit after
26 erythrocyte blood transfusion. *Am J Crit Care* 2009 March;18(2):124-31.
- 27
28 (11) Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, Mittelman M, Battler
29 A, Shotan A, Gottlieb S, Caspi A, Hasdai D. Blood transfusion for acute
30 decompensated heart failure--friend or foe? *Am Heart J* 2009 October;158(4):653-8.
- 31
32 (12) Jani SM, Smith DE, Share D, Kline-Rogers E, Khanal S, O'Donnell MJ, Gardin J,
33 Moscucci M. Blood transfusion and in-hospital outcomes in anemic patients with
34 myocardial infarction undergoing percutaneous coronary intervention. *Clin Cardiol*
35 2007 October;30(10 Suppl 2):II49-II56.
- 36
37 (13) Johnston P, Wynn-Jones H, Chakravarty D, Boyle A, Parker MJ. Is perioperative blood
38 transfusion a risk factor for mortality or infection after hip fracture? *J Orthop*
39 *Trauma* 2006 November;20(10):675-9.
- 40
41 (14) Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood
42 transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch*
43 *Intern Med* 2008 November 24;168(21):2377-81.
- 44
45 (15) Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone
46 EH. Morbidity and mortality risk associated with red blood cell and blood-
47 component transfusion in isolated coronary artery bypass grafting. *Crit Care Med*
48 2006 June;34(6):1608-16.
- 49
50 (16) Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion
51 in coronary artery bypass grafting is associated with reduced long-term survival. *Ann*
52 *Thorac Surg* 2006 May;81(5):1650-7.
- 53
54 (17) Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased
55 mortality, postoperative morbidity, and cost after red blood cell transfusion in
56 patients having cardiac surgery. *Circulation* 2007 November 27;116(22):2544-52.
- 57
58
59
60


- 1
2
3 (18) Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tchong JE, Griffin JJ,
4 Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of
5 blood transfusion after primary angioplasty for acute myocardial infarction: analysis
6 from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late
7 Angioplasty Complications) Trial. *JACC Cardiovasc Interv* 2009 July;2(7):624-32.
8
9 (19) Pedersen AB, Mehnert F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and
10 prognosis following total hip replacement: a population-based follow up study. *BMC*
11 *Musculoskelet Disord* 2009;10:167.
12
13 (20) Rogers MA, Blumberg N, Saint SK, Kim C, Nallamotheu BK, Langa KM. Allogeneic blood
14 transfusions explain increased mortality in women after coronary artery bypass graft
15 surgery. *Am Heart J* 2006 December;152(6):1028-34.
16
17 (21) Rogers MA, Blumberg N, Saint S, Langa KM, Nallamotheu BK. Hospital variation in
18 transfusion and infection after cardiac surgery: a cohort study. *BMC Med* 2009;7:37.
19
20 (22) Salehiomran A, Ahmadi H, Karimi A, Tazik M, Dowlatshahi S, Fathollahi M.S., Abbasi
21 S.H. Transfusion associated in-hospital mortality and morbidity in isolated coronary
22 artery bypass graft surgery. *Central European Journal of Medicine* 2009;4(3):286-92.
23
24 (23) Stone TJ, Riesenman PJ, Charles AG. Red blood cell transfusion within the first 24
25 hours of admission is associated with increased mortality in the pediatric trauma
26 population: a retrospective cohort study. *J Trauma Manag Outcomes* 2008;2(1):9.
27
28 (24) Surgenor SD, Kramer RS, Olmstead EM, Ross CS, Sellke FW, Likosky DS, Marrin CA,
29 Helm RE, Jr., Leavitt BJ, Morton JR, Charlesworth DC, Clough RA, Hernandez F,
30 Frumiento C, Benak A, DioData C, O'Connor GT. The association of perioperative red
31 blood cell transfusions and decreased long-term survival after cardiac surgery.
32 *Anesth Analg* 2009 June;108(6):1741-6.
33
34 (25) Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K,
35 Cappadoro C, Fu M, Plisco MS, Sadaka FG, Veremakis C. Red blood cell transfusions
36 and nosocomial infections in critically ill patients. *Crit Care Med* 2006
37 September;34(9):2302-8.
38
39 (26) van Straten AH, Bekker MW, Soliman Hamad MA, van Zundert AA, Martens EJ,
40 Schonberger JP, de Wolf AM. Transfusion of red blood cells: the impact on short-
41 term and long-term survival after coronary artery bypass grafting, a ten-year follow-
42 up. *Interact Cardiovasc Thorac Surg* 2010 January;10(1):37-42.
43
44 (27) Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated
45 with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients
46 study. *Anesthesiology* 2008 January;108(1):31-9.
47
48 (28) Weinberg JA, McGwin G, Jr., Marques MB, Cherry SA, III, Reiff DA, Kerby JD, Rue LW,
49 III. Transfusions in the less severely injured: does age of transfused blood affect
50 outcomes? *J Trauma* 2008 October;65(4):794-8.
51
52 (29) Wu WC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G, Mor V, Sharma SC,
53 Vezeridis M, Khuri SF, Friedmann PD. Operative blood loss, blood transfusion, and
54 30-day mortality in older patients after major noncardiac surgery. *Ann Surg* 2010
55 July;252(1):11-7.
56
57
58
59
60

- 1
2
3 (30) Zilberberg MD, Stern LS, Wiederkehr DP, Doyle JJ, Shorr AF. Anemia, transfusions
4 and hospital outcomes among critically ill patients on prolonged acute mechanical
5 ventilation: a retrospective cohort study. *Crit Care* 2008;12(2):R60.
6
7 (31) Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB.
8 Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with
9 increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general
10 surgery patients. *J Am Coll Surg* 2009 May;208(5):931-7, 937.
11
12 (32) Charles A, Shaikh AA, Walters M, Huehl S, Pomerantz R. Blood transfusion is an
13 independent predictor of mortality after blunt trauma. *Am Surg* 2007
14 January;73(1):1-5.
15
16 (33) O'Keeffe SD, Davenport DL, Minion DJ, Sorial EE, Endean ED, Xenos ES. Blood
17 transfusion is associated with increased morbidity and mortality after lower
18 extremity revascularization. *J Vasc Surg* 2010 March;51(3):616-21, 621.
19
20 (34) Ruttinger D, Wolf H, Kuchenhoff H, Jauch KW, Hartl WH. Red cell transfusion: an
21 essential factor for patient prognosis in surgical critical illness? *Shock* 2007
22 August;28(2):165-71.
23
24 (35) Weightman WM, Gibbs NM, Sheminant MR, Newman MA, Grey DE. Moderate
25 exposure to allogeneic blood products is not associated with reduced long-term
26 survival after surgery for coronary artery disease. *Anesthesiology* 2009
27 August;111(2):327-33.
28
29 (36) Edgren G, Kamper-Jorgensen M, Eloranta S, Rostgaard K, Custer B, Ullum H, Murphy
30 EL, Busch MP, Reilly M, Melbye M, Hjalgrim H, Nyren O. Duration of red blood cell
31 storage and survival of transfused patients (CME). *Transfusion* 2010
32 June;50(6):1185-95.
33
34 (37) Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH.
35 Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*
36 2008 March 20;358(12):1229-39.
37
38 (38) van de Watering L, Lorinser J, Versteegh M, Westendorp R, Brand A. Effects of
39 storage time of red blood cell transfusions on the prognosis of coronary artery
40 bypass graft patients. *Transfusion* 2006 October;46(10):1712-8.
41
42 (39) Weinberg JA, McGwin G, Jr., Griffin RL, Huynh VQ, Cherry SA, III, Marques MB, Reiff
43 DA, Kerby JD, Rue LW, III. Age of transfused blood: an independent predictor of
44 mortality despite universal leukoreduction. *J Trauma* 2008 August;65(2):279-82.
45
46 (40) Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a
47 systematic review of the literature. *Crit Care Med* 2008 September;36(9):2667-74.
48
49 (41) Wilkinson KL, Brunskill SJ, Doree C, Hopewell S, Stanworth S, Murphy MF, Hyde C.
50 The clinical effects of red blood cell transfusions: an overview of the randomized
51 controlled trials evidence base. *Transfus Med Rev* 2011 April;25(2):145-55.
52
53 (42) Fergusson DA, Hebert P, Hogan DL, LeBel L, Rouvinez-Bouali N, Smyth JA, Sankaran
54 K, Tinmouth A, Blajchman MA, Kovacs L, Lachance C, Lee S, Walker CR, Hutton B,
55 Ducharme R, Balchin K, Ramsay T, Ford JC, Kakadekar A, Ramesh K, Shapiro S. Effect
56
57
58
59
60

1
2
3 of fresh red blood cell transfusions on clinical outcomes in premature, very low-
4 birth-weight infants: the ARIPI randomized trial. *JAMA* 2012 October
5 10;308(14):1443-51.
6

- 7 (43) Lacroix J, Hebert P, Fergusson D, Tinmouth A, Blajchman MA, Callum J, Cook D,
8 Marshall JC, McIntyre L, Turgeon AF. The Age of Blood Evaluation (ABLE) randomized
9 controlled trial: study design. *Transfus Med Rev* 2011 July;25(3):197-205.
10
11 (44) Steiner ME, Assmann SF, Levy JH, Marshall J, Pulkrabek S, Sloan SR, Triulzi D, Stowell
12 CP. Addressing the question of the effect of RBC storage on clinical outcomes: the
13 Red Cell Storage Duration Study (RECESS) (Section 7). *Transfus Apher Sci* 2010
14 August;43(1):107-16.
15
16 (45) Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show
17 larger treatment effects than multicenter trials: evidence from a meta-epidemiologic
18 study. *Ann Intern Med* 2011 July 5;155(1):39-51.
19
20 (46) Scherer RW, Langenberg P, von EE. Full publication of results initially presented in
21 abstracts. *Cochrane Database Syst Rev* 2007;(2):MR000005.
22
23 (47) Goodnough LT, Levy JH, Murphy MF. Current concepts in transfusion. *Lancet*
24 2013;[in press].
25
26 (48) Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on
27 preoperative anaemia, transfusion rate, and outcome after primary hip or knee
28 arthroplasty: a quality improvement cycle. *Br J Anaesth* 2012 June;108(6):943-52.
29
30 (49) Freedman J, Luke K, Escobar M, Vernich L, Chiavetta JA. Experience of a network of
31 transfusion coordinators for blood conservation (Ontario Transfusion Coordinators
32 [ONTraC]). *Transfusion* 2008 February;48(2):237-50.
33
34 (50) Helm RE, Rosengart TK, Gomez M, Klemperer JD, DeBois WJ, Velasco F, Gold JP,
35 Altorki NK, Lang S, Thomas S, Isom OW, Krieger KH. Comprehensive multimodality
36 blood conservation: 100 consecutive CABG operations without transfusion. *Ann*
37 *Thorac Surg* 1998 January;65(1):125-36.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Flow diagram of study inclusion (1 January 2006 to 31 December 2010)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Figure 2: Effect of red blood cell transfusion versus no red blood cell transfusion on mortality (adjusted results)




Table 1: Summary of characteristics of included studies

Type of comparison	RBC vs. no RBC (n=23)	Volume 'A' vs. Volume 'B'(n=5)	Old RBC vs. new RBC (n=4)
Design			
Prospective	8 (35%)	1 (20%)	
Retrospective	15 (65%)	4 (80%)	4 (100%)
Country			
Australia		1 (20%)	
Belgium	1 (4%)		
Denmark	1 (4%)		
Germany		1 (20%)	
Iran	1 (4%)		
Israel	2 (9%)		
Netherlands	1 (4%)		1 (25%)
Sweden			1 (25%)
USA	14 (61%)	3 (60%)	2 (50%)
UK	2 (9%)		
(multiple sites)	1 (4%)		
Time period assessed			
	1989-2008	1993-2007	1993-2007
Sample size (median, IQR)			
All patients	4344 (IQR 2085-11963)	8215 (IQR 3037-8799)	4358 (2264-185019)
RBC transfusion	1068 (IQR 430-5812)		
No RBC transfusion	2325 (IQR 1636-6151)		
Disease area			
Cardiac surgery	12 (52%)	2 (40%)	2 (50%)
Hip fracture/replacement	2 (9%)		
Intensive care	5 (22%)	1 (20%)	
Oncology	1 (4%)		
Surgery		1 (20%)	
Trauma adults	2 (9%)	1 (20%)	1 (25%)
Trauma paediatrics	1 (4%)		
Not reported			1 (25%)
Prescribing guidance			
Reported	7 (30%)	3 (60%)	
Not reported	16 (70%)	2 (40%)	4 (100%)
Mortality assessed*			
In hospital	8	2	2
30 days	10	2	1
3 months	3		
6 months	3		
>1 year	4	1	2
Time period not specified	2		1

*studies reported mortality for >1 time point based on binary only and / or time-to-event outcome

Table 2: Method of adjusted analysis

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Choice of covariates			
Pre-specified	13 (57%)	5 (100%)	4 (100%)
Post hoc			
Unclear	10 (43%)		
No. of covariates measured			
1-5	2 (9%)		
6-10	4 (17%)	1 (20%)	2 (50%)
11-20	3 (13%)	2 (40%)	
>20	12 (52%)	2 (40%)	1 (25%)
Unclear	2 (9%)		1 (25%)
Important covariates assessed			
Age	23 (100%)	5 (100%)	4 (100%)
Sex	23 (100%)	5 (100%)	4 (100%)
Smoking	8 (35%)	1 (20%)	1 (25%)
Co-morbidity	21 (91%)	5 (100%)	3 (75%)
Hb level	14 (61%)	4 (80%)	2 (50%)
Important covariates incorporated into analysis			
Yes	8 (35%)	1 (20%)	1 (25%)
No	15 (65%)	4 (80%)	3 (75%)
Method of adjustment			
Cox proportional hazard	6 (26%)	1 (20%)	1 (25%)
Logistic regression	14 (61%)	4 (80%)	2 (50%)
Both *	3 (13%)		
Not reported			1 (25%)

*studies reported >1 method of adjustment when mortality was assessed for >1 time point

Table 3: Presentation of results for unadjusted and adjusted analysis (mortality)

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Summary statistic for each group			
Unadjusted only	5 (22%)	2 (40%)	
Adjusted only	1 (4%)		
Both	7 (30%)		1 (25%)
Not reported	10 (44%)	3 (60%)	3 (75%)
Treatment effect			
Unadjusted only	1 (4%)		
Adjusted only	12 (52%)	5 (100%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	2 (9%)		1 (25%)
Confidence interval of treatment effect			
Unadjusted only			
Adjusted only	10 (43%)	3 (60%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	5 (22%)	2 (40%)	1 (25%)
P-value for treatment effect			
Unadjusted only	7 (30%)		
Adjusted only		1 (20%)	
Both	1 (4%)		1 (25%)
Not reported	15 (66%)	4 (80%)	3 (75%)
Unadjusted analysis*			
Statistically significant	17 (74%)		2 (50%)
Statistically non-significant	1 (4%)		
Not reported	5 (22%)	5 (100%)	2 (50%)
Adjusted analysis*			
Statistically significant	15 (65%)	2 (40%)	1 (25%)
Statistically non-significant	7 (31%)	2 (40%)	3 (75%)
Not reported	1 (4%)	1 (20%)	

*mortality outcome – if >1 time point analysed the time point with the non-significant result was recorded

Table 4: Assessment of methodological quality of the included studies

Study ID	Data collected prospectively	Sample representative	Important covariates measured	Important covariates incorporated into analysis	Method of dealing with confounding adequate*
Aronson 2008 (3)	Yes	Unclear	Yes	Yes	Yes
Bernard 2009 (27)	No	Yes	Yes	Yes	Yes
Bochicchio 2008 (4)	Yes	Yes	No	No	No
Charles 2007 (28)	No	Yes	No	No	No
Edgren 2010 (32)	No	Yes	No	No	No
Engoren 2009 (5)	No	Yes	No	No	No
Engoren 2009 (6)	No	Yes	No	No	No
Garty 2009 (7)	No	Yes	Yes	Yes	Yes
Jani 2007 (8)	No	No (>60 years)	Yes	Yes	Yes
Johnson 2006 (9)	No	Unclear	No	No	No
Khorana 2008 (10)	No	Yes	No	No	No
Koch 2006 (11,12)	Yes	Yes	Yes	Yes	Yes
Koch 2008 (33)	No	Yes	Yes	Yes	Yes
Murphy 2007 (13)	No	Yes	Yes	Yes	Yes
Nikolsky 2009 (14)	Yes	Yes	Yes	Yes	Yes
O'Keefe 2010 (29)	Yes	Yes	No	No	No
Pederson 2009 (15)	No	Yes	No	No	No
Rogers 2006 (16)	No	No (>65 years)	No	No	No
Rogers 2009 (17)	No	No (> 65 years)	No	No	No
Ruttinger 2007 (30)	No	Yes	No	No	No
Salehiomran 2009 (18)	No	Yes	Yes	Yes	Yes
Stone 2008 (19)	No	No (< 16 years))	No	No	No
Surgenor 2009 (20)	Yes	Yes	No	No	No
Taylor 2006 (21)	Yes	Yes	No	No	No
van de Watering 2006 (34)	No	Yes	No	No	No
van Straten 2010 (22)	Yes	Yes	No	No	No
Vincent 2008 (23)	Yes	Yes	No	No	No
Weightman 2009 (31)	Yes	Yes	No	No	No
Weinburg 2008 (24)	No	Yes	No	No	No
Weinburg 2008 (35)	No	Yes	No	No	No

Wu 2010 (25)	No	No (> 65 years)	Yes	Yes	Yes
Zilberberg 2008 (26)	No	Yes	No	No	No

*The method of dealing with confounding was deemed adequate if important covariates were measured and adjusted for in the analysis.

For peer review only

1
2
3
4
5
6
7
8 **Time to act on evidence from recent A systematic review of the effect**
9
10 **of red blood cell transfusion on mortality: evidence from large scale**
11 **observational studies published between 2006 and 2010 of the clinical**
12 **outcomes efficacy of red blood cell transfusions? Insights from a**
13 **systematic review**
14
15
16
17
18
19
20
21
22
23
24
25

26 Sally Hopewell^{1,2}, Omar Omar², Chris Hyde³, Ly-Mee Yu², Carolyn Doree¹, Mike F. Murphy¹
27
28
29

- 30
31
32
33
34
35
36
37
38
39
40
1. Systematic Review Initiative, NHS Blood and Transplant, Department of Haematology, Oxford University Hospitals and University of Oxford, UK.
 2. Centre for Statistics in Medicine, University of Oxford, Oxford, UK
 3. PenTAG, Peninsula College of Medicine and Dentistry, Exeter, UK

41 Correspondence to:

42
43 Dr Sally Hopewell, Centre for Statistics in Medicine, University of Oxford, Wolfson College,
44 Linton Road, Oxford, OX2 6UD, UK. Tel: +44 1865 284400; Fax: +44 1865 284424; Email:

45
46 sally.hopewell@csm.ox.ac.uk
47

48
49 **Keywords**

50 Systematic review, observational studies, transfusion, mortality.
51

52
53 Word count 4324
54
55
56
57
58
59
60

ABSTRACT

Objective: To carry out a systematic review of recently published large scale observational studies assessing the effect of red blood cell transfusion (RBCT) on mortality the efficacy clinical outcomes of red blood cell transfusion (RBCT), with particular emphasis on the statistical methods used to adjust for confounding. Given the limited number of randomized trials of the efficacy of RBCT, clinicians often use evidence from observational studies. However, confounding factors, for example individuals receiving blood generally being sicker than those who do not, makes their interpretation challenging.

Design: Systematic review.

Information sources: We searched MEDLINE and EMBASE for studies published from 1 January 2006 to 31 December 2010.

Eligibility criteria for included studies: We included prospective cohort, case control studies or retrospective analyses of databases or disease registers where the effect of risk factors for mortality or survival was examined. Studies must have included more than 1000 participants receiving RBCT for any cause. We assessed the effects of RBCT versus no RBCT and different volumes and age of RBCT.

Results: Thirty two studies were included in the review; 23 assessed the effects of RBCT versus no RBCT; five assessed different volumes and four older versus newer RBCT. There was considerable variability in the patient populations, study designs and level of statistical adjustment. Overall, most studies showed a higher rate of mortality when comparing patients who received RBCT with those who did not, even when these rates were adjusted for confounding; the majority of these increases were statistically significant. The same pattern was observed in studies where protection from bias was likely to be greater, such as prospective studies.

Conclusion: Recent observational studies do show a consistent adverse effect of RBCT on mortality. Whether this is a true effect remains uncertain as it is possible that even the best

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~conducted adjustments cannot completely eliminate the impact of confounding, and should be addressed by conducting further well designed and powered clinical studies, and where possible well designed and powered randomized controlled trials.~~

For peer review only

ARTICLE SUMMARY

Article focus

- Given the limited number of randomized trials of the efficacy of red blood cell transfusion (RBCT), clinicians often use evidence from observational studies.
- Confounding factors, for example individuals receiving blood generally being sicker than those who do not, can make their interpretation challenging.
- Our objective was to systematically review ~~recent~~ large observational studies (n>1000 patients) published in the last five years ~~-assessing~~ the ~~effect~~ efficacy of RBCT on mortality, with particular emphasis on the statistical methods used to adjust for confounding.

Key messages

- We identified considerable variability in the patient populations, study designs and level of statistical adjustment.
- Most studies showed higher mortality rates when comparing patients who received RBCT with those who did not, even when adjusting for confounding. We identified similar patterns in studies where protection from bias was likely to be greatest.

Strengths and limitations of this study

- Overall, observational studies do show a consistent adverse effect of RBCT on mortality.
- However, even the best conducted adjustments for confounding cannot completely eliminate its impact, particularly when investigating the effect of RBCT on mortality.

Introduction

Randomized controlled trials are considered the gold standard with which to evaluate the efficacy of a particular health care intervention. In 2005, Blajchman (1) published a study that explored the impact that ten landmark randomized controlled trials have had on the practice of transfusion medicine. The use of randomized trials to evaluate transfusion medicine has only been established since the 1980s (1). Given the limited number of high quality randomized trials of the efficacy of blood transfusion and the challenges of conducting new trials, clinicians often rely on evidence from observational studies. In a randomized trial patients are allocated to comparison groups at random, so the level of disease is likely to be similar in each group and differences in disease severity unlikely to be the explanation for any differences in outcome seen. In an observational study, ~~whether a treatment is received or not is likely to be heavily influenced by perceived need by the treating doctor and this will be particularly true where the outcomes of transfused patients are being compared with those not transfused. In this case~~ the groups of patients being compared are not likely to be comparable and the differences in prognostic factors may of themselves lead to difference in outcome. The impact of such "confounding" can be reduced by adjustment in the statistical analysis, but the success of this is dependent on the technique used, complete identification of the factors which might influence outcome and their accurate measurement in the patients in the study (2). As all the factors influencing outcome may never be known, adjustment is unlikely to ever completely account for the confounding occurring in observational studies. The unknown inter-dependence of multiple factors is also a major challenge.

~~The impact that the contribution of data from observational studies has made to the practice of transfusion medicine has not been systematically explored. There is increasing implementation of restrictive policies for transfusion, and evidence of reduction in blood use~~

1
2
3 in several countries such as the United Kingdom (UK) and the United States of America (USA)
4 with no evidence of poorer clinical outcomes(3;4). However, there remains considerable
5 variation between hospitals in blood reduction in the UK (5) and elsewhere (6) suggesting
6 that overall blood usage could be further reduced without compromising patient safety.
7
8 However, Observational studies may have influenced these changes in transfusion practice
9 along with evidence from randomized controlled trials, national guidelines, and process
10 driven initiatives, but the impact that the contribution of data from observational studies
11 has made to the practice of transfusion medicine has not been systematically explored.
12 given their publication in major journals, their impact on clinicians may be greater than is
13 appropriate for the types of studies and the limitations associated with their design. The
14 aims of this systematic review were therefore to identify recently published (2006 to 2010),
15 large scale observational studies assessing the effectsiveness of red blood cell transfusion
16 (RBCT) on mortality. In particular ,we aimed to critique them with particular emphasis on the
17 statistical methods, and the assumptions made in the analyses of the observational data,
18 and to consider the validity of these data as an evidence base for the practice of transfusion
19 medicine and to inform future research in this field.

Methods

Criteria for selecting studies

Type of participants

We included both adults and children receiving RBCT for any cause. We also included studies which stated that patients received red blood cells and other blood products. When reported by the primary studies we assessed the effects of RBCT separately from other blood products.

Type of intervention and comparator

We included the following risk factors:

- RBCT versus no RBCT
- Volume 'A' of RBCT versus volume 'B' of RBCT (as defined by the primary studies)
- 'Older' RBCT versus 'newer' RBCT (as defined by the primary studies)

Type of outcome measure

Our primary outcome measure was death, mortality or survival measured at any time point.

Type of studies

We included prospective cohort, case control studies or retrospective analyses of databases or disease registers where the effect of the above risk factors on death, mortality or survival is examined. Studies must have included more than 1000 participants. This was a pragmatic limit designed to focus attention on studies most likely to have had an impact and least likely to have been affected by chance.

Search strategy

We carried out a comprehensive search ([21 January 2011](#)) of MEDLINE and EMBASE for studies published from 1 January 2006 to 31 December 2010 using the strategies in Appendix 1. [Again we chose to use a pragmatic approach and limited our search to studies published in the last five years.](#) We [also](#) excluded conference abstracts unless they had subsequently been published as full articles.

Data collection and analysis

One review author (CD) initially screened all search results for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter, another author (SH) independently screened all remaining hits. We retrieved full text articles for all

1
2
3 those references where we are unable to decide on eligibility based on the title and abstract
4
5 alone. All full text articles were independently screened by two review authors (SH, MM) to
6
7 ensure that they met the eligibility criteria.
8
9

10 11 **Data extraction and management**

12
13 Two review authors (SH, OO) independently extracted data from all included studies. Any
14
15 disagreements were resolved by discussion or by consulting a third author if there was still
16
17 uncertainty. We extracted data on the following study characteristics: the study design, how
18
19 patients were recruited, the country where the study was conducted, the source of funding,
20
21 the type of participants, their age, disease area, setting, the type of intervention /
22
23 comparator and nature of the exposure, the number of participants in each group, whether
24
25 any formal prescribing guidance was reported, the type of outcome measure (i.e. mortality)
26
27 and the time point at which it was measured.
28
29

30
31
32
33 We also extracted information on the statistical methods used to adjust for differences
34
35 between study groups, in particular the number of study covariates measured, whether
36
37 important covariates relating to red cell transfusion were assessed (i.e. age, sex, co-
38
39 morbidity, hemoglobin) and whether these were incorporated into the analysis, whether the
40
41 choice of covariates were pre-specified or data driven and the statistical model used for the
42
43 statistical adjustment. We also assessed the effects of smoking as a study covariate in
44
45 relation to blood transfusion and its effect on mortality. In terms of the study results we
46
47 extracted data on the presentation of both the unadjusted and adjusted result for the effect
48
49 of red cell transfusion on mortality as reported by each study. If not reported by the primary
50
51 study we calculated (where there were sufficient data) the odds ratio for the effect of blood
52
53 transfusion on mortality for unadjusted analyses using STATA (version 11). We assessed, for
54
55 the unadjusted and adjusted result, whether the study reported summary statistics for each
56
57
58
59
60

1
2
3 comparison group, the treatment effect, confidence interval, p value and whether the result
4
5 was statistically significant. If a study reported more than one adjusted analysis we selected
6
7 in order of preference (i) the main adjusted analysis mentioned in the abstract, (ii) the main
8
9 adjusted analysis mentioned in the conclusions, (iii) the main adjusted analysis mentioned in
10
11 the results section. If mortality was assessed for more than one time point (i.e. at 30 days
12
13 and 1 year) then we used the shorter time point in our analysis.
14
15

16 17 18 **Assessment of methodological quality**

19
20 We also assessed whether studies met important methodological criteria for the reporting
21
22 of observational studies⁽²⁾: whether the samples were representative of those to whom the
23
24 results might be generalised, whether important covariates in relation to RBCT and mortality
25
26 (e.g. sex, age, smoking, co-morbidity, hemoglobin level) were measured and incorporated
27
28 into the analysis, whether the method of dealing with confounding between patient groups
29
30 was adequate, whether a statistician was listed as an author of the study and whether the
31
32 data were collected prospectively following an agreed study design. We included smoking as
33
34 a covariate as, while not directly correlated with transfusion, it is considered important
35
36 when assessing mortality.
37
38
39
40
41

42 **Method of analysis**

43
44 We have presented the results separately for the three different types of comparisons.
45
46 Within each, due to the varied nature of the clinical conditions, study designs and level of
47
48 statistical adjustment, we decided a priori not to combine the results of individual studies in
49
50 a meta-analysis and instead present the results of the individual studies descriptively in the
51
52 text, tables and figures.
53
54

55 56 57 **Results**

1
2
3 Searches of MEDLINE and EMBASE identified 4318 possible records. 4272 did not meet the
4 eligibility criteria for this study. Full articles were retrieved for 45 studies; 13 further studies
5 were excluded as they did not fulfil our eligibility criteria (see [Appendix 2 for list of excluded](#)
6 [studiesFigure 1](#)). Thirty two studies were included in the review; 23 (7-30) studies assessed
7 the effects of RBCT versus no RBCT, five studies (31-35) assessed different volumes of RBCT
8 and four (36-39) assessed giving older versus newer RBCT: [\(see Figure 1\)](#).
9
10
11
12
13
14
15
16
17

18 **Red blood cell transfusion versus no red blood cell transfusion**

19
20 Twenty three studies (7-30) assessed the effects of RBCT versus no RBCT on mortality. Four
21 of these studies (8;12;14;21) included both red cell transfusion and other blood products
22 (e.g. platelets, plasma, cryoprecipitate); for one study, data were available separately for
23 RBCT and mortality (14). For three studies it was unclear if other blood products were
24 transfused along with red blood cells (11;13;22).
25
26
27
28
29
30
31
32

33 *Study characteristics (Table 1)*

34
35 Eight studies were prospective cohort studies following up a planned group of patients
36 (7;8;15;16;18;24-27), the other 15 studies assessed data from a retrospective patient
37 registry or database. Fourteen studies were conducted in the USA, two in the UK, two in
38 Israel and the remainder in Belgium, the Netherlands, Iran and Denmark; one study was
39 conducted in multiple countries. The time period assessed was between 1989 and 2008.
40
41 Twelve of the studies (7;9;11;12;15-18;20-22;24;26) specifically looked at adults undergoing
42 cardiac surgery, five were in patients in the intensive care unit (10;25;27;29;30), two were in
43 adults trauma patients (8;28), two were in patients following hip fracture/replacement
44 (13;19) one was in oncology patients (14) and the other in pediatric trauma patients (23).
45
46 Three of the studies (12;20;21) specifically looked at the effects of RBCT in older adults (e.g.
47 > 60 years). The size of the studies varied from 1,624 participants to 504,208 participants
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with an overall median sample size of 4344 (IQR 2085 to 11963); median 1068 (IQR 430 to
4
5 5812) for patients undergoing RBCT compared to median 2325 (IQR 1636 to 6151) for
6
7 patient with no RBCT. The time period at which mortality was assessed also varied across
8
9 studies from in-hospital to mortality at seven years; the most common time point being
10
11 mortality at or within 30 days. Several studies reported mortality for more than one time
12
13 period. Only seven of the 23 studies provided any mention of guidelines for the prescription
14
15 of RBCT; two studies said no formal protocol was used (8;23), two studies stated a
16
17 hemoglobin of <8g/dl (10;13), one study stated a hematocrit of less than 25-26% (22) and
18
19 two studies said prescription was at the discretion of the patient care team (24;25). For full
20
21 details of the characteristics of the included studies see Appendix [32](#).

22 23 24 25 26 27 *Statistical methods (Table 2)*

28
29 All 23 studies provided information on the statistical methods used to adjust for differences
30
31 in the baseline characteristics of patients who received RBCT and those who did not.
32
33 However, the amount of detail and appropriateness of the method used varied across
34
35 studies. In 13 studies (7;9;10;14-19;22;24;25;27;30) the choices of covariates measured
36
37 were reported as pre-specified and not data driven, but this was unclear for the remaining
38
39 10 studies. The number of covariates measured and incorporated in the analysis also varied
40
41 across studies with half the studies reported to assess more than 20 different covariates.
42
43 Despite the high number of covariates assessed in these studies, not all measured covariates
44
45 which appeared to be of specific importance in relation to RBCT. All of the 23 studies did
46
47 report measuring the age and sex of the patients and 21 reported measuring patient co-
48
49 morbidity. Overall, only eight (7;11;12;15-18;22;29) studies measured and incorporated the
50
51 covariates age, sex, smoking, co-morbidity and haemoglobin level into the adjusted analysis..
52
53 Fourteen of the 23 studies reported using logistic regression (i.e. mortality was reported as a
54
55 binary outcome) as the method of adjusting for differences in the baseline characteristics
56
57
58
59
60

1
2
3 between the two patients groups; six studies reported using Cox proportional hazard (i.e.
4 mortality was reported as a time to event outcome) and three studies reporting using both
5 methods; in these three studies mortality was assessed for more than one time period. Nine
6 studies (7;12;17-19;21;27;29) reported using propensity scores prior to adjusting for
7 confounders, however, sometimes this matching was only using a much smaller subgroup of
8 patients. For full details of the statistical methods see Appendix 43.
9
10
11
12
13
14
15
16
17

18 *Presentation of adjusted and unadjusted results (Table 3)*

19
20 There were marked differences in the presentation and reporting of the unadjusted and
21 adjusted results when comparing the effects of RBCT versus no RBCT on mortality. Seven of
22 the 23 studies reported a summary statistic for each group for both the unadjusted and
23 adjusted analysis. Five studies reported a summary statistics for only the unadjusted analysis
24 and one study for the adjusted analysis only; no summary statistic comparing the effects of
25 RBCT versus no RBCT on mortality was reported in the remained 10 studies. Eight studies
26 reported the treatment effect (e.g. odds ratio, risk ratio, hazard ratio) and the corresponding
27 confident interval (six studies) for both the unadjusted and adjusted analysis (7;15;16;18-
28 20;24;26;30), whereas 12 studies reported the treatment effect and confident interval (10
29 studies) for adjusted analysis only and one study for the unadjusted analysis only. Where
30 possible we calculated the odds ratio for the effect of RBCT on mortality for unadjusted
31 analyses if it was not reported in the published article.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 Seventeen of the 23 studies reported a statistically significant result for the unadjusted
49 analysis, and 15 for the adjusted analysis (Figure 2), when comparing the effect of RBCT
50 versus no RBCT on mortality, with more deaths occurring in patients receiving transfusion.
51 This effect was statistically non-significant in seven studies based on the result of the
52 adjusted analysis. Prospective studies were more likely to show a statistically significant
53
54
55
56
57
58
59
60

1
2
3 effect for blood transfusion on mortality compared to retrospective studies for both the
4
5 unadjusted and adjusted analysis. For full details see Appendix [54](#).
6
7

8 9 **Volume 'A' red blood versus volume 'B' red blood cells**

10
11 Five studies (31-35) assessed the effect of different volumes of RBCT on mortality. One of
12
13 these studies (35) included both RBCT and other blood products.
14
15

16 17 *Study characteristics (Table 1)*

18
19 One study assessed a prospective cohort and followed up a planned group of patients (35),
20
21 the other four studies assessed data from a retrospective patient registry or database. Two
22
23 of the studies (33;35) specifically looked at adults undergoing cardiac surgery, one was in
24
25 trauma patients (32), one was in patients undergoing major surgery (31) and one in patients
26
27 in the intensive care unit (34). The size of the studies varied from 1,841 participants to
28
29 125,177 participants, with an overall median sample size of 8215 (IQR 3037 to 8799). The
30
31 volume of RBCT varied considerably across studies from 1-2 units to more than eight units.
32
33 The time period at which mortality was assessed also varied across studies from in-hospital
34
35 to mortality at eight years. Three of the five studies provided any mention of guidelines for
36
37 the prescription of red blood cells, however only one gave any specific requirement stating a
38
39 hemoglobin of <8g/dl (34) (See Appendix [32](#)).
40
41
42
43
44
45

46 47 *Statistical methods (Table 2)*

48
49 All five studies provided information on the statistical methods used to adjust for differences
50
51 in the baseline characteristics of patients who received different volumes of red blood
52
53 transfusion, however, as with the studies of RBCT versus no RBCT, the amount of detail and
54
55 appropriateness of the method used varied across studies. In all five studies (31-35) the
56
57 choices of covariates measured were reported as pre-specified. The number of covariates
58
59
60

1
2
3 measured and incorporated in the analysis varied across studies with two the studies
4 reported to assess more than 20 different covariates. Once again, despite the high number
5 of covariates assessed in these studies, not all measured covariates seem to be of specific
6 importance in relation to RBCT. All five studies reported measuring age and sex and patient
7 co-morbidity, however, one (31) measured and incorporated the covariates age, sex,
8 smoking, co-morbidity and hemoglobin level into the adjusted analysis.
9
10
11
12
13
14
15
16
17

18 *Presentation of adjusted and unadjusted results (Table 3)*

19
20 As with the studies of RBCT versus no RBCT, there were marked difference in the
21 presentation and reporting of the unadjusted and adjusted results when comparing the
22 effects of different volumes of RBCT on mortality. Two studies reported a statistically
23 significant result for the adjusted analysis with more deaths occurring in patients receiving
24 larger volumes of RBCT. This effect was statistically non significant in two studies based on
25 the result for adjusted analysis and was not reported for the remaining one study. No
26 studies reported on the statistical significance of the result of the unadjusted analysis (See
27 Appendix [43](#) and [54](#)).
28
29
30
31
32
33
34
35
36
37
38
39

40 **'Older' red blood cells versus 'newer' red blood cells**

41 Four (36-39) studies assessed the effects of age of RBCT on mortality, one of which
42 specifically looked at leukodepleted RBCT (39).
43
44
45
46
47

48 *Study characteristics (Table 1)*

49
50 All four studies assessed data from a retrospective patient registry or database. Two of the
51 studies (37;38) specifically looked at adults undergoing cardiac surgery, one was in trauma
52 patients (39), while the other did not mention a specific patient group. The size of the
53 studies varied from 1,813 participants to 364,037 participants, with an overall median
54
55
56
57
58
59
60

1
2
3 sample size of 4358 (IQR 2264 to 185019). The period of time in which the blood was stored
4
5 varied considerably across studies. Two studies (37;39) assessed RBCT stored for less than 14
6
7 days compared to those stored for more than 14 days, one study (38) compared blood
8
9 stored for less than 18 days and with blood stored for more than 18 days and one study (36)
10
11 looked at multiple storage periods ranging from 1 to 42 days. None of the studies provided
12
13 any mention of guidelines for the prescription of red blood cells (See Appendix 2).
14
15

16 17 18 *Statistical methods (Table 2)*

19
20 All four studies provided information on the statistical methods used to adjust for
21
22 differences in the baseline characteristics of patients who received RBCT stored for different
23
24 time periods, however, once again the amount of detail and appropriateness of the method
25
26 used varied across studies. The number of covariates measured and incorporated in the
27
28 analysis also varied across studies. All of the four studies reported measuring the age and
29
30 sex of the participants. Only ~~one study reported measuring smoking status,~~ two studies
31
32 reported measuring patient hemoglobin levels and three studies reported assessing patient
33
34 co-morbidities. Only one (37) of the four studies measured and incorporated the covariates
35
36 age, sex, smoking, co-morbidity and haemoglobin level into the adjusted analysis.
37
38
39

40 41 42 *Presentation of adjusted and unadjusted results (Table 3)*

43
44 As with the studies of RBCT versus no RBCT and of volume 'A' red blood cells versus volume
45
46 'B' RBCT, there were marked differences in the presentation and reporting of the unadjusted
47
48 and adjusted results when comparing the effects of RBCT stored for different time periods
49
50 on mortality. Two studies reported a statistically significant result for the unadjusted
51
52 analysis and one study reported a statistically significant result for the adjusted analysis. In
53
54 two of these three studies there were more deaths occurring in patients receiving older
55
56 blood and in one study there were more deaths in patients receiving newer blood. This
57
58
59
60

1
2
3 effect was statistically non significant in three studies based on the result for adjusted
4
5 analysis (See Appendix [43](#) and [54](#)).
6
7

8 9 **Assessment of methodological quality (Table 4)**

10
11 Overall the assessment of methodological quality varied across studies and by study group
12
13 with only 10 of the 32 included studies assessing a prospective cohort following up a
14
15 planned group of patients over time, the remaining two-third of the studies assessed data
16
17 from a retrospective patient registry or database. In most studies the sample of patients
18
19 included in the study was considered representative of those to whom the results might be
20
21 generalised. Four studies (12;20;21;29) specifically focussed on older adults (>60 years) and
22
23 one study (23) on children, so the findings from these studies should only be interpreted in
24
25 relation to these specific patient groups. The baseline characteristics of patients who
26
27 received RBCT compared to those patients who did not receive RBCT (or patients who
28
29 received different volumes or age of blood) were often very different and so we wanted to
30
31 assess whether studies had adjusted for these differences when carrying out their statistical
32
33 analysis. Only 10 studies measured and incorporated in the analysis covariates which we
34
35 deemed of specific importance in relation to RBCT (i.e. age, sex, smoking, co-morbidity and
36
37 haemoglobin level), thus we deemed the method of dealing with confounding between
38
39 patient groups as adequate in only 31% of studies. Critically however, when we restricted
40
41 our analysis of results to studies with adequate methods, the pattern of an increase in
42
43 mortality associated with RBCT remained unchanged.
44
45
46
47
48
49

50 **Discussion**

51 *Summary of main findings*

52
53 We identified 32 observational studies of more than 1000 participants published between
54
55 2006 and 2010 assessing the effect of RBCT on mortality. Twenty three studies compared
56
57
58
59
60

1
2
3 RBCT versus no RBCT, five compared different volumes and four compared different storage
4
5 times. Overall there was considerable variability in the characteristics of the observational
6
7 studies. However, the majority, of studies were retrospective designs assessing patients
8
9 from an existing patient register or database.
10

11
12
13
14 We also identified considerable variability in the statistical methods used to adjust for
15
16 differences in the baseline characteristics of patients who received RBCT and those who did
17
18 not. It was often unclear if the choice of covariates measured and used in the adjusted
19
20 analyses were pre-specified at the start of the study or were driven by the underlying data.
21
22 Perhaps most importantly, around half of the 32 studies did not measure and adjust for
23
24 covariates which we deemed of specific importance to blood transfusion. ~~for example,~~
25
26 ~~patient hemoglobin levels, age, sex and existing co-morbidities. Less than a third of studies~~
27
28 ~~assessed smoking which, while not directly correlated with transfusion, is an important~~
29
30 ~~covariate when assessing mortality.~~
31
32
33
34

35
36 Overall, more studies found a higher rate of mortality in patients receiving RBCT compared
37
38 with those who did not, and this effect was seen in both the adjusted and unadjusted
39
40 results. In general, where measured equivalently within the same study, the unadjusted
41
42 estimate of risk was greater than the adjusted risk, emphasising that adverse prognostic
43
44 factors are more common in patients receiving RBCT and that adjusting for them leads to a
45
46 smaller estimate of risk. Considering the adjusted risks, although the size of the effect was
47
48 not consistent across all studies, the direction of the effect was. Most studies suggest an
49
50 increased risk of mortality associated with RBCT. Further, those studies which were designed
51
52 prospectively and which used better methods of adjusting for differences in the baseline
53
54 characteristics between groups were more likely to show an increase in the risk of mortality
55
56 compared to studies which were based on retrospective registries or databases, although,
57
58
59
60

1
2
3 again the size of the effect was not consistent across all studies. However, it is important to
4
5 remember that even with the best methods of adjustment it cannot completely eliminate
6
7 the impact of confounding (2), as the sicker the patients (thus an increased risk of mortality)
8
9 the more likely they are to have received RBCT.
10

11 12 13 14 *Comparison with other studies*

15
16 We are aware of one other systematic review of observational studies looking at the effects
17
18 of RBCT on mortality, which focussed specifically on critically ill adults in intensive care units
19
20 and adult trauma and surgical patients (40). This systematic review by Marik and colleagues
21
22 included more studies (n=45) than our review as it did not restrict its inclusion criteria to
23
24 studies with >1000 patients; the median number of patients analysed was 687. They also
25
26 found that RBCT was associated with an increased risk of mortality based on a meta-analysis
27
28 of 12 studies (odds ratio 1.7; 95% CI 1.4 to 1.9). However there was considerable
29
30 heterogeneity in the meta-analysis, suggesting that it might not have been appropriate to
31
32 combine the results of the individual studies and supports our decision not to conduct a
33
34 meta-analysis.
35
36
37
38
39

40 In an overview of evidence from randomized controlled trials Wilkinson and colleagues (41)
41
42 identified 142 trials in RBCT. The majority compared the effects of leucoreduced RBCT or
43
44 different transfusion triggers (n=71). However, they did identify 12 trials comparing the
45
46 effects of RBCT versus no transfusion, seven looking at different volumes of RBCT and 11
47
48 different ages of red blood cells. The size of the trials was very small (median 30 to 40
49
50 patients) and the overview did not specifically examine the effect of RBCT on mortality.
51
52 Currently, we are aware of at least 14 ongoing or recently completed randomized controlled
53
54 trials examining the effects of the age of RBCT on clinical outcomes including the ARIPI (Age
55
56 of Red blood cells In Premature Infants) (42) ABLE, (Age of Blood Evaluation trial in the
57
58 of Red blood cells In Premature Infants) (42) ABLE, (Age of Blood Evaluation trial in the
59
60

1
2
3 resuscitation of critically ill patients) (43), RECESS (REd CELL Storage duration Study) (44) and
4
5 INFORM (Effects of transfusing fresh versus standard-issue red cells on in-hospital mortality)
6
7 trials, for which mortality or survival is a specified outcome measure.
8
9

10 11 *Limitations*

12
13 Our study has several limitations. Firstly, we only included studies published in the last five
14
15 years and which included more than 1,000 patients. This was because we took a pragmatic
16
17 approach as we hypothesised that more recent studies were more likely to use better
18
19 statistical methods and also hypothesised that studies with a larger sample size we are more
20
21 likely to show a truer effect of the intervention (45) ~~and that more recent studies are more~~
22
23 ~~likely to use better statistical methods.~~ Thus we aimed to provide a “snap shot” of current
24
25 practice rather provide a comprehensive review of all available evidence. It is possible
26
27 therefore that the overall effect seen here might be different in older studies and/or in
28
29 those carried out in smaller numbers of patients. Secondly, we decided not to combine the
30
31 results of individual studies because of the variability in clinical settings and study methods,
32
33 and instead presented the results of individual studies descriptively in the text and in tables
34
35 and figures. More formal statistical analysis might have given a more precise indication of
36
37 the overall effect of red cell transfusion on mortality, but would have ignored the significant
38
39 amount of clinical and methodological heterogeneity between studies which we identified a
40
41 priori and which was very apparent in the analysis done by Marik and colleagues (40).
42
43 However, in the absence of a more formal statistical analysis we have inevitably had to rely
44
45 on a vote-counting approach which also has great dangers, particularly the assumption that
46
47 each included study has equal weight. Our main protection against this is the very
48
49 pronounced nature of the pattern we have observed and the fact that we have limited our
50
51 conclusions to the direction of effect.
52
53
54
55
56
57
58
59
60

1
2
3 Finally, we limited our inclusion criteria to published articles and excluded unpublished
4 studies or those published only as conference abstracts; thus our study could be subject to
5 publication bias, as studies which did not show a significant effect of red cell transfusion on
6 mortality might be less likely to be published in full (46). Outcome reporting bias may also be
7 a problem, although difficult to combat, in the case where a risk has been measured at
8 different time points but only those time points which are “positive” are reported. However,
9 in the case of both publication and outcome reporting bias, the extreme nature of the
10 pattern makes it relatively implausible that there are sufficient unpublished studies or time
11 points to reverse it.
12
13
14
15
16
17
18
19
20
21

[Implications for clinical practice](#)

22
23
24 [In recent years, many developed countries including the UK, USA and Australia have](#)
25 [developed national initiatives for better blood transfusion practice, sometimes called](#)
26 [‘patient blood management’ \(4;5\). These include the development of guidelines on blood](#)
27 [usage promoting restrictive transfusion strategies and initiatives for using alternatives to](#)
28 [transfusion \(e.g. cell salvage techniques; improvements in the education and training of](#)
29 [clinical staff prescribing blood; the provision of mechanisms for reviewing blood use with](#)
30 [feedback of data to clinicians\). National data on blood usage in the USA suggests an](#)
31 [estimated decline of 3% over each of the last two years \(2009-2010\) \(4\), and similar data are](#)
32 [available in the UK where the demand for red cell units, which steadily increased during the](#)
33 [1990s, has decreased by about 20% in the last 10 years. However, there remains](#)
34 [considerable variation between hospitals in blood reduction, and national audits of blood](#)
35 [components in the UK and elsewhere suggest that overall blood usage could be further](#)
36 [reduced without compromising patient safety \(3\).](#)
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 It is difficult to assess how observational studies may have influenced these changes in
4 transfusion practice in comparison to evidence from randomized controlled trials, national
5 guidelines, and process driven initiatives. The most likely answer is that they have all played
6 a role in changing practice. Randomized controlled trials have found that 'restrictive'
7 transfusion strategies are associated with similar or improved clinical outcomes compared to
8 'liberal' transfusion strategies (47). Many national guidelines have adopted restrictive
9 transfusion strategies (47), while needing to make assumptions about the generalisability of
10 the findings of randomized controlled trials in specific clinical groups of patients. There have
11 been many smaller observational studies of process initiatives to reduce transfusion that
12 also indicate reductions in the use of blood without any significant impact on clinical
13 outcomes (48-50).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

29 *Conclusion*

30
31 The findings from this systematic review of recent large scale observational studies show
32 considerable variability in the patient populations and study methods when comparing the
33 effects of RBCT on mortality. Overall, observational studies do show a consistent adverse
34 effect of RBCT on mortality. Although it seems unlikely that this can be entirely explained by
35 selective sampling or a predominance of poorer quality observational studies, it remains
36 possible that even the best conducted adjustments cannot completely eliminate the impact
37 of confounding, particularly when investigating the effect of RBCT. We therefore believe
38 that this can only be resolved through well designed and adequately powered randomized
39 controlled trials. Before these can be conducted, the importance of the research question
40 and the uncertainty of the current evidence need to be accepted. This requires clearer and
41 more widespread presentation and understanding of the existing research evidence, to
42 which we believe this study is a significant contribution.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5 **Author contributions:** SH and OO were involved in the design, implementation, and analysis
6
7 of the study and in writing the final manuscript. CH, MM and LY were involved in the design
8
9 and analysis of the study and in writing the final manuscript.
10

11 **Financial disclosures:** None reported.
12

13 **Funding/support:** This study was funded by NHS Blood and Transplant, Research and
14
15 Development, UK.
16

17 **Additional contributions:** We are grateful to Susan Brunskill for her helpful comments on
18
19 this manuscript.
20
21
22
23
24

25 References

- 26
27 (1) Blajchman MA. Landmark studies that have changed the practice of transfusion
28 medicine. *Transfusion* 2005 September;45(9):1523-30.
29
30 (2) Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew M,
31 Altman DG. Evaluating non-randomised intervention studies. *Health Technol Assess*
32 2003;7(27):iii-173.
33
34 (3) Murphy MF, Stanworth SJ, Yazer M. Transfusion practice and safety: current status
35 and possibilities for improvement. *Vox Sang* 2011 January;100(1):46-59.
36
37 (4) Goodnough LT, Shander A. Patient blood management. *Anesthesiology* 2012
38 June;116(6):1367-76.
39
40 (5) NHS blood transfusion and transplant / Royal College of Physicians national
41 comparative audit of blood transfusion programme. [http://hospital](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp)
42 [blood co](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp)
43 [uk/safe_use/clinical_audit/national_comparative/index](http://hospital.blood.co.uk/safe_use/clinical_audit/national_comparative/index.asp) asp [accessed 5 March
44 2013] 2013.
45
46 (6) Bennett-Guerrero E, Zhao Y, O'Brien SM, Ferguson TB, Jr., Peterson ED, Gammie JS,
47 Song HK. Variation in use of blood transfusion in coronary artery bypass graft
48 surgery. *JAMA* 2010 October 13;304(14):1568-75.
49
50 (7) Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, Markiewicz W,
51 Hammerman H. Impact of red blood cell transfusion on clinical outcomes in patients
52 with acute myocardial infarction. *Am J Cardiol* 2008 July 15;102(2):115-9.
53
54 (8) Bochicchio GV, Napolitano L, Joshi M, Bochicchio K, Meyer W, Scalea TM. Outcome
55 analysis of blood product transfusion in trauma patients: a prospective, risk-adjusted
56 study. *World J Surg* 2008 October;32(10):2185-9.
57
58
59
60

- 1
- 2
- 3 (9) Engoren M, Habib RH, Hadaway J, Zacharias A, Schwann TA, Riordan CJ, Durham SJ,
4 Shah A. The effect on long-term survival of erythrocyte transfusion given for cardiac
5 valve operations. *Ann Thorac Surg* 2009 July;88(1):95-100, 100.
- 6
- 7 (10) Engoren M, Arslanian-Engoren C. Long-term survival in the intensive care unit after
8 erythrocyte blood transfusion. *Am J Crit Care* 2009 March;18(2):124-31.
- 9
- 10 (11) Garty M, Cohen E, Zuchenko A, Behar S, Boyko V, Iakobishvili Z, Mittelman M, Battler
11 A, Shotan A, Gottlieb S, Caspi A, Hasdai D. Blood transfusion for acute
12 decompensated heart failure--friend or foe? *Am Heart J* 2009 October;158(4):653-8.
- 13
- 14 (12) Jani SM, Smith DE, Share D, Kline-Rogers E, Khanal S, O'Donnell MJ, Gardin J,
15 Moscucci M. Blood transfusion and in-hospital outcomes in anemic patients with
16 myocardial infarction undergoing percutaneous coronary intervention. *Clin Cardiol*
17 2007 October;30(10 Suppl 2):II49-II56.
- 18
- 19 (13) Johnston P, Wynn-Jones H, Chakravarty D, Boyle A, Parker MJ. Is perioperative blood
20 transfusion a risk factor for mortality or infection after hip fracture? *J Orthop*
21 *Trauma* 2006 November;20(10):675-9.
- 22
- 23 (14) Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood
24 transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch*
25 *Intern Med* 2008 November 24;168(21):2377-81.
- 26
- 27 (15) Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone
28 EH. Morbidity and mortality risk associated with red blood cell and blood-
29 component transfusion in isolated coronary artery bypass grafting. *Crit Care Med*
30 2006 June;34(6):1608-16.
- 31
- 32 (16) Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH. Transfusion
33 in coronary artery bypass grafting is associated with reduced long-term survival. *Ann*
34 *Thorac Surg* 2006 May;81(5):1650-7.
- 35
- 36 (17) Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased
37 mortality, postoperative morbidity, and cost after red blood cell transfusion in
38 patients having cardiac surgery. *Circulation* 2007 November 27;116(22):2544-52.
- 39
- 40 (18) Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ,
41 Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic impact of
42 blood transfusion after primary angioplasty for acute myocardial infarction: analysis
43 from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late
44 Angioplasty Complications) Trial. *JACC Cardiovasc Interv* 2009 July;2(7):624-32.
- 45
- 46 (19) Pedersen AB, Mehnert F, Overgaard S, Johnsen SP. Allogeneic blood transfusion and
47 prognosis following total hip replacement: a population-based follow up study. *BMC*
48 *Musculoskelet Disord* 2009;10:167.
- 49
- 50 (20) Rogers MA, Blumberg N, Saint SK, Kim C, Nallamotheu BK, Langa KM. Allogeneic blood
51 transfusions explain increased mortality in women after coronary artery bypass graft
52 surgery. *Am Heart J* 2006 December;152(6):1028-34.
- 53
- 54 (21) Rogers MA, Blumberg N, Saint S, Langa KM, Nallamotheu BK. Hospital variation in
55 transfusion and infection after cardiac surgery: a cohort study. *BMC Med* 2009;7:37.
- 56
- 57
- 58
- 59
- 60

- 1
2
3 (22) Salehiomran A, Ahmadi H, Karimi A, Tazik M, Dowlatshahi S, Fathollahi M.S., Abbasi
4 S.H. Transfusion associated in-hospital mortality and morbidity in isolated coronary
5 artery bypass graft surgery. *Central European Journal of Medicine* 2009;4(3):286-92.
6
7 (23) Stone TJ, Riesenman PJ, Charles AG. Red blood cell transfusion within the first 24
8 hours of admission is associated with increased mortality in the pediatric trauma
9 population: a retrospective cohort study. *J Trauma Manag Outcomes* 2008;2(1):9.
10
11 (24) Surgenor SD, Kramer RS, Olmstead EM, Ross CS, Sellke FW, Likosky DS, Marrin CA,
12 Helm RE, Jr., Leavitt BJ, Morton JR, Charlesworth DC, Clough RA, Hernandez F,
13 Frumiento C, Benak A, DioData C, O'Connor GT. The association of perioperative red
14 blood cell transfusions and decreased long-term survival after cardiac surgery.
15 *Anesth Analg* 2009 June;108(6):1741-6.
16
17 (25) Taylor RW, O'Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, Arnzen K,
18 Cappadoro C, Fu M, Plisco MS, Sadaka FG, Veremakis C. Red blood cell transfusions
19 and nosocomial infections in critically ill patients. *Crit Care Med* 2006
20 September;34(9):2302-8.
21
22 (26) van Straten AH, Bekker MW, Soliman Hamad MA, van Zundert AA, Martens EJ,
23 Schonberger JP, de Wolf AM. Transfusion of red blood cells: the impact on short-
24 term and long-term survival after coronary artery bypass grafting, a ten-year follow-
25 up. *Interact Cardiovasc Thorac Surg* 2010 January;10(1):37-42.
26
27 (27) Vincent JL, Sakr Y, Sprung C, Harboe S, Damas P. Are blood transfusions associated
28 with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients
29 study. *Anesthesiology* 2008 January;108(1):31-9.
30
31 (28) Weinberg JA, McGwin G, Jr., Marques MB, Cherry SA, III, Reiff DA, Kerby JD, Rue LW,
32 III. Transfusions in the less severely injured: does age of transfused blood affect
33 outcomes? *J Trauma* 2008 October;65(4):794-8.
34
35 (29) Wu WC, Smith TS, Henderson WG, Eaton CB, Poses RM, Uttley G, Mor V, Sharma SC,
36 Vezeridis M, Khuri SF, Friedmann PD. Operative blood loss, blood transfusion, and
37 30-day mortality in older patients after major noncardiac surgery. *Ann Surg* 2010
38 July;252(1):11-7.
39
40 (30) Zilberberg MD, Stern LS, Wiederkehr DP, Doyle JJ, Shorr AF. Anemia, transfusions
41 and hospital outcomes among critically ill patients on prolonged acute mechanical
42 ventilation: a retrospective cohort study. *Crit Care* 2008;12(2):R60.
43
44 (31) Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB.
45 Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with
46 increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general
47 surgery patients. *J Am Coll Surg* 2009 May;208(5):931-7, 937.
48
49 (32) Charles A, Shaikh AA, Walters M, Huehl S, Pomerantz R. Blood transfusion is an
50 independent predictor of mortality after blunt trauma. *Am Surg* 2007
51 January;73(1):1-5.
52
53 (33) O'Keefe SD, Davenport DL, Minion DJ, Sorial EE, Endean ED, Xenos ES. Blood
54 transfusion is associated with increased morbidity and mortality after lower
55 extremity revascularization. *J Vasc Surg* 2010 March;51(3):616-21, 621.
56
57
58
59
60

- 1
2
3 (34) Ruttinger D, Wolf H, Kuchenhoff H, Jauch KW, Hartl WH. Red cell transfusion: an
4 essential factor for patient prognosis in surgical critical illness? *Shock* 2007
5 August;28(2):165-71.
6
7 (35) Weightman WM, Gibbs NM, Sheminant MR, Newman MA, Grey DE. Moderate
8 exposure to allogeneic blood products is not associated with reduced long-term
9 survival after surgery for coronary artery disease. *Anesthesiology* 2009
10 August;111(2):327-33.
11
12 (36) Edgren G, Kamper-Jorgensen M, Eloranta S, Rostgaard K, Custer B, Ullum H, Murphy
13 EL, Busch MP, Reilly M, Melbye M, Hjalgrim H, Nyren O. Duration of red blood cell
14 storage and survival of transfused patients (CME). *Transfusion* 2010
15 June;50(6):1185-95.
16
17 (37) Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH.
18 Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*
19 2008 March 20;358(12):1229-39.
20
21 (38) van de Watering L, Lorinser J, Versteegh M, Westendorp R, Brand A. Effects of
22 storage time of red blood cell transfusions on the prognosis of coronary artery
23 bypass graft patients. *Transfusion* 2006 October;46(10):1712-8.
24
25 (39) Weinberg JA, McGwin G, Jr., Griffin RL, Huynh VQ, Cherry SA, III, Marques MB, Reiff
26 DA, Kerby JD, Rue LW, III. Age of transfused blood: an independent predictor of
27 mortality despite universal leukoreduction. *J Trauma* 2008 August;65(2):279-82.
28
29 (40) Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a
30 systematic review of the literature. *Crit Care Med* 2008 September;36(9):2667-74.
31
32 (41) Wilkinson KL, Brunskill SJ, Doree C, Hopewell S, Stanworth S, Murphy MF, Hyde C.
33 The clinical effects of red blood cell transfusions: an overview of the randomized
34 controlled trials evidence base. *Transfus Med Rev* 2011 April;25(2):145-55.
35
36 (42) Fergusson DA, Hebert P, Hogan DL, LeBel L, Rouvinez-Bouali N, Smyth JA, Sankaran
37 K, Tinmouth A, Blajchman MA, Kovacs L, Lachance C, Lee S, Walker CR, Hutton B,
38 Ducharme R, Balchin K, Ramsay T, Ford JC, Kakadekar A, Ramesh K, Shapiro S. Effect
39 of fresh red blood cell transfusions on clinical outcomes in premature, very low-
40 birth-weight infants: the ARIPI randomized trial. *JAMA* 2012 October
41 10;308(14):1443-51.
42
43 (43) Lacroix J, Hebert P, Fergusson D, Tinmouth A, Blajchman MA, Callum J, Cook D,
44 Marshall JC, McIntyre L, Turgeon AF. The Age of Blood Evaluation (ABLE) randomized
45 controlled trial: study design. *Transfus Med Rev* 2011 July;25(3):197-205.
46
47 (44) Steiner ME, Assmann SF, Levy JH, Marshall J, Pulkrabek S, Sloan SR, Triulzi D, Stowell
48 CP. Addressing the question of the effect of RBC storage on clinical outcomes: the
49 Red Cell Storage Duration Study (RECESS) (Section 7). *Transfus Apher Sci* 2010
50 August;43(1):107-16.
51
52 (45) Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P. Single-center trials show
53 larger treatment effects than multicenter trials: evidence from a meta-epidemiologic
54 study. *Ann Intern Med* 2011 July 5;155(1):39-51.
55
56
57
58
59
60

- 1
2
3 (46) Scherer RW, Langenberg P, von EE. Full publication of results initially presented in
4 abstracts. *Cochrane Database Syst Rev* 2007;(2):MR000005.
5
6 (47) Goodnough LT, Levy JH, Murphy MF. Current concepts in transfusion. *Lancet*
7 2013;[in press].
8
9 (48) Kotze A, Carter LA, Scally AJ. Effect of a patient blood management programme on
10 preoperative anaemia, transfusion rate, and outcome after primary hip or knee
11 arthroplasty: a quality improvement cycle. *Br J Anaesth* 2012 June;108(6):943-52.
12
13 (49) Freedman J, Luke K, Escobar M, Vernich L, Chiavetta JA. Experience of a network of
14 transfusion coordinators for blood conservation (Ontario Transfusion Coordinators
15 [ONTraC]). *Transfusion* 2008 February;48(2):237-50.
16
17 (50) Helm RE, Rosengart TK, Gomez M, Klemperer JD, DeBois WJ, Velasco F, Gold JP,
18 Altorki NK, Lang S, Thomas S, Isom OW, Krieger KH. Comprehensive multimodality
19 blood conservation: 100 consecutive CABG operations without transfusion. *Ann*
20 *Thorac Surg* 1998 January;65(1):125-36.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Flow diagram of study inclusion (1 January 2006 to 31 December 2010)




Figure 2: Effect of red blood cell transfusion versus no red blood cell transfusion on mortality (adjusted results)




Table 1: Summary of characteristics of included studies

Type of comparison	RBC vs. no RBC (n=23)	Volume 'A' vs. Volume 'B'(n=5)	Old RBC vs. new RBC (n=4)
Design			
Prospective	8 (35%)	1 (20%)	
Retrospective	15 (65%)	4 (80%)	4 (100%)
Country			
Australia		1 (20%)	
Belgium	1 (4%)		
Denmark	1 (4%)		
Germany		1 (20%)	
Iran	1 (4%)		
Israel	2 (9%)		
Netherlands	1 (4%)		1 (25%)
Sweden			1 (25%)
USA	14 (61%)	3 (60%)	2 (50%)
UK (multiple sites)	2 (9%) 1 (4%)		
Time period assessed			
	1989-2008	1993-2007	1993-2007
Sample size (median, IQR)			
All patients	4344 (IQR 2085-11963)	8215 (IQR 3037-8799)	4358 (2264-185019)
RBC transfusion	1068 (IQR 430-5812)		
No RBC transfusion	2325 (IQR 1636-6151)		
Disease area			
Cardiac surgery	12 (52%)	2 (40%)	2 (50%)
Hip fracture/replacement	2 (9%)		
Intensive care	5 (22%)	1 (20%)	
Oncology	1 (4%)		
Surgery		1 (20%)	
Trauma adults	2 (9%)	1 (20%)	1 (25%)
Trauma paediatrics	1 (4%)		
Not reported			1 (25%)
Prescribing guidance			
Reported	7 (30%)	3 (60%)	
Not reported	16 (70%)	2 (40%)	4 (100%)
Mortality assessed*			
In hospital	8	2	2
30 days	10	2	1
3 months	3		
6 months	3		
>1 year	4	1	2
Time period not specified	2		1

*studies reported mortality for >1 time point based on binary only and / or time-to-event outcome

Table 2: Method of adjusted analysis

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Choice of covariates			
Pre-specified	13 (57%)	5 (100%)	4 (100%)
Post hoc			
Unclear	10 (43%)		
No. of covariates measured			
1-5	2 (9%)		
6-10	4 (17%)	1 (20%)	2 (50%)
11-20	3 (13%)	2 (40%)	
>20	12 (52%)	2 (40%)	1 (25%)
Unclear	2 (9%)		1 (25%)
Important covariates assessed			
Age	23 (100%)	5 (100%)	4 (100%)
Sex	23 (100%)	5 (100%)	4 (100%)
Smoking	8 (35%)	1 (20%)	1 (25%)
Co-morbidity	21 (91%)	5 (100%)	3 (75%)
Hb level	14 (61%)	4 (80%)	2 (50%)
Important covariates incorporated into analysis			
Yes	8 (35%)	1 (20%)	1 (25%)
No	15 (65%)	4 (80%)	3 (75%)
Method of adjustment			
Cox proportional hazard	6 (26%)	1 (20%)	1 (25%)
Logistic regression	14 (61%)	4 (80%)	2 (50%)
Both *	3 (13%)		
Not reported			1 (25%)

*studies reported >1 method of adjustment when mortality was assessed for >1 time point

Table 3: Presentation of results for unadjusted and adjusted analysis (mortality)

Type of comparison	RBCT vs. no RBCT (n=23)	Volume 'A' vs. Volume 'B' (n=5)	Old RBC vs. new RBC (n=4)
Summary statistic for each group			
Unadjusted only	5 (22%)	2 (40%)	
Adjusted only	1 (4%)		
Both	7 (30%)		1 (25%)
Not reported	10 (44%)	3 (60%)	3 (75%)
Treatment effect			
Unadjusted only	1 (4%)		
Adjusted only	12 (52%)	5 (100%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	2 (9%)		1 (25%)
Confidence interval of treatment effect			
Unadjusted only			
Adjusted only	10 (43%)	3 (60%)	2 (50%)
Both	8 (35%)		1 (25%)
Not reported	5 (22%)	2 (40%)	1 (25%)
P-value for treatment effect			
Unadjusted only	7 (30%)		
Adjusted only		1 (20%)	
Both	1 (4%)		1 (25%)
Not reported	15 (66%)	4 (80%)	3 (75%)
Unadjusted analysis*			
Statistically significant	17 (74%)		2 (50%)
Statistically non-significant	1 (4%)		
Not reported	5 (22%)	5 (100%)	2 (50%)
Adjusted analysis*			
Statistically significant	15 (65%)	2 (40%)	1 (25%)
Statistically non-significant	7 (31%)	2 (40%)	3 (75%)
Not reported	1 (4%)	1 (20%)	

*mortality outcome – if >1 time point analysed the time point with the non-significant result was recorded

Table 4: Assessment of methodological quality of the included studies

Study ID	Data collected prospectively	Sample representative	Important covariates measured	Important covariates incorporated into analysis	Method of dealing with confounding adequate*
Aronson 2008 (3)	Yes	Unclear	Yes	Yes	Yes
Bernard 2009 (27)	No	Yes	Yes	Yes	Yes
Bochicchio 2008 (4)	Yes	Yes	No	No	No
Charles 2007 (28)	No	Yes	No	No	No
Edgren 2010 (32)	No	Yes	No	No	No
Engoren 2009 (5)	No	Yes	No	No	No
Engoren 2009 (6)	No	Yes	No	No	No
Garty 2009 (7)	No	Yes	Yes	Yes	Yes
Jani 2007 (8)	No	No (>60 years)	Yes	Yes	Yes
Johnson 2006 (9)	No	Unclear	No	No	No
Khorana 2008 (10)	No	Yes	No	No	No
Koch 2006 (11,12)	Yes	Yes	Yes	Yes	Yes
Koch 2008 (33)	No	Yes	Yes	Yes	Yes
Murphy 2007 (13)	No	Yes	Yes	Yes	Yes
Nikolsky 2009 (14)	Yes	Yes	Yes	Yes	Yes
O'Keeffe 2010 (29)	Yes	Yes	No	No	No
Pederson 2009 (15)	No	Yes	No	No	No
Rogers 2006 (16)	No	No (>65 years)	No	No	No
Rogers 2009 (17)	No	No (> 65 years)	No	No	No
Ruttinger 2007 (30)	No	Yes	No	No	No
Salehiomran 2009 (18)	No	Yes	Yes	Yes	Yes
Stone 2008 (19)	No	No (< 16 years))	No	No	No
Surgenor 2009 (20)	Yes	Yes	No	No	No
Taylor 2006 (21)	Yes	Yes	No	No	No
van de Watering 2006 (34)	No	Yes	No	No	No
van Straten 2010 (22)	Yes	Yes	No	No	No
Vincent 2008 (23)	Yes	Yes	No	No	No
Weightman 2009 (31)	Yes	Yes	No	No	No
Weinburg 2008 (24)	No	Yes	No	No	No
Weinburg 2008 (35)	No	Yes	No	No	No

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Wu 2010 (25)	No	No (> 65 years)	Yes	Yes	Yes
Zilberberg 2008 (26)	No	Yes	No	No	No

*The method of dealing with confounding was deemed adequate if important covariates were measured and adjusted for in the analysis.

For peer review only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6-7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7-8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis)	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Appendix 2
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14 & table 4
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	8-14 & figure 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Figure 2
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	8-14 & table 4
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	15-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16-17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17-18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19



PRISMA 2009 Checklist

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

APPENDIX 1: Search strategies**MEDLINE (Ovid)**

1. ERYTHROCYTE TRANSFUSION/
2. *BLOOD TRANSFUSION/
3. (hemotransfus* or haemotransfus*).tw.
4. ((transfus* or retransfus*) adj1 (trigger* or level* or threshold* or rule* or restrict* or limit*)).tw.
5. (transfusion* adj1 (management or practice* or polic* or strateg* or guideline* or indication* or protocol* or criteri*)).tw.
6. ((blood adj1 management) or (management adj1 blood) or (blood adj1 support) or (blood adj1 requirement*)).tw.
7. ((red cell* adj1 management) or (red cell* adj1 support) or (red cell adj1 requirement*)).tw.
8. (blood adj1 need*).tw. or transfus*.ti.
9. or/1-8
10. BLOOD TRANSFUSION/
11. ERYTHROCYTES/
12. (red cell* or red blood cell* or erythrocyte* or RBC*).tw.
13. 11 or 12
14. 10 and 13
15. (critical* or intensive or trauma or surg* or injur* or postinjur* OR organ failure* OR sepsis or septic OR infection* OR infectious OR ARDS OR acute respiratory distress OR multiorgan).ti. and transfus*.ab.
16. 9 or 14 or 15
17. BLOOD PRESERVATION/
18. transfus*.mp.
19. 17 and 18
20. ((storage or stored or storing or age* or aging or old or older or duration or fresh* or preserv* or conserv*) adj2 (whole blood or red blood cell* or red cell* or RBC*)).tw. and transfus*.mp.
21. (fresh blood or new blood or old* blood or fresh red blood cells or new red blood cells or old* red blood cells or fresh red cells or new red cells or old* red cells).tw.
22. 16 or 19 or 20 or 21
23. PROGNOSIS/
24. DISEASE FREE SURVIVAL/
25. exp CRITICAL CARE/
26. TREATMENT FAILURE/
27. exp MORTALITY/
28. SURVIVAL/
29. SURVIVAL ANALYSIS/
30. RISK ASSESSMENT/ or RISK FACTORS/
31. TREATMENT OUTCOME/
32. (survival* or survivor* or nonsurvivor* or survived or surviving).ti,ab.
33. ((predictor* or prediction*) adj1 death).tw.
34. (prognos* or mortality).tw.
35. (outcome* adj2 (therap* or treatment*)).ti,ab.
36. ((risk adj assessment) or (associated adj risk)).tw.
37. (risk* or association* or causalit* or causation or cause*).ti.
38. exp POSTOPERATIVE COMPLICATIONS/
39. exp INTRAOPERATIVE COMPLICATIONS/

40. or/23- 39
41. 22 and 40
42. BLOOD TRANSFUSION/ae, co, mo, ut or ERYTHROCYTE TRANSFUSION/ae, co, mo, ut
43. ((reaction* or effect* or efficac* or complication* or risk* or adverse* or hazard* or accident* or incident* or morbid* or death* or mortalit* or outcome*) adj3 (transfus* or postransfus* or RBC* or red cell* or erythrocyte*)).tw.
44. (transfus* or posttransfus*).ti.
45. or/41-44
46. EPIDEMIOLOGIC STUDIES/
47. exp CASE CONTROL STUDIES/
48. exp COHORT STUDIES/
49. (case* adj2 control*).tw.
50. cohort*.ti,ab.
51. (follow up adj (study or studies)).tw.
52. (observational adj2 (study or studies)).tw.
53. ((controlled adj2 trial*1) or (controlled adj2 stud*) or (comparative adj trial*) or (comparative adj stud*) or (comparison adj group*) or (comparator adj group*)).tw.
54. longitudinal.tw.
55. retrospective*.tw.
56. cross sectional.tw.
57. CROSS-SECTIONAL STUDIES/
58. Controlled clinical trial.pt.
59. CROSSOVER STUDIES/
60. Comparative study.pt.
61. CLINICAL TRIALS AS TOPIC/
62. exp CONTROLLED CLINICAL TRIALS AS TOPIC/
63. (nonrandomi* or (non adj randomi*)).tw.
64. or/46-63
65. 45 and 64

EMBASE (Ovid)

1. ERYTHROCYTE TRANSFUSION/
2. *BLOOD TRANSFUSION/ or *BLOOD COMPONENT THERAPY/
3. (hemotransfus* or haemotransfus*).tw.
4. ((transfus* or retransfus*) adj1 (trigger* or level* or threshold* or rule* or restrict* or limit*)).tw.
5. (transfusion* adj1 (management or practice* or polic* or strateg* or guideline* or indication* or protocol* or criteri*)).tw.
6. ((blood adj1 management) or (management adj1 blood) or (blood adj1 support) or (blood adj1 requirement*)).tw.
7. ((red cell* adj1 management) or (red cell* adj1 support) or (red cell adj1 requirement*)).tw.
8. (blood adj1 need*).tw. or transfus*.ti.
9. or/1-8
10. BLOOD TRANSFUSION/
11. ERYTHROCYTE/
12. (red cell* or red blood cell* or erythrocyte* or RBC*).tw.
13. 11 or 12
14. 10 and 13

- 1
- 2
- 3 15. (critical* or intensive or trauma or surg* or injur* or postinjur* OR organ failure* OR
- 4 sepsis or septic OR infection* OR infectious OR ARDS OR acute respiratory distress OR
- 5 multiorgan).ti. and transfus*.ab.
- 6 16. 9 or 14 or 15
- 7 17. BLOOD STORAGE/ or ERYTHROCYTE PRESERVATION/
- 8 18. transfus*.mp.
- 9 19. 17 and 18
- 10 20. ((storage or stored or storing or age* or aging or old or older or duration or fresh* or
- 11 preserv* or conserv*) adj2 (whole blood or red blood cell* or red cell* or RBC*)).tw. and
- 12 transfus*.mp.
- 13 21. (fresh blood or new blood or old* blood or fresh red blood cells or new red blood cells or
- 14 old* red blood cells or fresh red cells or new red cells or old* red cells).tw.
- 15 22. 16 or 19 or 20 or 21
- 16 23. PROGNOSIS/
- 17 24. exp SURVIVAL/
- 18 25. exp INTENSIVE CARE/
- 19 20 26. exp TREATMENT OUTCOME/
- 21 27. exp EPIDEMIOLOGY/
- 22 28. RISK ASSESSMENT/ or
- 23 29. RISK BENEFIT ANALYSIS/ or RISK FACTOR/
- 24 30. RISK MANAGEMENT/
- 25 31. RISK REDUCTION/
- 26 32. (survival* or survivor* or nonsurvivor* or survived or surviving).ti,ab.
- 27 33. ((predictor* or prediction*) adj1 death).tw.
- 28 34. (prognos* or mortality).tw.
- 29 30 35. (outcome* adj2 (therap* or treatment*)).ti,ab.
- 31 36. (risk assessment or associated risk).tw.
- 32 37. (risk* or association* or causalit* or causation or cause*).ti.
- 33 38. exp POSTOPERATIVE COMPLICATION/
- 34 39. PEROPERATIVE COMPLICATION/
- 35 40. or/23-39
- 36 41. 22 and 40
- 37 42. ((reaction* or effect* or efficac* or complication* or risk* or adverse* or hazard* or
- 38 accident* or incident* or morbid* or death* or mortalit* or outcome*) adj3 (transfus* or
- 39 postransfus* or RBC* or red cell* or erythrocyte*)).tw.
- 40 43. (transfus* and posttransfus*).ti.
- 41 44. or/41-43
- 42 45. Clinical Study/
- 43 44 46. exp Case Control Study/
- 45 47. Family Study/
- 46 48. Longitudinal Study/
- 47 49. Retrospective Study/
- 48 50. Prospective Study/
- 49 51. Randomized Controlled Trials/
- 50 52. 50 not 51
- 51 53. Cohort Analysis/
- 52 54. Comparative Study/
- 53 55. cohort*.ti,ab.
- 54 55 56. (case* adj2 control*).tw.
- 56 57. (follow up adj (study or studies)).tw.
- 57 58 59 60 58. (observational adj2 (study or studies)).tw.

- 1
- 2
- 3 59. (epidemiologic* adj (study or studies)).tw.
- 4 60. (cross sectional adj (study or studies)).tw.
- 5 61. (retrospective* or longitudinal*).tw.
- 6 62. ((controlled adj2 trial*1) or (controlled adj2 stud*) or (comparative adj trial*) or
- 7 (comparative adj stud*) or (comparison adj group*) or (comparator adj group*)).tw.
- 8 63. (nonrandomi* or (non adj randomi*)).tw.
- 9 64. or/45-49, 52-63
- 10 65. 44 and 64
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

APPENDIX 2: Table of excluded studies

Study ID	Reference	Reason for exclusion
Bennett-Guerrero 2010	Bennett-Guerrero E, Zhao Y, O'Brien SM, et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA. 2010 Oct 13;304(14):1568-75.	Mortality data not reported
Duchesne 2008	Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusions strategies in a mature level I trauma center: were we wrong for the last 60 years? J Trauma. 2008 Aug;65(2):272-6	<1000 patients
Fung 2006	Fung MK, Moore K, Ridenour M, et al. Clinical effects of reverting from leukoreduced to nonleukoreduced blood in cardiac surgery. Transfusion. 2006 Mar;46(3):386-91.	<1000 patients
Karkouti 2006a	Karkouti K, Wijeyesundera DN, Yau TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anaesth. 2006 Mar;53(3):279-87.	Platelets only
Karkouti 2006b	Karkouti K, Yau TM, Rensburg Av, et al. The effects of a treatment protocol for cardiac surgical patients with excessive blood loss on clinical outcomes. Vox Sang. 2006 Aug;91(2):148-56.	Mortality data not reported
Kneyber 2009	Kneyber MC, Gazendam RP, Markhorst DG, et al. Length of storage of red blood cells does not affect outcome in critically ill children. Intensive Care Med. 2009 Jan;35(1):179-80.	<1000 patients
Lelubre 2009	Lelubre C, Piaquerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009 Jul;49(7):1384-94.	Systematic review
Marik 2008	Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med. 2008 Sep;36(9):2667-74.	Systematic review
Muller 2008	Müller MH, Moubarak P, Wolf H, et al. Independent determinants of early death in critically ill surgical patients. Shock. 2008 Jul;30(1):11-6.	Mortality data not reported
Oliver 2009	Oliver E, Carrio ML, Rodríguez-Castro D, et al. Relationships among haemoglobin level, packed red cell transfusion and clinical outcomes in patients after cardiac surgery. Intensive Care Med. 2009 Sep;35(9):1548-55.	Mortality data not reported
Van de Watering 2008	van de Watering LM, Brand A. Effects of Storage of Red Cells. Transfus Med Hemother. 2008;35(5):359-367.	Systematic review
Welsby 2010	Welsby IJ, Lockhart E, Phillips-Bute B, et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion. 2010 Nov;50(11):2311-7.	Platelets only
Whyte 2009	Whyte RK, Kirpalani H, Asztalos EV, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics. 2009 Jan;123(1):207-13	<1000 patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

APPENDIX 32: Characteristics of included studies

Study ID	Design	Objective	Participants	Intervention (exposure)	Comparator (control)	Outcome
Red blood cells versus no red blood cells – prospective studies						
Aronson 2008 (7)	Design: prospective cohort How pts recruited: admitted to intensive care unit Country: Israel Year: 2000 to 2006 Funding: not reported	Effects of RBCT in patients with acute myocardial infarction	Adults with acute MI in an intensive coronary care unit (n=2358)	RBCT (n=192) Prescribing guidance: not reported	No RBCT(n=2134)	Mortality at 6 months #
Bochicchio 2008 (8)	Design: prospective cohort How pts recruited: admitted to Adams Cowley Shock Trauma Centre Country: USA Year: 2002 to 2004 Funding: not reported	Effects of RBC and other blood product transfusion (RBC and FFP) on outcome in trauma patients	Adults admitted to intensive care unit (n=1172)	RBC and other blood product transfusion (n=786); RBC only (n=246) Prescribing guidance: no formal protocol used	No RBC or other blood product transfusion (n=386).	Mortality (time period not specified)
Koch 2006 (15,16)	Design: prospective cohort How pts recruited: admitted to large tertiary hospital (Cleveland Clinic) Country: USA Year: 1995 to 2002 Funding: Non industry funded	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass grafting (n=11963)	RBCT (n=5812) Prescribing guidance: not reported	No RBCT(n=6151)	Mortality in-hospital
Nikolsky 2009 (18)	Design: prospective cohort How pts recruited: part of CADILLAC randomized trial comparing different mechanical reperfusion strategies Country: multi centre Year: 1997 to 1999 Funding: not reported	Effect of RBCT in patients undergoing angioplasty for acute myocardial infarction	Adults undergoing angioplasty for acute myocardial infarction (n=2060)	RBCT (n=82) Prescribing guidance: not reported	No RBCT (n=1978)	Mortality at 30 days and 1 year #
Surgenor 2009 (24)	Design: prospective cohort How pts recruited: admitted to one of eight medical centres as part of the Northern New	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass surgery (n=9079)	RBCT (n=3254) Prescribing guidance: reported as at the	No RBCT (n=5825)	Mortality over 5 years #

	England Cardiovascular Disease Study Group Country: USA Year: 2001 to 2004 Funding: not reported			discretion of the patient care team		
Taylor 2006 (25)	Design: prospective cohort How pts recruited: admitted to intensive care unit at the St John's Mercy Medical Centre Country: USA Year: 2001 to 2003 Funding: not reported	Effect of RBCT on nosocomial infection and mortality in critically ill patients	Adults admitted to critical care unit (n=2085)	RBCT (n=449) Prescribing guidance: reported as at the discretion of the patient care team	No RBCT (n=1636)	Mortality (time period not specified)
Van Straten 2010 (26)	Design: prospective cohort How pts recruited: admitted to hospital (centre not specified) Country: Netherlands Year: 1998 to 2007 Funding: not reported	Effect of RBCT on long and short term survival in patients undergoing coronary artery bypass grafting	Patients undergoing coronary artery bypass grafting (n=10425)	RBCT (n=3597) Prescribing guidance: not reported	No RBCT (n=6828)	Mortality ≤ 30 days and mortality > 30 days #
Vincent 2008 (27)	Design: prospective cohort How pts recruited: admitted to European intensive care unit (n=198 units) Country: Belgium Year: 1 May to 15 May 2002 Funding: industry supported	Effect of RBCT on mortality in European intensive care units	Adults admitted intensive care unit (n=3147)	RBCT (n=1040) Prescribing guidance: not reported	No RBCT (n=2107)	Mortality in hospital at 30 days #
Red blood cells versus no red blood cells – retrospective studies						
Engoren 2009 (9)	Design: retrospective database How pts recruited: admitted to St Vincent Mercy Medical Centre intensive care unit Country: USA Year: 2001 to 2002 Funding: not reported	Effects of RBCT in critically ill patients (excluded cardiac surgery patients)	Adults admitted to intensive care unit (n=2213)	RBCT (n=404) Prescribing guidance: haemoglobin <8 g/dl	No RBCT (n=1809)	Mortality at 30 days and 180 days #
Engoren 2009 (10)	Design: retrospective database How pts recruited: admitted to St Vincent Mercy Medical Centre	Effects of RBCT in cardiac surgery patients	Adults admitted for cardiac surgery (n=1823)	RBCT (n=378) CABG and value	No RBCT (n=615) CABG and value	Mortality within 30 days >30 days

	for cardiac surgery Country: USA Year: 1991 to 2007 Funding: not reported			RBCT (n=534) Prescribing guidance: not reported	No RBCT (n=296)	
Garty 2009 (11)	Design: retrospective database How pts recruited: admitted to cardiac or internal medicine ward in 25 public hospitals Country: Israel Year: 2003 Funding: Non industry funded	Effect of RBCT (unclear if included other blood products) on patients with acute decompressed heart failure	Adults with acute decompressed heart failure (n=2335)	RBCT (n=166) Prescribing guidance: not reported	No RBCT(n=2169)	Mortality in-hospital, 30 days, 1 year and 4 years #
Jani 2007 (12)	Design: retrospective database (Blue Cross Blue Shield of Michigan Cardiovascular Consortium) How pts recruited: admitted to academic medical centres Country: USA Year: 1997 to 2004 Funding: Blue Cross Blue Shield of Michigan	Effect of RBCT and other blood product on in-patient mortality in anaemic patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI)	Adults (>60 years) with anaemia undergoing PCI within 7 days for having a MI (n=4623).	RBCT and other blood product (n=1033) Prescribing guidance: no formal protocol used	No RBCT or other blood product (n=3590).	Mortality in-hospital
Johnson 2006 (13)	Design: retrospective database How pts recruited: admitted to orthopaedic unit (District General Hospital, Peterborough) Country: UK Year: 1989 to 2002 Funding: Non industry funded	Effect of RBCT (unclear if included other blood products) on mortality in patients with hip fracture	Adults admitted to orthopaedic unit with hip fracture (n=3625)	RBCT (n=1068) Prescribing guidance: haemoglobin <8 g/dl	No RBCT (n=2503)	Mortality at 30, 120 and 365 days #
Khorana 2008 (14)	Design: retrospective database (University Health System Consortium) How pts recruited: admitted to academic medical centres Country: USA Year: 1995 to 2003 Funding: National Cancer Institute and National Heart, Lung and Blood Institute	Effect of RBCT and other blood product on thrombosis and mortality in hospitalised patients with cancer	Adults with cancer admitted to hospital (n=504208)	RBCT and other blood product (n=74051); RBC only (n=58814) Prescribing guidance: not reported	No RBCT or other blood product (n=430157)	Mortality in-hospital

Murphy 2007 (17)	Design: 3 retrospective databases (PATS (Patient analysis and Tracking System), haematological and blood bank studys) How pts recruited: admitted to Bristol Royal Infirmary for adult cardiac surgery Country: UK Year: 1996 to 2003 Funding: British Heart Foundation	Effect of RBCT on mortality, post operative morbidity and cost in patients undergoing cardiac surgery	Adults > 16 years undergoing cardiac surgery (n=8598)	RBCT (n=4909) Prescribing guidance: not reported	No RBCT (n=3689)	Mortality up to 7 years post surgery (median 4.15 years) #
Pederson 2009 (19)	Design: retrospective database (Danish Hip Arthroplasty Registry) How pts recruited: admitted from 20 orthopaedic departments Country: Denmark Year: 1999 to 2007 Funding: not reported	Effect of RBCT on mortality in patients undergoing total hip replacement	Adults undergoing surgery for total hip replacement (n=28087)	RBCT (n=9063) Prescribing guidance: not reported	No RBCT (n=19024)	Mortality at 90 days
Rogers 2006 (20)	Design: retrospective database (Center for Medicare and Medicaid Services) How pts recruited: Medicare beneficiaries hospitalised for coronary artery bypass surgery Country: USA Year: 1997 to 1998 Funding: non industry funded	Effect of RBCT on mortality in patients undergoing coronary artery bypass surgery	Older adults (> 65 Years) undergoing coronary artery bypass surgery (n=9218)	RBCT (n=6893) Prescribing guidance: not reported	No RBCT (n=2325)	Mortality within 100 days
Rogers 2009 (21)	Design: retrospective database How pts recruited: Medicare beneficiaries who received coronary artery bypass surgery Country: USA Year: 2003 to 2006 Funding: Michigan Foundation	Effect of RBCT and other blood product on infection and mortality in patients undergoing coronary artery bypass surgery	Older adults (> 65 years) undergoing coronary artery bypass surgery (n=24789)	RBCT and other blood product (n=20789) Prescribing guidance: not reported	No RBCT or other blood product (n=4000)	Mortality in hospital and at 30 days post discharge

Salehiomran 2009 (22)	Design: retrospective database How pts recruited: patients admitted to Tehran Heart Centre who received coronary artery bypass surgery Country: Iran Year: 2002 to 2008 Funding: not reported	Effect of RBCT (unclear if included other blood products) on mortality in patients undergoing coronary artery bypass surgery	Adults undergoing coronary artery bypass surgery (n=14152)	RBCT (n=2333) Prescribing guidance: hematocrit <25-26%	No RBCT (n=11773)	Mortality at 30 days
Stone 2008 (23)	Design: retrospective database How pts recruited: admitted to paediatric trauma centre Country: USA Year: 1998 to 2006 Funding: not reported	Effect of RBCT on mortality in paediatric trauma patients	Children with blunt or penetrating injury admitted to trauma centre (n=1639)	RBCT (n=106) Prescribing guidance: reported no specific transfusion protocol was used	No RBCT (n=1533)	Mortality in-hospital
Weinberg 2008 (28)	Design: retrospective database How pts recruited: admitted to trauma centre at University of Alabama Country: USA Year: 2000 to 2007 Funding: not reported	Effect of RBCT on mortality in trauma patients	Less severely injured adults admitted to trauma centre (n=1624)	RBCT (n=430) Prescribing guidance: not reported	No RBCT (n=1194)	Mortality in hospital
Wu 2010 (29)	Design: retrospective database (Department of Veteran Affairs and National Surgical Quality Improvement Program) How pts recruited: admitted to one of 142 veteran hospitals and requiring major non cardiac surgery Country: USA Year: 1997 to 2004 Funding: not reported	Effect of RBCT on mortality in older adults after major non cardiac surgery	Older adults (>65 years) undergoing major non cardiac surgery (n=239286)	RBCT(n=22515) Prescribing guidance: not reported	No RBCT (n=216771)	Mortality at 30 days
Zilberberg 2008 (30)	Design: retrospective database (Henry Ford Health System includes data from 7 hospitals in USA) How pts recruited: admitted to hospital and requiring	Effect of RBCT on mortality in critically ill patients requiring prolonged ventilation	Adults critically ill and requiring prolonged ventilation 96 ≥hours (n=4344)	RBCT (n=2912) Prescribing guidance: not reported	No RBCT (n=1432)	Mortality in-hospital

	ventilation Country: USA Year: 2000 to 2005 Funding: industry supported					
Volume 'A' red blood cells versus volume 'B' red blood cells						
Bernard 2009 (31)	Design: retrospective database How pts recruited: admitted to hospital and requiring major surgery Country: USA Year: 2005 to 2006 Funding: industry supported	Effect of RBCT and volume of blood in patients undergoing major surgery	Adults undergoing major surgery (n=125177)	Volume of RBCT (classified as: 0 units RBC, 1 unit, 2 units, 3-4 units, 5-9 units >10 units intra operative and >4 units post operative) Prescribing guidance: no formal protocol used	Another volume of RBCT (classified as: 0 units RBC, 1 unit, 2 units, 3-4 units, 5-9 units >10 units intra operative and >4 units post operative) Prescribing guidance: no formal protocol used	Mortality at 30 days
Charles 2007 (32)	Design: retrospective database (NTRACS trauma registry) How pts recruited: admitted to Level 2 trauma centre Country: USA Year: 1994 to 2004 Funding: not reported	Effect of RBCT and volume of blood in patients with blunt trauma injuries	Adults >18 yrs with blunt trauma injuries admitted to trauma centre (n=8215)	Volume of RBCT (classified as: 0 units RBC, 1-2 units, 3-5 units, >6 units) Prescribing guidance: no formal protocol used	Another volume of RBCT (classified as: 0 units RBC, 1-2 units, 3-5 units, >6 units) Prescribing guidance: no formal protocol used	Mortality at 24 hours
O'Keefle 2010 (33)	Design: retrospective database (American College of Surgeons National Quality Improvement Program) How pts recruited: admitted from 173 hospitals and undergoing vascular surgery Country: USA Year: 2005 to 2007 Funding: not reported	Effect of RBCT on mortality in patients undergoing lower extremity revascularization	Adults with peripheral arterial disease (n=8799)	Volume of RBCT (classified as: 0 units RBC, 1 to 2 and >3 units) Prescribing guidance: not reported	Another volume of RBCT (classified as: 0 units RBC, 1 to 2 and >3 units) Prescribing guidance: not reported	Mortality at 30 days
Ruttinger 2007 (34)	Design: retrospective database How pts recruited: admitted to surgical intensive care unit LMU University Hospital., Munich Country: Germany	Effect of RBCT on mortality in critically ill patients	Patients admitted to intensive care unit (n=3037)	Volume of RBCT (classified as: 1 to 2 units (n=676) RBC, 3 to 4 (n=345), 5 to 8 (n=301) and >8 units	Another volume of RBCT (classified as: 1 to 2 units RBC, 3 to 4, 5 to 8 and >8 units)	Mortality in-hospital

	Year: 1993 to 2005 Funding: not reported			(n=471) Prescribing guidance: haemoglobin <8-9 g/dl	Prescribing guidance: haemoglobin <8-9 g/dl	
Weightman 2009 (35)	Design: prospective cohort How pts recruited: admitted to Sir Charles Gairdner hospital Country: Australia Year: 1993 to 2000 Funding: not reported	Effect of RBCT and other blood product on long term survival in patients undergoing coronary artery bypass grafting	Patients undergoing coronary artery bypass grafting (n=1841) and survived longer than 60 days	Volume of RBCT and other blood product (classified as: 0 units (n=779), 1-2 units (n=402), 3-6 units (n=333) and > 6units (n=327)) Prescribing guidance: not reported	Another volume of RBCT and other blood product (classified as: 0 units, 1-2 units, 3-6 units and > 6units) Prescribing guidance: not reported	Mortality (mean follow up 8.1 years)#
'Older' red blood cells versus 'newer' red blood cell						
Edgren 2010 (36)	Design: retrospective database How pts recruited: received blood transfusion as recorded in Scandinavian Donations and Transfusion Study Country: Sweden and Denmark Year: 1995 to 2002 Funding: National Heart, Lung and Blood Institute of NIH	Effect of RBCT duration of storage on mortality	Adults receiving ≥ 1 RBC transfusion (n=364037)	RBCT stored for 0-9 days, 10-19 days, 20-29 days, 30-42 days Prescribing guidance: no formal protocol used	RBCT stored for 0-9 days, 10-19 days, 20- 29 days, 30-42 days Prescribing guidance: no formal protocol used	Mortality ≤ 7 days and mortality 8 to 730 days#
Koch 2008 (37)	Design: retrospective database (Cleveland clinic blood bank and cardiac registries) How pts recruited: admitted to Cleveland Clinic Country: USA Year: 1998 to 2006 Funding: National Institute for Health Research and Joseph Drown Foundation	Effect of RBCT duration of storage on mortality and serious complication in patients undergoing cardiac surgery	Adults >18 years undergoing coronary- artery bypass grafting, cardiac-valve surgery, or both (n=6002)	RBCT stored for ≤ 14 days (n=2872) Prescribing guidance: no formal protocol used	RBCT stored for >14 days (n=3130) Prescribing guidance: no formal protocol used	Mortality in-hospital and at 1 year
Van de Watering 2006 (38)	Design: retrospective database (Leiden University Medical Centre)	Effect of RBCT duration of storage on mortality in	Adults undergoing cardiothoracic surgery (n=2715)	RBCT stored for <18 days (n=942)	RBCT stored for >18 days (n=941)	Mortality at 30 days#

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	How pts recruited: admitted to cardiothoracic surgery unit Country: Netherlands Year: 1993 to 1999 Funding: none industry	cardiac patients		Prescribing guidance: no formal protocol used	Prescribing guidance: no formal protocol used	
Weinberg 2008 (39)	Design: retrospective database How pts recruited: admitted to trauma centre at University of Alabama Country: USA Year: 2000 to 2007 Funding: not reported	Effect of leukodepleted RBCT transfusion and duration of storage on mortality in trauma patients	Severely injured adults admitted to trauma centre (n=1813)	RBCT stored for <14 days Prescribing guidance: no formal protocol used	RBCT stored for ≥14 days Prescribing guidance: no formal protocol used	Mortality (time period not specified)

RBCT=red blood cell transfusion; NR: not reported; #time-to-event outcome

Peer review only

APPENDIX 43: Statistical methods and presentation of unadjusted and adjusted results of the included studies

Study ID	Study covariates	Comparison	Unadjusted results	Adjusted results	Method of adjustment
Red blood cells versus no red blood cells – prospective studies					
Aronson 2008 (7)	Number covariates: 16 Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality at 6 months#	RBCT (n): NR No RBCT (n): NR Hazard ratio 4.4 (95% CI 3.2 to 5.9)	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.9 (95% CI 1.3 to 2.9)	Nature of adjustment: transfusion propensity, baseline characteristics, nadir haemoglobin Type of model used: logistic regression Number covariates in model: 16
Bochicchio 2008 (8)	Number covariates: 5 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT or other blood products Mortality (time period not specified)	RBCT: 147/786 No RBCT: 32/386 p<0.001 (Odds ratio not reported)	RBCT: 147/786 No RBCT: 32/386 Odds ratio 1.05 (95% CI 1.03 to 1.07)	Nature of adjustment: age, ISS, admission GCS Type of model used: logistic regression Number covariates in model: 3
Koch 2006 (15,16)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates were pre-specified	RBCT versus no RBCT Mortality in hospital	RBCT (n): NR No RBCT (n): NR Odds ratio 1.78 (95% CI 1.70 to 1.87)	RBCT (n): NR No RBCT (n): NR Odds ratio 1.77 (1.67 to 1.87)	Nature of adjustment: multiple covariates Type of model used: logistic regression Number covariate in model: multiple covariates
Nikolsky 2009 (18)	Number covariates: 25 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days and 1 year#	Not reported	Mortality at 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 4.71(95% CI 1.97 to 11.26) Mortality at 1 year RBCT (n): NR	Nature of adjustment: transfusion propensity Type of model used: Cox proportional hazards model Number covariate in model: 19

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

				No RBCT (n): NR Hazard ratio 3.16 (95% CI 1.66 to 6.03)	
Surgenor 2009 (24)	Number covariates: multiple Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT versus no RBCT Mortality within 5 years#	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.94 (95% CI 1.71 to 2.20)	RBCT (n): NR No RBCT (n): NR Hazard ratio 1.16 (95% CI 1.01 to 1.33)	Nature of adjustment: propensity model Type of model used: Cox proportion hazard model Number covariates in model: 13
Taylor 2006 (25)	Number covariates: 5 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: no Covariates pre-specified	RBCT versus no RBCT Mortality (time period not specified)	RBCT: 98/449 No RBCT: 166/1636 p<0.001 (only p value reported)	POS ≤ 25% RBCT: 47/147 No RBCT: 105/336 p=0.88 POS 25% ≤ 50% RBCT: 17/126 No RBCT: 23/358 p=0.013 POS 50% ≤ 75% RBCT: 14/94 No RBCT: 100/390 P<0.0001 POS >75% RBCT: 3/39 No RBCT: 4/444 p=0.14 (only p value reported)	Nature of adjustment: mortality predication model (POS) Type of model used: logistic regression Number covariates in model: NR
Van Straten 2010 (26)	Number covariates: 16 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: no Unclear if covariates pre-	RBCT versus no RBCT Mortality ≤ 30 days and mortality > 30 days#	Mortality ≤ 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 1.31 (95% CI 1.27 to 1.35) Mortality > 30 days	Mortality ≤ 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 1.21 (95% CI 1.13 to 1.30) Mortality > 30 days	Nature of adjustment: unclear Type of model used: Cox proportional hazards model Number covariates in model: NR

	specified or data driven		Hazard ratio 1.16 (95% CI 1.13 to 1.20)	Hazard ratio 1.04 (95% CI 0.99 to 1.07)	
Vincent 2008 (27)	Number covariates: 8 Age: yes Sex: yes Smoking :no Co-morbidity: yes Hb level: no Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days in hospital#	RBCT: 311/1040 No RBCT: 436/2107 p<0.001 (only p value reported)	RBCT: NR No RBCT: NR Hazard ratio 0.89 (95% CI 0.76 to 1.05) p=0.16	Nature of adjustment: multiple covariates Type of model used: Cox proportional hazards model Number covariates in model: 8
Red blood cells versus no red blood cells – retrospective studies					
Engoren 2009 (9)	Number covariates: 25 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality at 30 days and 180 days#	Mortality 30 days RBCT: 101/404 No RBCT: 265/1809 Mortality 180 days RBCT: 150/404 No RBCT: 414/1809 p<0.01 (Hazard ratios not reported)	Mortality 30 days RBCT: NR No RBCT: NR Hazard ratio 1.11 (95% CI 0.86 to 1.42) Mortality 180 days RBCT: NR No RBCT: NR Hazard ratio 1.14 (95% CI 0.83 to 1.58)	Nature of adjustment: multiple variables Type of model used: Cox proportional hazard modelling Number covariates in model: NR
Engoren 2009 (10)	Number covariates: multiple Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: Yes Covariates pre-specified	RBCT versus no RBCT Mortality within 30 days and >30 days	Mortality within 30 days Value only: RBCT: 26/993 No RBCT: 16/993 CABG and value: RBCT: 69/830 No RBCT: 14/830 Mortality >30 days Value only: RBCT: 160/993 No RBCT: 165/993 CABG and value: RBCT: 279/830 No RBCT: 113/830	Mortality within 30 days Value only: Odds ratio 1.95 (95% CI 0.97 to 3.91) CABG and value: Odds ratio 2.23 (95% CI 1.12 to 4.46) Mortality >30 days Value only: Risk ratio 1.25 (95% CI 0.97 to 1.61) CABG and value: Risk ratio 1.44 (95% CI 1.13 to 1.84)	Nature of adjustment: propensity score Type of model used: Cox proportional hazard modelling (mortality >30 days) and logistic regression (mortality within 30 days) Number covariates in model: NR
Garty 2009	Number covariates:	RBCT (unclear if included)	Mortality in hospital	Mortality in hospital	Nature of adjustment: propensity

(11)	unclear Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Unclear if covariates pre-specified or data driven	other blood product) versus no RBCT Mortality in hospital, 30 days, 1 year and 4 years#	RBCT: 18/166 (10.8%) No RBCT: 113/2169 (5.2%) Mortality 30 days RBCT: 18/166 (11%) No RBCT: 183/2169 (8.5%) Mortality 1 year RBCT: 65/166 (39.6%) No RBCT: 616/2169 (28.5%) Mortality 4 years RBCT: 114/166 (69.5%) No RBCT: 1284/2169 (59.5%)	RBCT: 9/103 (8.7%) No RBCT: 15/103 (14.6%) Hazard ratio: 0.48 (95% CI 0.21 to 1.11) Mortality 30 days RBCT: 10/103 (9.7%) No RBCT: 19/103 (18.4%) Hazard ratio: 0.29 (95% CI 0.13 to 0.64) Mortality 1 year RBCT: 40/103 (38.8%) No RBCT: 44/103 (42.7%) Hazard ratio: 0.74 (95% CI 0.50 to 1.09) Mortality 4 years RBCT: 75/103 (72.8%) No RBCT: 79/103 (76.7%) Hazard ratio: 0.86 (95% CI 0.64 to 1.14)	score Type of model used: Cox proportional hazard modelling (1-4 year mortality) and logistic regression (mortality up to 30 days) Number covariates in model: 9
Jani 2007 (12)	Number covariates: 31 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT Mortality in hospital	RBCT: 150/1033 No RBCT: 108/3590 p<0.001 (only p value reported)	RBCT: 76/598 No RBCT: 44/598 Odds ratio 2.02 (95% CI 1.47 to 2.79)	Nature of adjustment: transfusion propensity and co morbidities Type of model used: logistic regression Number covariate in model: 10
Johnson 2006 (13)	Number covariates: 7 Age: yes Sex: yes Smoking: no Co-morbidity: no HB level: yes Unclear if covariates pre-specified or data driven	RBCT (unclear if included other blood product) versus no RBCT Mortality at 30, 120, 365 days#	Mortality 30 days RBCT: 95/1068 No RBCT: 181/2503 p=0.10 Mortality 120 days RBCT: 247/1068 No RBCT: 374/2503 p<0.0001 Mortality 365 days	Mortality 30 days (not reported) Mortality 120 days (not reported) Mortality 365 days	Nature of adjustment: age, sex, ASA grade, preoperative haemoglobin, residential status, mobility score Type of model used: Cox regression Number covariate in model: 7

			RBCT : 381/1068 No RBCT: 626/2503 p<0.001 (only p values reported)	RBCT: 381/1068 No RBCT: 626/2503 Hazard ratio 1.11 (95% CI 0.96 to 1.29)	
Khorana 2008 (14)	Number covariates: Unclear Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: no Covariates pre-specified	RBCT and other blood product versus no RBCT Mortality in hospital	RBCT (n): 11.9% No RBCT (n): NR	RBCT (n): NR No RBCT (n): NR Odds ratio 1.34 (95% 1.29 to 1.38)	Nature of adjustment: NR Type of model used: multivariate logistic regression Number covariate in model: NR
Murphy 2007 (17)	Number covariates: 21 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality up to 7 years post surgery#	Not reported	Mortality 0 - 30 days RBCT (n): NR No RBCT (n): NR Hazard ratio 6.69(95% CI 3.66 to 15.1) Mortality 31 days to 1 year Hazard ratio 2.59 (95% CI 1.68 to 4.18) Mortality > 1 year Hazard ratio 1.32 (95% CI 1.08 to 1.64)	Nature of adjustment: transfusion propensity Type of model used: logistic regression and Cox proportional hazards regression Number covariate in model: NR
Pederson 2009 (19)	Number covariates: 69 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT versus no RBCT Mortality at 90 day	RBCT (n): NR No RBCT (n): NR Odds ratio 2.17 (95% CI 1.24 to 3.79)	RBCT: 39/2254 No RBCT: 18/2254 Odds ratio 2.17 (95% CI 1.24 to 3.80)	Nature of adjustment: transfusion propensity Type of model used: multivariate logistic regression Number covariate in model: NR
Rogers 2006 (20)	Number covariates: 33 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: unclear	RBCT versus no RBCT Mortality within 100 days	RBCT: 648/6893 No RBCT: 44/2325 Odds ratio 6.6 (95% CI 4.4 to 9.9)	RBCT: 648/6893 No RBCT: 44/2325 Odds ratio 5.6 (95% CI 3.7 to 8.6)	Nature of adjustment: sex, age, race, co morbidity, urgency of admission Type of model used: generalised linear regression Number covariate in model: 5

	Unclear if covariates pre-specified or data driven				
Rogers 2009 (21)	Number covariates: 13 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: no Unclear if covariates pre-specified or data driven	RBCT and other blood product versus no RBCT Mortality in hospital and at 30 days	Not reported	Mortality in hospital RBCT (n): NR No RBCT (n): NR Elective surgery: Odds ratio 4.67 (95% CI 2.38 to 9.18) Urgent surgery: Odds ratio 1.82 (95% CI 1.51 to 2.20) Mortality 30 days post discharge Elective surgery: Odds ratio 2.88 (95% CI 1.38 to 5.98) Urgent surgery: Odds ratio 4.65 (95% CI 1.90 to 11.39)	Nature of adjustment: propensity score, surgical volume, hospital volume Type of model used: multivariate mixed effect logistic regression Number covariate in model: 3
Salehiomran 2009 (22)	Number covariates: 31 Age: yes Sex: yes Smoking: yes Co-morbidity: yes HB level: yes Covariates pre-specified	RBCT (unclear if included other blood products) versus no RBCT Mortality at 30 days	RBCT: 60/2333 No RBCT: 42/11773 p<0.001 (Odds ratio not reported)	RBCT: 60/2333 No RBCT: 42/11773 Odds ratio 3.98 (95% CI 2.44 to 6.47)	Nature of adjustment: not reported Type of model used: multivariate logistic regression Number covariate in model: 13
Stone 2008 (23)	Number covariates: 7 Age: yes Sex: yes Smoking: N/A Co-morbidity: yes Hb level: no Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality in hospital	RBCT: 31/106 No RBCT: 42/1533 Odds ratio 14.67 (95% CI not reported)	Not reported (authors said statistical model was to unreliable to provide reliable conclusions)	Nature of adjustment: injury severity Type of model used: logistic regression Number covariate in model: NR
Weinberg 2008 (28)	Number covariates: 9 Age: yes Sex: yes Smoking: no Co-morbidity: no Hb level: no Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality in hospital	RBCT (n): 4.2% No RBCT (n): 2.3% p=0.04	RBCT (n): NR No RBCT (n): NR Odds ratio 0.96 (95% CI 0.48 to 1.94)	Nature of adjustment: age, gender, ISS, injury, ventilation, transfusion volume Type of model used: logistic regression Number of covariates in model: 5

Wu 2010 (29)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes Hb level: yes Unclear if covariates pre-specified or data driven	RBCT versus no RBCT Mortality at 30 days	Not reported	RBCT (n): NR No RBCT (n): NR Odds ratio 1.37 (95% CI 1.27 to 1.48)	Nature of adjustment: mean operative time, ASA classification, rate of general anaesthesia Type of model used: logistic regression Number covariates in model: NR
Zilberberg 2008 (30)	Number covariates: multiple Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT versus no RBCT Mortality in hospital	RBCT: 938/2912 No RBCT: 342/1432 Odds ratio 1.51 (95% CI 1.31 to 1.75)	RBCT : 938/2912 No RBCT: 342/1432 Odds ratio 1.21 (95% CI 1.00 to 1.48)	Nature of adjustment: multiple variables Type of model used: logistic regression Number covariates in model: 13
Volume 'A' red blood cells versus volume 'B' red blood cells					
Bernard 2009 (31)	Number covariates: multiple Age: Yes Sex: Yes Smoking: Yes Co-morbidity: Yes Hb level: Yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 30 days	Intra operative 1 unit: 136/1343 2 units: 194/1903 3-4 units: 151/977 5-9 units: 67/412 >10 units: 45/153 Post operative >4 units: 153/575 (Odds ratios not reported)	Intra operative 1 unit: Odds ratio 1.32 2 units: Odds ratio 1.38 3-4 units: Odds ratio 1.97 5-9 units: Odds ratio 2.17 >10 units: Odds ratio 9.83 Post operative >4 units: Odds ratio 2.65 (95% CI not reported)	Nature of adjustment: transfusion propensity, type of procedure, wound class, operative duration Type of model used: logistic regression Number covariates in model: multiple
Charles 2007 (32)	Number covariates: 7 Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 24 hours	0 RBCT: 1.8% 1-2 units: 6.5% 3-5 units: 16.1% ≥6 units: 29.8% (Odds ratios not reported)	1-2 units: p=0.18 3-5 units: Odds ratio 3.22 p=0.002 ≥6 units: Odds ratio 4.87 p=0.000 (95% CI not reported)	Nature of adjustment: age, gender, ISS score, SI Type of model used: logistic regression Number covariates in model: 4

O'Keeffe 2010 (33)	Number covariates: 23 Age: yes Sex: yes Smoking: unclear Co-morbidity: yes HB level: yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality at 30 days	Not reported	1-2 units: Odds ratio 1.92 (95% CI 1.36 to 2.70) >3 units: Odds ratio 2.48 (95% CI 1.55 to 3.98)	Nature of adjustment: transfusion propensity Type of model used: logistic regression Number covariate in model: 19
Ruttinger 2007 (34)	Number covariates: 14 Age: yes Sex: yes Smoking: no Co-morbidity: yes HB level: yes Covariates pre-specified	Volume of RBCT versus another volume of RBCT Mortality in hospital	% reported in figure only (Odds ratios not reported)	1-2 units: Odds ratio 0.68 (95% CI 0.35 to 1.28) 3-4 units: Odds ratio 1.11 (95% CI 0.52 to 2.39) 5-8 units: Odds ratio 1.16 (95% CI 0.60 to 2.26) 8 units: Odds ratio 0.74 (95% CI 0.36 to 1.51)	Nature of adjustment: extended analysis Type of model used: logistic regression Number covariate in model: NR
Weightman 2009 (35)	Number covariates: 16 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	Volume of RBCT and other blood product (classified as: 0 units, 1-2 units, 3-6 units and > 6units) Mortality (mean follow up 8.1 years)	0 units: 80/779 1-2 units: 56/402 3-6 units: 58/333 > 6 units: 72/327	1-2 units: Hazard ratio 1.00 (95% CI 0.70 to 1.44) 3-6 units: Hazard ratio 0.98 (95% CI 0.67 to 1.41) > 6 units: Hazard ratio 1.25 (95% CI 0.87 to 1.79)	Nature of adjustment: multiple measures Type of model used: Cox proportional hazard model Number covariates in model: 12
'Older red blood cells versus 'newer' red blood cells					
Edgren 2010 (36)	Number covariates: unclear Age: Yes Sex: Yes Smoking: No Co-morbidity: Yes Hb level: No Covariates pre-specified	RBCT storage for 0- days, 10-19 days, 20-29 and 30-42 days Mortality ≤ 7 days and mortality 8 to 730 days#	Not reported	Mortality 1 to 7 days Stored 0- 9 days: Hazard ratio 0.96 (95% CI 0.91 to 1.00) Stored 10-19 days: Hazard ratio 1.00 (95% CI not reported) Stored 20-29 days: Hazard ratio 1.06 (95% CI 0.96 to 1.06) Stored 30-42 days: Hazard ratio 1.05 (95% CI 0.97 to 1.12) Mortality 8 to 730 days Stored 0- 9 days: Hazard ratio 1.01 (95% CI 0.99 to 1.02) Stored 10-19 days: Hazard ratio 1.00 (95% CI not reported)	Nature of adjustment: number transfusions, age, sex, blood group, calendar period, season, weekday, hospital, indication Type of model used: Cox proportional hazards regression Number covariates in model: 9

				Stored 20-29 days: Hazard ratio 0.99 (95% CI 0.97 to 1.01) Stored 30-42 days: Hazard ratio 1.05 (95% CI 1.02 to 1.08)	
Koch 2008 (37)	Number covariates: multiple Age: yes Sex: yes Smoking: yes Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT stored for ≤ 14 days versus RBCT stored for > 14 days Mortality in hospital and at 1 year	Mortality in hospital Stored ≤ 14 days: 49/2872 Stored > 14 days: 88/3130 p=0.004 (only p value reported)	Mortality at 1 year Stored ≤ 14 days: 7.4% Stored > 14 days: 11% p<0.001 (only p value reported)	Nature of adjustment: transfusion propensity Type of model used: logistic regression Number covariate in model: NR
Van de Watering 2006 (38)	Number covariates: 7 Age: yes Sex: yes Smoking: no Co-morbidity: yes Hb level: yes Covariates pre-specified	RBCT stored for <18 days versus RBCT stored for >18 days Mortality at 30 days#	Stored <18 days (n): NR Hazard ratio 1.33 (95% CI 1.04 to 1.68) Stored > 18 days (n): NR Hazard ratio: 0.85 (95% CI 0.69 to 1.05)	Stored <18 days (n): NR Hazard ratio 0.93 (95% CI 0.71 to 1.23) Stored > 18 days (n): NR Hazard ratio 0.98 (95% CI 0.76 to 1.25)	Nature of adjustment: number of transfusions, duration of surgery, previous CABG, number of distal anatomises, age, sex, Hb level Type of model used: NR Number covariates in model: 7
Weinberg 2008 (39)	Number covariates: 6 Age: yes Sex: yes Smoking: no Co-morbidity: no Hb level: no Covariates pre-specified	RBCT stored for <14 days versus RBCT stored for >14 days Mortality (time period not specified)	Not reported	Stored <14 days: 1-2 units: Odds ratio 1.65 (95% CI 1.01 to 2.70) ≥ 3 units: Odds ratio 1.70 (95% CI 0.96 to 2.99) Stored ≥ 14 days: 1-2 units: Odds ratio 1.78 (95% CI 1.06 to 2.98) ≥ 3 units: Odds ratio 2.78 (95% CI 1.58 to 4.88)	Nature of adjustment: age, gender, ISS, type injury, number units transfused first 24 hours, length of hospital stay Type of model used: logistic regression Number covariates in model: 6

RBCT=red blood cell transfusion; NR: not reported; OR = odds ratio; RR = risk ratio; HR = hazard ratio; #time-to-event outcome

APPENDIX 54: Summary of unadjusted and adjusted results of the included studies

Study ID	Disease area	Comparison	Mortality	Unadjusted results	Adjusted result
Red blood cells versus no red blood cells – prospective studies					
Aronson 2008 (7)	Cardiac surgery	RBCT versus no RBCT	6 months	HR 4.4 (95% CI 3.2 to 5.9)	HR 1.9 (95% CI 1.3 to 2.9)
Bochicchio 2008 (8)	Trauma	RBCT and other blood product versus no RBCT	Time period not specified	OR 2.54 (95% CI 1.70 to 3.81)*	OR 1.05 (95% CI 1.03 to 1.07)
Koch 2006 (15,16)	Cardiac surgery	RBCT versus no RBCT	In hospital	OR 1.78 (95% CI 1.70 to 1.87)	OR 1.77 (1.67 to 1.87)
Nikolsky 2009 (18)	Cardiac surgery	RBCT versus no RBCT	30 days and 1 year	Not reported	Mortality at 30 days HR 4.71(95% CI 1.97 to 11.26) Mortality at 1 year HR 3.16 (95% CI 1.66 to 6.03)
Surgenor 2009 (24)	Cardiac surgery	RBCT versus no RBCT	≤ 5 years	HR 1.94 (95% CI 1.71 to 2.20)	HR 1.16 (95% CI 1.01 to 1.33)
Taylor 2006 (25)	Intensive care	RBCT versus no RBCT	Time period not specified	OR 2.47 (95% CI 1.88 to 3.26)*	POS ≤ 25% p=0.88 POS 25% ≤ 50% p=0.013 POS 50% ≤ 75% p<0.0001 POS >75% p=0.14
Van Straten 2010 (26)	Cardiac surgery	RBCT versus no RBCT	≤ 30 days and > 30 days	Mortality ≤ 30 days HR 1.31 (95% CI 1.27 to 1.35) Mortality > 30 days HR 1.16 (95% CI 1.13 to 1.20)	Mortality ≤ 30 days HR 1.21 (95% CI 1.13 to 1.30) Mortality > 30 days HR 1.04 (95% CI 0.99 to 1.07)
Vincent 2008 (27)	Intensive care	RBCT versus no RBCT	30 days in hospital	OR 1.64 (95% CI 1.38 to 1.94)*	HR 0.89 (95% CI 0.76 to 1.05)

Red blood cells versus no red blood cells – retrospective studies					
Engoren 2009 (9)	Intensive care	RBCT versus no RBCT	30 and 180 days	Mortality 30 days OR 1.94 (95% CI 1.50 to 2.52)* Mortality 180 days OR 1.99 (95% CI 1.58 to 2.50)*	Mortality 30 days HR 1.11 (95% CI 0.86 to 1.42) Mortality 180 days HR 1.14 (95% CI 0.83 to 1.58)
Engoren 2009 (10)	Cardiac surgery	RBCT versus no RBCT	≤ 30 days and >30 days	Mortality ≤30 days Valve only: OR 1.65 (95% CI 0.88 to 3.08)* CABG and valve: OR 5.28 (95% CI 2.95 to 9.47)* Mortality >30 days Valve only: RR 0.97 (95% CI 0.79 to 1.18)* CABG and valve: RR 2.47 (95% CI 2.03 to 3.00)*	Mortality ≤30 days Valve only: OR 1.95 (95% CI 0.97 to 3.91) CABG and valve: OR 2.23 (95% CI 1.12 to 4.46) Mortality >30 days Valve only: RR 1.25 (95% CI 0.97 to 1.61) CABG and valve: RR 1.44 (95% CI 1.13 to 1.84)
Garty 2009 (11)	Cardiac surgery	RBCT (unclear if other blood product) versus no RBCT	In hospital, 30 days, 1 year and 4 years	Mortality in hospital OR 0.77 (95% CI 0.46 to 1.31)* Mortality 30 days OR 2.21 (95% CI 1.31 to 3.74)* Mortality 1 year OR 1.62 (95% CI 1.17 to 2.25)* Mortality 4 years OR 1.51 (95% CI 1.08 to 2.12)*	Mortality in hospital HR 0.48 (95% CI 0.21 to 1.11) Mortality 30 days HR 0.29 (95% CI 0.13 to 0.64) Mortality 1 year HR 0.74 (95% CI 0.50 to 1.09) Mortality 4 years HR 0.86 (95% CI 0.64 to 1.14)
Jani 2007 (12)	Cardiac surgery	RBCT and other blood product versus no RBCT	In hospital	OR 5.48 (95% CI 4.23 to 7.09)*	OR 2.02 (95% CI 1.47 to 2.79)
Johnson 2006 (13)	Hip fracture and replacement	RBCT (unclear if other blood product) versus no RBCT	30 days, 120 days, 365 days	Mortality 30 days OR 1.84 (95% CI 1.42 to 2.38)* Mortality 120 days OR 1.71 (95% CI 1.43 to 2.05)*	Mortality 365 days HR 1.11 (95% CI 0.96 to 1.29)

				Mortality 365 days OR 1.66 (95% CI 1.42 to 1.94)*	
Khorana 2008 (14)	Oncology	RBCT and other blood product versus no RBCT	In hospital	Not reported	OR 1.34 (95% 1.29 to 1.38)
Murphy 2007 (17)	Cardiac surgery	RBCT versus no RBCT	≤7 years	Not reported	Mortality 0 - 30 days HR 6.69 (95% CI 3.66 to 15.1) Mortality 31 days to 1 year HR 2.59 (95% CI 1.68 to 4.18) Mortality > 1 year HR 1.32 (95% CI 1.08 to 1.64)
Pederson 2009 (19)	Hip fracture and replacement	RBCT versus no RBCT	90 day	OR 2.17 (95% CI 1.24 to 3.79)	OR 2.17 (95% CI 1.24 to 3.80)
Rogers 2006 (20)	Cardiac surgery	RBCT versus no RBCT	≤100 days	OR 6.6 (95% CI 4.4 to 9.9)	OR 5.6 (95% CI 3.7 to 8.6)
Rogers 2009 (21)	Cardiac surgery	RBCT and other blood product versus no RBCT	In hospital and 30 days	Not reported	Mortality in hospital Elective surgery: OR 4.67 (95% CI 2.38 to 9.18) Urgent surgery: OR 1.82 (95% CI 1.51 to 2.20) Mortality 30 days post discharge Elective surgery: OR 2.88 (95% CI 1.38 to 5.98) Urgent surgery: OR 4.65 (95% CI 1.90 to 11.39)
Salehiomran 2009 (22)	Cardiac surgery	RBCT (unclear if other blood product) versus no RBCT	30 days	OR 1.55 (95% CI 1.04 to 2.30)*	OR 3.98 (95% CI 2.44 to 6.47)
Stone 2008 (23)	Paediatric trauma	RBCT versus no RBCT	In hospital	OR 14.67 (95% CI not reported)	Not reported
Weinberg 2008 (28)	Adult trauma	RBCT versus no RBCT	In hospital	OR 1.89 (95% CI 0.97 to 3.60)*	OR 0.96 (95% CI 0.48 to 1.94)
Wu 2010 (29)	Intensive care	RBCT versus no RBCT	30 days	Not reported	OR 1.37 (95% CI 1.27 to 1.48)

Zilberberg 2008 (30)	Intensive care	RBCT versus no RBCT	In hospital	OR 1.51 (95% CI 1.31 to 1.75)	OR 1.21 (95% CI 1.00 to 1.48)
Volume 'A' red blood cells versus volume 'B' red blood cells					
Bernard 2009 (31)	Surgery	Volume RBCT versus another volume RBCT	30 days	Not reported	Intra operative 1 unit: OR 1.32(95% CI not reported) 2 units: OR 1.38(95% CI not reported) 3-4 units: OR 1.97(95% CI not reported) 5-10 units: OR 2.17(95% CI not reported) >10 units: OR 9.83(95% CI not reported) Post operative >4 units: OR 2.65 (95% CI not reported)
Charles 2007 (32)	Trauma	Volume RBCT versus another volume RBCT	24 hours	Not reported	3-5 units: OR 3.22 (95% CI not reported) ≥6 units: OR 4.87 (95% CI not reported)
O'Keeffe 2010 (33)	Cardiac surgery	Volume RBCT versus another volume RBCT	30 days	Not reported	1-2 units: OR 1.92 (95% CI 1.36 to 2.70) >3 units: OR 2.48 (95% CI 1.55 to 3.98)
Ruttinger 2007 (34)	Intensive care	Volume RBCT versus another volume of RBCT	In hospital	Not reported	1-2 units: OR 0.68 (95% CI 0.35 to 1.28) 3-4 units: OR 1.11 (95% CI 0.52 to 2.39) 5-8 units: OR 1.16 (95% CI 0.60 to 2.26) 8 units: OR 0.74 (95% CI 0.36 to 1.51)
Weightman	Cardiac surgery	Volume RBCT and other blood	Mean 8.1 year follow up	Not reported	1-2 units:

2009 (35)		product versus another volume RBCT			HR 1.00 (95% CI 0.70 to 1.44) 3-6 units: HR 0.98 (95% CI 0.67 to 1.41) > 6 units: HR 1.25 (95% CI 0.87 to 1.79)
'Older red blood cells versus 'newer' red blood cells					
Edgren 2010 (36)	Not specified	RBCT stored for 0- days, 10-19 days, 20-29 and 30-42 days	≤ 7 days and 8 to 730 days	Not reported	Mortality 1 to 7 days Stored 0- 9 days: HR 0.96 (95% CI 0.91 to 1.00) Stored 10-19 days: HR 1.00 (95% CI not reported) Stored 20-29 days: HR 1.06 (95% CI 0.96 to 1.06) Stored 30-42 days: HR 1.05 (95% CI 0.97 to 1.12) Mortality 8 to 730 days Stored 0- 9 days: HR 1.01 (95% CI 0.99 to 1.02) Stored 10-19 days: HR 1.00 (95% CI not reported) Stored 20-29 days: HR 0.99 (95% CI 0.97 to 1.01) Stored 30-42 days: HR 1.05 (95% CI 1.02 to 1.08)
Koch 2008 (37)	Cardiac surgery	RBCT stored for ≤ 14 days versus RBCT stored for > 14 days	In hospital and 1 year	Mortality in hospital OR 0.60 (95% CI 0.42 to 0.85)*	Mortality at 1 year p<0.001
Van de Watering 2006 (38)	Cardiac surgery	RBCT stored for <18 days versus RBCT stored for >18 days	30 days	Stored <18 days HR 1.33 (95% CI 1.04 to 1.68) Stored > 18 days HR 0.85 (95% CI 0.69 to 1.05)	Stored <18 days HR 0.93 (95% CI 0.71 to 1.23) Stored > 18 days HR 0.98 (95% CI 0.76 to 1.25)
Weinberg 2008 (39)	Trauma	RBCT stored for <14 days versus RBCT stored for >14 days	Time period not specified	Not reported	Stored <14 days 1-2 units: OR 1.65 (95% CI 1.01 to 2.70)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

					≥ 3 units: OR 1.70 (95% CI 0.96 to 2.99)
					Stored ≥ 14 days 1-2 units: OR 1.78 (95% CI 1.06 to 2.98)
					≥ 3 units: OR 2.78 (95% CI 1.58 to 4.88)

RBCT=red blood cell transfusion; *calculated from raw data; OR = odds ratio; RR = risk ratio; HR = hazard ratio

For peer review only